Document And Entity Information
Document And Entity Information - shares | 9 Months Ended | |
Sep. 30, 2023 | Oct. 31, 2023 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0001487428 | |
Entity Registrant Name | Horizon Technology Finance Corp | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2023 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Sep. 30, 2023 | |
Document Transition Report | false | |
Entity File Number | 814-00802 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 27-2114934 | |
Entity Address, Address Line One | 312 Farmington Avenue | |
Entity Address, City or Town | Farmington | |
Entity Address, State or Province | CT | |
Entity Address, Postal Zip Code | 06032 | |
City Area Code | 860 | |
Local Phone Number | 676‑8654 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 33,330,529 | |
The 6.25% Notes due 2027 [Member] | ||
Document Information [Line Items] | ||
Title of 12(b) Security | 6.25% Notes due 2027 | |
Trading Symbol | HTFC | |
Security Exchange Name | NYSE | |
The 4.875% Notes due 2026 [Member] | ||
Document Information [Line Items] | ||
Title of 12(b) Security | 4.875% Notes due 2026 | |
Trading Symbol | HTFB | |
Security Exchange Name | NYSE | |
Common Stock [Member] | ||
Document Information [Line Items] | ||
Title of 12(b) Security | Common Stock, par value $0.001 per share | |
Trading Symbol | HRZN | |
Security Exchange Name | NASDAQ |
Consolidated Statements of Asse
Consolidated Statements of Assets and Liabilities (Current Period Unaudited) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Assets | ||
Investments at fair value | $ 729,053 | $ 720,026 |
Cash | 34,816 | 20,612 |
Investments in money market funds | 12,457 | 7,066 |
Restricted investments in money market funds | 2,838 | 2,788 |
Interest receivable | 14,135 | 13,573 |
Other assets | 3,945 | 2,761 |
Total assets | 797,244 | 766,826 |
Liabilities | ||
Borrowings (Note 7) | 435,500 | 434,078 |
Distributions payable | 10,991 | 9,159 |
Base management fee payable (Note 3) | 1,080 | 1,065 |
Incentive fee payable (Note 3) | 0 | 1,392 |
Other accrued expenses | 3,098 | 2,684 |
Total liabilities | 450,669 | 448,378 |
Commitments and contingencies (Notes 3 and 8) | ||
Net assets | ||
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized, zero shares issued and outstanding as of September 30, 2023 and December 31, 2022 | 0 | 0 |
Common stock, par value $0.001 per share, 100,000,000 shares authorized, 33,474,423 and 27,920,838 shares issued and 33,306,958 and 27,753,373 shares outstanding as of September 30, 2023 and December 31, 2022, respectively | 35 | 29 |
Paid-in capital in excess of par | 451,722 | 385,921 |
Distributable loss | (105,182) | (67,502) |
Total net assets | 346,575 | 318,448 |
Total liabilities and net assets | $ 797,244 | $ 766,826 |
Net asset value per common share (in dollars per share) | $ 10.41 | $ 11.47 |
Investment, Unaffiliated Issuer [Member] | ||
Assets | ||
Investments at fair value | $ 695,423 | $ 720,026 |
Investment, Affiliated Issuer, Noncontrolled [Member] | ||
Assets | ||
Investments at fair value | 20,485 | 0 |
Investment, Affiliated Issuer, Controlled [Member] | ||
Assets | ||
Investments at fair value | $ 13,145 | $ 0 |
Consolidated Statements of As_2
Consolidated Statements of Assets and Liabilities (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Investments at cost | $ 754,814 | $ 721,248 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 1,000,000 | 1,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares oustanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, shares issued (in shares) | 33,474,423 | 27,920,838 |
Common stock, shares outstanding (in shares) | 33,306,958 | 27,753,373 |
Investment, Unaffiliated Issuer [Member] | ||
Investments at cost | $ 700,932 | $ 721,248 |
Investment, Affiliated Issuer, Noncontrolled [Member] | ||
Investments at cost | 39,666 | 0 |
Investment, Affiliated Issuer, Controlled [Member] | ||
Investments at cost | $ 14,216 | $ 0 |
Consolidated Statements of Oper
Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Investment income | ||||
Payment-in-kind interest income | $ 3,900 | $ 0 | $ 6,088 | $ 0 |
Total investment income | 29,138 | 23,254 | 85,292 | 56,046 |
Expenses | ||||
Interest expense | 7,107 | 5,339 | 21,407 | 12,987 |
Base management fee (Note 3) | 3,213 | 2,788 | 9,621 | 7,555 |
Performance based incentive fee (Note 3) | 0 | 2,784 | 3,094 | 6,353 |
Administrative fee (Note 3) | 441 | 412 | 1,249 | 1,147 |
Professional fees | 452 | 314 | 1,558 | 1,163 |
General and administrative | 392 | 381 | 1,384 | 1,088 |
Total expenses | 11,605 | 12,018 | 38,313 | 30,293 |
Net investment income before excise tax | 17,533 | 11,236 | 46,979 | 25,753 |
Provision for excise tax | 179 | 100 | 542 | 306 |
Net investment income | 17,354 | 11,136 | 46,437 | 25,447 |
Net realized and unrealized loss | ||||
Net realized gain (loss) on investments | (11,816) | (8,585) | (28,513) | (9,484) |
Net unrealized appreciation (depreciation) on investments | (17,518) | 3,442 | (24,448) | 1,169 |
Net realized and unrealized loss | (29,334) | (5,143) | (52,961) | (8,315) |
Net (decrease) increase in net assets resulting from operations | $ (11,980) | $ 5,993 | $ (6,524) | $ 17,132 |
Net investment income per common share (in dollars per share) | $ 0.53 | $ 0.43 | $ 1.54 | $ 1.06 |
Net (decrease) increase in net assets resulting from operations per common share (in dollars per share) | (0.37) | 0.23 | (0.22) | 0.71 |
Distributions declared per share (in dollars per share) | $ 0.33 | $ 0.30 | $ 0.99 | $ 0.90 |
Weighted average shares outstanding (in shares) | 32,451,900 | 25,738,054 | 30,155,287 | 23,995,369 |
Investment, Unaffiliated Issuer [Member] | ||||
Investment income | ||||
Interest income | $ 23,825 | $ 22,745 | $ 75,695 | $ 54,317 |
Fee income | 124 | 509 | 2,255 | 1,729 |
Payment-in-kind interest income | 3,777 | 0 | 5,930 | 0 |
Net realized and unrealized loss | ||||
Net realized gain (loss) on investments | (11,816) | (8,665) | (28,513) | (8,364) |
Net unrealized appreciation (depreciation) on investments | 180 | 3,442 | (7,656) | (281) |
Investment, Affiliated Issuer, Noncontrolled [Member] | ||||
Investment income | ||||
Interest income | 1,246 | 0 | 1,246 | 0 |
Net realized and unrealized loss | ||||
Net realized gain (loss) on investments | 0 | 30 | 0 | 30 |
Net unrealized appreciation (depreciation) on investments | (19,055) | 0 | (18,149) | 0 |
Investment, Affiliated Issuer, Controlled [Member] | ||||
Investment income | ||||
Interest income | 8 | 0 | 8 | 0 |
Payment-in-kind interest income | 158 | 0 | 158 | 0 |
Net realized and unrealized loss | ||||
Net realized gain (loss) on investments | 0 | 50 | 0 | (1,150) |
Net unrealized appreciation (depreciation) on investments | $ 1,357 | $ 0 | $ 1,357 | $ 1,450 |
Consolidated Statements of Chan
Consolidated Statements of Changes in Net Assets (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Common Stock Outstanding [Member] | ||||
Balance (in shares) | 32,096,259 | 24,857,104 | 27,753,373 | 21,217,460 |
Issuance of common stock, net of offering costs (in shares) | 1,186,303 | 1,523,519 | 5,490,326 | 5,141,920 |
Issuance of common stock under dividend reinvestment plan (in shares) | 24,396 | 13,150 | 63,259 | 34,393 |
Balance (in shares) | 33,306,958 | 26,393,773 | 33,306,958 | 26,393,773 |
Common Stock [Member] | ||||
Balance | $ 34 | $ 26 | $ 29 | $ 22 |
Issuance of common stock, net of offering costs | 1 | 1 | 6 | 5 |
Net investment income, net of excise tax | 0 | 0 | 0 | 0 |
Net realized gain (loss) on investments | 0 | 0 | 0 | 0 |
Net unrealized appreciation (depreciation) on investments | 0 | 0 | 0 | 0 |
Issuance of common stock under dividend reinvestment plan | 0 | 0 | 0 | 0 |
Distributions declared | 0 | 0 | 0 | 0 |
Net realized gain (loss) on investments | 0 | 0 | 0 | 0 |
Balance | 35 | 27 | 35 | 27 |
Additional Paid-in Capital [Member] | ||||
Balance | 437,561 | 350,173 | 385,921 | 301,359 |
Issuance of common stock, net of offering costs | 13,854 | 18,995 | 65,025 | 67,519 |
Net investment income, net of excise tax | 0 | 0 | 0 | 0 |
Net realized gain (loss) on investments | 0 | 0 | 0 | 0 |
Net unrealized appreciation (depreciation) on investments | 0 | 0 | 0 | 0 |
Issuance of common stock under dividend reinvestment plan | 307 | 166 | 776 | 456 |
Distributions declared | 0 | 0 | 0 | 0 |
Net realized gain (loss) on investments | 0 | 0 | 0 | 0 |
Balance | 451,722 | 369,334 | 451,722 | 369,334 |
Retained Earnings [Member] | ||||
Balance | (82,176) | (59,594) | (67,502) | (56,046) |
Issuance of common stock, net of offering costs | 0 | 0 | 0 | 0 |
Net investment income, net of excise tax | 17,354 | 11,136 | 46,437 | 25,447 |
Net realized gain (loss) on investments | (11,816) | (8,585) | (28,513) | (9,484) |
Net unrealized appreciation (depreciation) on investments | (17,518) | 3,442 | (24,448) | 1,169 |
Issuance of common stock under dividend reinvestment plan | 0 | 0 | 0 | 0 |
Distributions declared | (11,026) | (8,073) | (31,156) | (22,760) |
Net realized gain (loss) on investments | (11,816) | (8,585) | (28,513) | (9,484) |
Balance | (105,182) | (61,674) | (105,182) | (61,674) |
Balance | 355,419 | 290,605 | 318,448 | 245,335 |
Issuance of common stock, net of offering costs | 13,855 | 18,996 | 65,031 | 67,524 |
Net investment income, net of excise tax | 17,354 | 11,136 | 46,437 | 25,447 |
Net realized gain (loss) on investments | (11,816) | (8,585) | (28,513) | (9,484) |
Net unrealized appreciation (depreciation) on investments | (17,518) | 3,442 | (24,448) | 1,169 |
Issuance of common stock under dividend reinvestment plan | 307 | 166 | 776 | 456 |
Distributions declared | (11,026) | (8,073) | (31,156) | (22,760) |
Net realized gain (loss) on investments | (11,816) | (8,585) | (28,513) | (9,484) |
Balance | $ 346,575 | $ 307,687 | $ 346,575 | $ 307,687 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Cash flows from operating activities: | ||||
Net (decrease) increase in net assets resulting from operations | $ (11,980) | $ 5,993 | $ (6,524) | $ 17,132 |
Adjustments to reconcile net (decrease) increase in net assets resulting from operations to net cash used in operating activities: | ||||
Amortization of debt issuance costs | 500 | 400 | 1,433 | 1,142 |
Net realized loss on investments | 28,513 | 9,484 | ||
Net unrealized depreciation on investments | 17,518 | (3,442) | 24,448 | (1,169) |
Purchase of investments | (154,488) | (348,347) | ||
Principal payments received on investments | 90,222 | 114,433 | ||
Payment-in-kind interest on investments | (3,900) | 0 | (6,088) | 0 |
Proceeds from sale of investments | 11,063 | 49,681 | ||
Equity received in settlement of fee income | (89) | 0 | ||
Warrants received in settlement of fee income | (80) | 0 | ||
Changes in assets and liabilities: | ||||
Decrease (increase) in interest receivable | 1,491 | (2,175) | ||
Increase in end-of-term payments | (1,960) | (3,003) | ||
Decrease in unearned income | (2,621) | (274) | ||
(Increase) decrease in other assets | (837) | 115 | ||
Increase in other accrued expenses | 414 | 193 | ||
Increase in base management fee payable | 15 | 1,164 | ||
(Decrease) increase in incentive fee payable | (1,392) | 769 | ||
Net cash used in operating activities | (16,480) | (160,855) | ||
Cash flows from financing activities: | ||||
Proceeds from issuance of 2027 Notes | 0 | 57,500 | ||
Proceeds from issuance of common stock, net of offering costs | 65,031 | 67,525 | ||
Advances on Credit Facilities | 59,250 | 119,000 | ||
Repayment of Credit Facilities | (35,000) | (47,000) | ||
Debt issuance costs | (732) | (2,470) | ||
Distributions paid | (28,548) | (20,752) | ||
Net cash provided by financing activities | 36,125 | 146,762 | ||
Net increase (decrease) in cash, cash equivalents and restricted cash | 19,645 | (14,093) | ||
Cash, cash equivalents and restricted cash: | ||||
Beginning of period | 30,466 | 47,281 | ||
End of period | 50,111 | 33,188 | 50,111 | 33,188 |
Supplemental disclosure of cash flow information: | ||||
Cash paid for interest | 19,956 | 11,543 | ||
Supplemental non-cash investing and financing activities: | ||||
Warrant investments received and recorded as unearned income | 1,870 | 2,969 | ||
Distributions payable | 10,991 | 7,918 | 10,991 | 7,918 |
End-of-term payments receivable | 11,743 | 8,240 | ||
Non-cash income | 12,861 | 4,504 | ||
Cash | 34,816 | 23,839 | 34,816 | 23,839 |
Investments in money market funds | 12,457 | 7,732 | 12,457 | 7,732 |
Restricted investments in money market funds | 2,838 | 1,617 | 2,838 | 1,617 |
Total cash, cash equivalents and restricted cash | $ 50,111 | $ 33,188 | 50,111 | 33,188 |
Asset-backed Notes 2019 [Member] | ||||
Cash flows from financing activities: | ||||
Repayment of notes | $ (23,876) | $ (27,041) |
Consolidated Schedule of Invest
Consolidated Schedule of Investments (Unaudited) | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Schedule of Investments [Text Block] | September 30, 2023 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Investments — 200.7% Non-Affiliate Debt Investments — 191.4% Non-Affiliate Debt Investments — Life Science — 69.7% Castle Creek Biosciences, Inc. (2)(12) Biotechnology Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,903 4,903 Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,975 4,975 Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,985 2,985 Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,975 4,975 Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,975 4,975 Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,985 2,985 Emalex Biosciences, Inc. (2)(12) Biotechnology Term Loan 13.22 % Prime 4.72 % 9.75 % - 5.00 % June 1, 2024 1,979 1,971 1,971 Term Loan 13.22 % Prime 4.72 % 9.75 % - 5.00 % June 1, 2024 1,979 1,972 1,972 Term Loan 13.22 % Prime 4.72 % 9.75 % - 5.00 % November 1, 2025 5,000 4,943 4,943 Term Loan 13.22 % Prime 4.72 % 9.75 % - 5.00 % May 1, 2026 5,000 4,939 4,939 Greenlight Biosciences, Inc. (2)(12) Biotechnology Term Loan 14.25 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 3,500 3,399 3,365 Term Loan 14.25 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 1,750 1,699 1,684 KSQ Therapeutics, Inc. (2)(12) Biotechnology Term Loan 13.25 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,193 6,193 Term Loan 13.25 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,193 6,193 Native Microbials, Inc (2)(12) Biotechnology Term Loan 13.75 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 3,750 3,716 3,716 Term Loan 13.75 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 2,500 2,478 2,478 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Term Loan 14.25 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 10,000 9,898 9,898 Term Loan 14.25 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,712 3,712 Term Loan 14.25 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,712 3,712 Provivi, Inc. (2)(12) Biotechnology Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 4,667 4,594 4,594 Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 4,667 4,594 4,594 Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,286 2,286 Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,286 2,286 Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,282 2,282 Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,282 2,282 Stealth Biotherapeutics Inc. (2)(12) Biotechnology Term Loan 14.00 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 4,500 4,434 4,434 Term Loan 14.00 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 2,250 2,217 2,217 Tallac Therapeutics, Inc. (2)(12) Biotechnology Term Loan 12.75 % Prime 4.25 % 12.25 % - 4.00 % August 1, 2027 2,500 2,226 2,226 Term Loan 12.75 % Prime 4.25 % 12.25 % - 4.00 % August 1, 2027 2,500 2,455 2,455 Aerobiotix, LLC (2)(12) Medical Device Term Loan 9.00 % Fixed - - - 18.00 % April 1, 2028 2,500 2,466 2,344 Term Loan 9.00 % Fixed - - - 18.00 % April 1, 2028 2,500 2,466 2,344 Term Loan 9.00 % Fixed - - - 18.00 % June 30, 2024 200 200 190 Candesant Biomedical, Inc. (2)(12) Medical Device Term Loan 12.00 % Prime 3.50 % 11.50 % - 5.00 % September 1, 2027 5,000 4,751 4,751 Term Loan 12.00 % Prime 3.50 % 11.50 % - 5.00 % September 1, 2027 2,500 2,451 2,451 Term Loan 12.00 % Prime 3.50 % 11.50 % - 5.00 % September 1, 2027 2,500 2,451 2,451 Ceribell, Inc. (2)(12) Medical Device Term Loan 12.00 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 5,000 4,985 4,985 Term Loan 12.00 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 5,000 4,985 4,985 Term Loan 12.00 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 2,500 2,488 2,488 Term Loan 12.00 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 2,500 2,488 2,488 Cognoa, Inc. (2)(12) Medical Device Term Loan 14.00 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 4,722 4,678 4,678 Term Loan 14.00 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 2,361 2,339 2,339 Conventus Orthopaedics, Inc. (2)(12) Medical Device Term Loan 13.32 % Prime 4.82 % 9.25 % - 10.36 % July 1, 2025 3,960 3,916 3,916 Term Loan 13.32 % Prime 4.82 % 9.25 % - 10.36 % July 1, 2025 3,960 3,916 3,916 CSA Medical, Inc. (2)(12) Medical Device Term Loan 13.59 % Prime 5.09 % 10.00 % - 5.00 % January 1, 2024 750 739 739 Term Loan 13.59 % Prime 5.09 % 10.00 % - 5.00 % January 1, 2024 50 49 49 Term Loan 13.59 % Prime 5.09 % 10.00 % - 5.00 % March 1, 2024 1,067 1,052 1,052 InfoBionic, Inc. (2)(12) Medical Device Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % October 1, 2024 2,771 2,733 2,733 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % June 1, 2025 1,000 982 982 Magnolia Medical Technologies, Inc. (2)(12) Medical Device Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,960 4,960 Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,960 4,960 Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,956 4,956 Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,956 4,956 Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % January 1, 2027 5,000 4,934 4,934 Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % January 1, 2027 5,000 4,934 4,934 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) September 30, 2023 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Robin Healthcare, Inc. (2)(12)(13) Medical Device Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % November 1, 2026 3,500 3,468 1,749 Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % November 1, 2026 3,500 3,468 1,749 Scientia Vascular, Inc. (2)(12) Medical Device Term Loan 13.25 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,663 3,663 Term Loan 13.25 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,718 3,718 Term Loan 13.75 % Prime 5.25 % 9.00 % - 5.00 % March 1, 2027 5,000 4,938 4,938 Sonex Health, Inc. (2)(12) Medical Device Term Loan 12.00 % Prime 3.50 % 11.75 % - 8.00 % September 1, 2027 2,500 2,295 2,295 Term Loan 12.00 % Prime 3.50 % 11.75 % - 8.00 % September 1, 2027 2,500 2,471 2,471 Term Loan 12.00 % Prime 3.50 % 11.75 % - 8.00 % September 1, 2027 5,000 4,943 4,943 Term Loan 12.00 % Prime 3.50 % 11.75 % - 8.00 % September 1, 2027 5,000 4,943 4,943 Spineology, Inc. (2)(12) Medical Device Term Loan 15.50 % Prime 7.00 % 10.25 % - 1.00 % October 1, 2025 5,000 4,975 4,975 Term Loan 15.50 % Prime 7.00 % 10.25 % - 1.00 % April 1, 2026 2,500 2,487 2,487 Swift Health Systems Inc. (2)(12) Medical Device Term Loan 13.75 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,464 3,464 Term Loan 13.75 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,464 3,464 Term Loan 13.75 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,453 3,453 Term Loan 13.75 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,453 3,453 Total Non-Affiliate Debt Investments — Life Science 245,317 241,576 Non-Affiliate Debt Investments — Sustainability — 23.8% New Aerofarms, Inc. assignee of Aerofarms, Inc. (2)(12)(15) Other Sustainability Term Loan 15.25 % Prime 6.75 % 10.00 % - 4.33 % December 1, 2026 3,750 3,675 3,675 Term Loan 15.25 % Prime 6.75 % 10.00 % - 4.33 % December 1, 2026 3,750 3,675 3,675 Nexii Building Solutions, Inc. (2)(12)(14) Other Sustainability Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 8,102 8,009 6,754 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 8,102 8,009 6,754 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 8,102 8,009 6,754 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % July 1, 2026 5,402 5,332 4,496 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % July 1, 2026 5,402 5,332 4,496 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 30, 2023 707 707 596 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 30, 2023 564 564 475 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 30, 2023 281 281 237 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 30, 2023 279 279 235 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 30, 2023 167 167 141 Soli Organic, Inc. (2)(12) Other Sustainability Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 5,000 4,951 4,951 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 2,500 2,475 2,475 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 5,000 4,948 4,948 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 2,500 2,474 2,474 Term Loan 14.00 % Prime 5.50 % 11.75 % - 2.75 % December 1, 2026 5,000 4,926 4,926 Term Loan 14.00 % Prime 5.50 % 11.75 % - 2.75 % December 1, 2026 2,500 2,463 2,463 Temperpack Technologies, Inc. (2)(12) Other Sustainability Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.50 % April 1, 2028 3,750 3,678 3,678 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.50 % April 1, 2028 3,750 3,692 3,692 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.50 % April 1, 2028 7,500 7,374 7,374 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.50 % April 1, 2028 3,750 3,687 3,687 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.50 % April 1, 2028 3,750 3,687 3,687 Total Non-Affiliate Debt Investments — Sustainability 88,394 82,643 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) September 30, 2023 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Debt Investments — Technology — 80.5% Axiom Space, Inc. (2)(12) Communications Term Loan 14.50 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 6,875 6,840 6,840 Term Loan 14.50 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 6,875 6,840 6,840 Term Loan 14.50 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 6,875 6,840 6,840 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Term Loan 15.75 % Prime 7.25 % 10.50 % - 3.00 % May 1, 2026 3,500 3,470 3,470 Clara Foods Co. (2)(12) Consumer-related Technologies Term Loan 14.25 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 1,833 1,821 1,821 Term Loan 14.25 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 1,833 1,821 1,821 Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,605 3,605 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,241 1,241 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,723 3,723 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,241 1,241 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,723 3,723 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,241 1,241 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % January 1, 2028 3,750 3,709 3,709 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % January 1, 2028 3,750 3,703 3,703 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % April 1, 2028 3,750 3,709 3,709 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2028 3,750 3,705 3,705 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2028 3,750 3,705 3,705 Havenly, Inc. (2)(12) Consumer-related Technologies Term Loan 13.50 % Prime 5.00 % 5.00 % - 4.00 % March 1, 2027 2,000 1,335 1,335 Term Loan 13.50 % Prime 5.00 % 5.00 % - 4.00 % March 1, 2027 3,000 2,003 2,003 Term Loan 12.00 % Prime 3.50 % 10.50 % - 7.78 % February 1, 2028 2,813 2,813 2,813 Term Loan 12.00 % Prime 3.50 % 10.50 % - 7.78 % February 1, 2028 2,813 2,813 2,813 Lyrical Foods, Inc. (2)(12) Consumer-related Technologies Term Loan 11.00 % Prime 2.50 % 8.00 % - - September 1, 2027 2,598 2,589 2,351 MyForest Foods Co. (2)(12) Consumer-related Technologies Term Loan 15.25 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 4,000 3,975 3,975 Term Loan 15.25 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 2,000 1,987 1,987 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 5,547 5,505 4,894 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,219 2,204 1,960 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,774 2,759 2,453 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 3,328 3,310 2,943 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,774 2,747 2,443 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,774 2,747 2,443 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 5,547 5,493 4,884 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,774 2,746 2,441 Optoro, Inc. (2)(12) Consumer-related Technologies Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % August 1, 2027 2,500 2,408 2,408 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % July 1, 2028 1,875 1,783 1,783 Primary Kids, Inc. (2)(12) Consumer-related Technologies Term Loan 15.75 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 1,700 1,683 1,683 Term Loan 15.75 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 1,700 1,683 1,683 Term Loan 15.75 % Prime 7.25 % 10.50 % - 3.00 % September 1, 2025 2,300 2,277 2,277 Unagi, Inc. (2)(12)(13) Consumer-related Technologies Term Loan 16.25 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 1,108 1,086 872 Term Loan 16.25 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 554 543 436 Term Loan 16.25 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 554 543 436 Liqid, Inc. (2)(12) Networking Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,833 1,807 1,807 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,833 1,807 1,807 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 917 903 903 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 917 903 903 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 917 887 887 BriteCore Holdings, Inc. (2)(12) Software Term Loan 14.00 % Prime 5.50 % 14.00 % - 3.00 % October 1, 2028 5,000 4,857 4,857 Term Loan 14.00 % Prime 5.50 % 14.00 % - 3.00 % October 1, 2028 2,500 2,464 2,464 Term Loan 14.00 % Prime 5.50 % 14.00 % - 3.00 % October 1, 2028 2,500 2,464 2,464 Term Loan 14.00 % Prime 5.50 % 14.00 % - 3.00 % October 1, 2028 2,500 2,464 2,464 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) September 30, 2023 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Dropoff, Inc. (2)(12) Software Term Loan 15.00 % (11) Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,550 6,432 6,377 Term Loan 15.00 % (11) Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,046 5,937 5,886 Term Loan 15.00 % (11) Prime 6.50 % 9.75 % - 3.50 % August 1, 2026 2,519 2,472 2,451 Engage3, LLC (2)(12) Software Term Loan 14.75 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,726 3,726 Term Loan 14.75 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,726 3,726 Kodiak Robotics, Inc. (2)(12) Software Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,877 9,877 Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,877 9,877 Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,939 4,939 Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,939 4,939 Lemongrass Holdings, Inc. (2)(12) Software Term Loan 15.00 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 5,000 4,965 4,965 Term Loan 15.00 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 2,500 2,483 2,483 Lytics, Inc. (2)(12) Software Term Loan 14.50 % Prime 6.00 % 14.25 % - 4.00 % November 1, 2026 2,500 2,418 2,350 Term Loan 14.50 % Prime 6.00 % 14.25 % - 4.00 % December 1, 2026 1,250 1,236 1,201 Term Loan 14.50 % Prime 6.00 % 14.25 % - 4.00 % April 1, 2027 1,000 993 966 Mirantis, Inc. (2)(12) Software Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2028 5,000 4,774 4,774 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2028 5,000 4,910 4,910 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2028 5,000 4,910 4,910 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2028 5,000 4,910 4,910 Noodle Partners, Inc. (2)(12) Software Term Loan 13.50 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 10,000 9,814 9,814 Term Loan 13.50 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 5,000 4,938 4,938 Term Loan 13.50 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 5,000 4,939 4,939 Reputation Institute, Inc. (2)(12) Software Term Loan 15.75 % Prime 7.25 % 10.50 % - 3.00 % August 1, 2025 3,833 3,785 3,785 Slingshot Aerospace, Inc. (2)(12) Software Term Loan 14.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,952 4,952 Term Loan 14.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,952 4,952 Term Loan 14.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,952 4,952 Term Loan 14.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,952 4,952 Supply Network Visibility Holdings LLC (2)(12) Software Term Loan 12.75 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 2,500 2,457 2,457 Term Loan 12.75 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 3,500 3,489 3,489 Term Loan 12.75 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 2,500 2,492 2,492 Term Loan 12.75 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 1,500 1,495 1,495 Viken Detection Corporation (2)(12) Software Term Loan 12.50 % Prime 4.00 % 11.75 % - 3.50 % June 1, 2027 5,000 4,768 4,768 Term Loan 12.50 % Prime 4.00 % 11.75 % - 3.50 % June 1, 2027 2,500 2,464 2,464 Term Loan 12.50 % Prime 4.00 % 11.75 % - 3.50 % June 1, 2027 2,500 2,464 2,464 Total Non-Affiliate Debt Investments — Technology 282,962 278,989 Non-Affiliate Debt Investments — Healthcare information and services — 17.4% Hound Labs inc. (2) (12) Diagnostics Term Loan 14.50 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,481 2,481 Term Loan 14.50 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,481 2,481 Term Loan 14.50 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 5,000 4,962 4,962 BrightInsight, Inc. (2)(12) Software Term Loan 14.00 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 7,000 6,677 6,677 Term Loan 14.00 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,459 3,459 Term Loan 14.00 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,459 3,459 Term Loan 14.00 % Prime 5.50 % 9.50 % - 3.00 % April 1, 2028 2,750 2,708 2,708 Elligo Health Research, Inc. (2)(12) Software Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2027 10,000 9,647 9,647 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2027 5,000 4,921 4,921 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2027 5,000 4,921 4,921 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2027 5,000 4,921 4,921 SafelyYou, Inc. (2)(12) Software Term Loan 11.75 % Prime 3.25 % 11.00 % - 5.00 % June 1, 2027 5,000 4,642 4,642 Term Loan 11.75 % Prime 3.25 % 11.00 % - 5.00 % June 1, 2027 5,000 4,912 4,912 Total Non-Affiliate Debt Investments — Healthcare information and services 60,191 60,191 Total Non- Affiliate Debt Investments 676,864 663,399 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) September 30, 2023 (Dollars in thousands) Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrant Investments — 7.6% Non-Affiliate Warrants — Life Science — 2.0% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 26,444 311 — Castle Creek Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 7,404 214 348 Emalex Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 110,402 176 269 Imunon, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 19,671 65 — KSQ Therapeutics, Inc. (2) (12) Biotechnology Preferred Stock Warrant 48,076 50 60 Mustang Bio, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 16,611 146 — Native Microbials, Inc (2)(12) Biotechnology Preferred Stock Warrant 103,679 64 165 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Common Stock Warrant 299,848 162 667 Provivi, Inc. (2)(12) Biotechnology Preferred Stock Warrant 345,327 487 205 Stealth Biotherapeutics Inc. (2)(12) Biotechnology Common Stock Warrant 318,181 264 127 Tallac Therapeutics, Inc. (2)(12) Biotechnology Preferred Stock Warrant 1,600,002 194 194 vTv Therapeutics Inc. (2)(5)(12) Biotechnology Common Stock Warrant 95,293 44 — Xeris Pharmaceuticals, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 126,000 72 17 AccuVein Inc. (2)(12) Medical Device Common Stock Warrant 1,175 24 — Aerin Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,818,183 66 1,210 Aerobiotix, LLC (2)(12) Medical Device Preferred Stock Warrant 8,800 48 10 Canary Medical Inc. (2)(12) Medical Device Preferred Stock Warrant 12,153 86 1,307 Candesant Biomedical, Inc. (2)(12) Medical Device Preferred Stock Warrant 93,336 152 152 Ceribell, Inc. (2)(12) Medical Device Preferred Stock Warrant 145,483 69 213 Cognoa, Inc. (2)(12) Medical Device Preferred Stock Warrant 4,106,174 148 184 Conventus Orthopaedics, Inc. (2)(12) Medical Device Preferred Stock Warrant 7,972,222 218 236 CSA Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,730,746 172 176 CVRx, Inc. (2)(5)(12) Medical Device Common Stock Warrant 47,410 76 272 Infobionic, Inc. (2)(12) Medical Device Preferred Stock Warrant 317,647 124 59 Magnolia Medical Technologies, Inc. (2)(12) Medical Device Preferred Stock Warrant 809,931 194 395 Meditrina, Inc. (2)(12) Medical Device Preferred Stock Warrant 233,993 83 104 Robin Healthcare, Inc. (2)(12) Medical Device Preferred Stock Warrant 86,066 16 — Scientia Vascular, Inc (2)(12) Medical Device Preferred Stock Warrant 27,036 59 230 Sonex Health, Inc. (2)(12) Medical Device Preferred Stock Warrant 2,637,043 275 304 VERO Biotech LLC (2)(12) Medical Device Preferred Stock Warrant 408 53 1 Swift Health Systems Inc. (2)(12) Medical Device Preferred Stock Warrant 135,484 71 40 Total Non-Affiliate Warrants — Life Science 4,183 6,945 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) September 30, 2023 (Dollars in thousands) Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrants — Sustainability — 0.2% New Aerofarms, Inc. assignee of Aerofarms, Inc. (2)(12)(15) Other Sustainability Preferred Stock Warrant 400,000 81 81 LiquiGlide, Inc. (2)(12) Other Sustainability Common Stock Warrant 61,359 41 59 Nexii Building Solutions, Inc. (2)(12)(14) Other Sustainability Common Stock Warrant 217,726 490 — Soli Organic, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 681 214 371 Temperpack Technologies, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 46,311 175 322 Total Non-Affiliate Warrants — Sustainability 1,001 833 Non-Affiliate Warrants — Technology — 4.7% Axiom Space, Inc. (2)(12) Communications Common Stock Warrant 1,991 46 69 Intelepeer Holdings, Inc. (2)(12) Communications Preferred Stock Warrant 2,936,535 138 3,283 PebblePost, Inc. (2)(12) Communications Preferred Stock Warrant 598,850 92 139 Alula Holdings, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 20,000 93 — Aterian, Inc. (2)(5)(12) Consumer-related Technologies Common Stock Warrant 76,923 195 — Caastle, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 268,591 68 1,060 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 75,997 22 30 Clara Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 46,745 31 128 CZV, Inc. (2)(12) Consumer-related Technologies Common Stock Warrant 65,569 81 81 Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 37,294 92 279 Havenly, Inc. (2)(12) Consumer-related Technologies Common Stock Warrant 1,312,500 2,945 2,676 MyForest Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 250 29 63 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Preferred and Common Stock Warrant 1,237,370 197 — Optoro, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 11,550 182 182 Primary Kids, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 553,778 57 596 Quip NYC Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 6,191 325 538 Unagi, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 171,081 32 — Updater, Inc.(2)(12) Consumer-related Technologies Common Stock Warrant 108,333 34 — CPG Beyond, Inc. (2)(12) Data Storage Preferred Stock Warrant 500,000 242 917 Silk, Inc. (2)(12) Data Storage Preferred Stock Warrant 394,110 175 153 Global Worldwide LLC (2)(12) Internet and Media Preferred Stock Warrant 245,810 75 63 Rocket Lawyer Incorporated (2)(12) Internet and Media Preferred Stock Warrant 261,721 92 336 Skillshare, Inc. (2)(12) Internet and Media Preferred Stock Warrant 139,074 162 1,216 Liqid, Inc. (2)(12) Networking Preferred Stock Warrant 344,102 364 251 Halio, Inc. (2)(12) Power Management Preferred Stock Warrant 5,002,574 1,585 2,901 Avalanche Technology, Inc. (2)(12) Semiconductors Preferred and Common Stock Warrant 6,081 56 — BriteCore Holdings, Inc. (2)(12) Software Preferred Stock Warrant 161,215 98 147 Dropoff, Inc. (2)(12) Software Common Stock Warrant 516,732 455 54 Mirantis, Inc. (2)(12) Software Common Stock Warrant 948,275 223 223 E La Carte, Inc. (2)(5)(12) Software Common Stock Warrant 147,361 60 — Everstream Holdings, LLC (2)(12) Software Preferred Stock Warrant 350,000 70 71 Kodiak Robotics, Inc. (2)(12) Software Preferred Stock Warrant 639,918 273 124 Lemongrass Holdings, Inc. (2)(12) Software Preferred Stock Warrant 101,308 32 43 Lotame Solutions, Inc. (2)(12) Software Preferred Stock Warrant 71,305 18 44 Lytics, Inc. (2)(12) Software Preferred Stock Warrant 85,543 43 1 Noodle Partners, Inc. (2)(12) Software Preferred Stock Warrant 84,037 115 79 Reputation Institute, Inc. (2)(12) Software Preferred Stock Warrant 3,731 56 48 Revinate Holdings, Inc. (2)(12) Software Preferred Stock Warrant 682,034 44 103 SIGNiX, Inc. (12) Software Preferred Stock Warrant 186,235 225 — Slingshot Aerospace, Inc. (2)(12) Software Preferred Stock Warrant 309,208 123 135 Supply Network Visibility Holdings LLC (2)(12) Software Preferred Stock Warrant 682 64 146 Topia Mobility, Inc. (2)(12) Software Preferred Stock Warrant 3,049,607 138 — Viken Detection Corporation (2)(12) Software Preferred Stock Warrant 345,443 120 122 xAd, Inc. (2)(12) Software Preferred Stock Warrant 4,343,348 177 12 Total Non-Affiliate Warrants — Technology 9,744 16,313 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) September 30, 2023 (Dollars in thousands) Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrants — Healthcare information and services — 0.6% Hound Labs, Inc (2) (12) Diagnostics Preferred Stock Warrant 171,370 47 15 Kate Farms, Inc. (2)(12) Other Healthcare Preferred Stock Warrant 82,965 102 1,379 BrightInsight, Inc. (2)(12) Software Preferred Stock Warrant 85,066 167 — Elligo Health Research, Inc. (2)(12) Software Preferred Stock Warrant 652,250 189 191 Medsphere Systems Corporation (2)(12) Software Preferred Stock Warrant 7,097,792 61 346 SafelyYou, Inc. (2)(12) Software Preferred Stock Warrant 150,353 163 167 Total Non-Affiliate Warrants — Healthcare information and services 729 2,098 Total Non-Affiliate Warrants 15,657 26,189 Non-Affiliate Other Investments — Life Science — 0.3% Lumithera, Inc. (12) Medical Device Royalty Agreement 1,200 1,100 ZetrOZ, Inc. (12) Medical Device Royalty Agreement — — Total Non-Affiliate Other Investments 1,200 1,100 Non-Affiliate Equity — 1.4% Cadrenal Therapeutics, Inc. (5) Biotechnology Common Stock 600,000 — 408 Castle Creek Biosciences, Inc. (12) Biotechnology Common Stock 1,162 250 250 Emalex Biosciences, Inc. (12) Biotechnology Common Stock 32,831 355 356 Getaround, Inc. (2)(5) Consumer-related Technologies Common Stock 87,082 253 30 NextCar Holding Company, Inc. (2)(12) Technology Preferred Stock 2,688,971 89 89 SnagAJob.com, Inc. (12) Consumer-related Technologies Common Stock 82,974 9 83 Lumithera, Inc. (12) Medical Device Common Stock 392,651 2,000 1,700 Tigo Energy, Inc. (5) Other Sustainability Common Stock 5,205 111 36 Branded Online, Inc. (2)(5) Software Common Stock 5,398 1,079 3 Decisyon, Inc. (12) Software Preferred Stock 280,000 2,800 1,281 Lotame, Inc. (12) Software Preferred Stock 66,127 4 193 Axiom Space, Inc. (12) Technology Preferred Stock 1,810 261 306 Total Non-Affiliate Equity 7,211 4,735 Total Non-Affiliate Portfolio Investment Assets $ 700,932 $ 695,423 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) September 30, 2023 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Controlled Affiliate Investments — 5.9% Non-Controlled Affiliate Debt Investments — Life Sciences — 3.5% Evelo Biosciences, Inc. (2)(5)(12)(13) Biotechnology Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 7,778 7,672 2,666 Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 11,667 11,509 3,997 Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 4,681 4,618 1,604 Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 4,667 4,603 1,597 Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 3,111 3,069 1,068 Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 3,111 3,069 1,068 Total Non-Controlled Affiliate Debt Investments 34,540 12,000 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-controlled Affiliate Equity — Life Sciences — 2.4% Aulea Medical, Inc. (12)(16) Medical Device Common Stock 660,537 — — Evelo Biosciences, Inc. (5) Biotechnology Common Stock 2,164,502 5,000 8,485 Total Non-Controlled Affiliate Equity 5,000 8,485 Non-controlled Affiliate Warrants — Life Sciences — 0.0% Evelo Biosciences, Inc. (2)(5)(12) Biotechnology Common Stock 23,196 126 — Total Non-Controlled Affiliate Warrants 126 — Total Non-Controlled Affiliate Portfolio Investment Assets $ 39,666 $ 20,485 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Controlled Affiliate Investments — 3.8% Controlled Affiliate Debt Investments — Technology — 1.3% Better Place Forests Co. (12) Consumer-related Technologies Term Loan 12.25 % (11) Prime 3.75 % 12.00 % - 2.78 % August 1, 2029 3,604 3,556 3,006 Term Loan 12.25 % (11) Prime 3.75 % 12.00 % - 2.78 % August 1, 2029 1,719 1,695 1,433 Total Controlled Affiliate Debt Investments 5,251 4,439 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Controlled Affiliate Equity — Technology — 0.7% Better Place Forests Co. (12) Technology Preferred and Common Stock 2,551,596 2,811 2,552 Total Controlled Affiliate Equity 2,811 2,552 Controlled Affiliate Other Investments — Life Sciences — 1.8% HIMV LLC (12)(17) Biotechnology Other Investment 6,154 6,154 Total Controlled Affiliate Equity 6,154 6,154 Total Controlled Affiliate Portfolio Investment Assets $ 14,216 $ 13,145 Total Portfolio Investment Assets — 210.4% $ 754,814 $ 729,053 ( 1 All investments of the Company are in entities which are organized under the laws of the United States and have a principal place of business in the United States, unless otherwise noted. ( 2 Has been pledged as collateral under the revolving credit facility (the “Key Facility”) with KeyBank National Association (“Key”), the Note Funding Agreement (the “NYL Facility”, together with the Key Facility, the "Credit Facilities") with several entities owned or affiliated with New York Life Insurance Company (“NYL Noteholders”), the term debt securitization in connection with which an affiliate of the Company made an offering of $100.0 million in aggregate principal amount of fixed rate asset-backed notes that were issued in conjuncti |
Note 1 - Organization
Note 1 - Organization | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | 1. Horizon Technology Finance Corporation (the “Company”) was organized as a Delaware corporation on March 16, 2010 1940 1986, not On October 28, 2010, Horizon Credit II LLC (“Credit II”) was formed as a Delaware limited liability company on June 28, 2011, not The Company formed Horizon Funding 2019‑1 “2019‑1 May 2, 2019 2019‑1 May 15, 2019 “2019‑1 2019‑1 “2019‑1 2019‑1 2019‑1 2019 Horizon Funding I, LLC (“HFI”) was formed as a Delaware limited liability company on May 9, 2018, not April 21, 2020, The Company formed Horizon Funding 2022‑1 “2022‑1 September 30, 2022 2022‑1 October 18, 2022 ( “2022‑1 2022‑1 “2022‑1 2022‑1 2022‑1 2022 The Company has established wholly owned subsidiaries, which are structured as Delaware limited liability companies, either to hold assets of portfolio companies acquired in connection with a foreclosure or bankruptcy or to hold equity in portfolio companies which the Company may The Company, together with its co-lender to IMV, established HIMV LLC, a Delaware limited liability company to purchase and sell the assets of IMV, a borrower of the Company. HIMV LLC is 70% owned by the Company and 30% owned by the co-lender. The Company’s investment strategy is to maximize the investment portfolio’s return by generating current income from the debt investments the Company makes and capital appreciation from the warrants the Company receives when making such debt investments. The Company has entered into an investment management agreement (the “Investment Management Agreement”) with Horizon Technology Finance Management LLC (the “Advisor”) under which the Advisor manages the day-to-day operations of, and provides investment advisory services to, the Company. |
Note 2 - Basis of Presentation
Note 2 - Basis of Presentation and Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Basis of Presentation and Significant Accounting Policies [Text Block] | Note 2. The consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and pursuant to the requirements for reporting on Form 10‑Q 6 10 X X” 1933, not may December 31, 2022 Principles of consolidation As required under GAAP and Regulation S- X, Assets related to transactions that do not 860, Transfers and Servicing 2019‑1 2022 1 not Use of estimates In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments. Fair value The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three 6. not The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3. See Note 6 Segments The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment. Investments Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a 5 1940 July 29, 2022, Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 not may may September 30, 2023 three December 31, 2022 three three nine September 30, 2023 2022, not The Company has a limited number of debt investments in its portfolio that contain a PIK provision. Contractual PIK interest, which represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on an accrual basis to the extent such amounts are expected to be collected. The Company will generally cease accruing PIK interest if there is insufficient value to support the accrual or management does not three nine September 30, 2023 three nine September 30, 2022 The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not not three September 30, 2023 2022 not nine September 30, 2023 2022 In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments. Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not Debt issuance costs Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 three September 30, 2023 2022 nine September 30, 2023 2022 Income taxes As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% no 946, Financial Services Investment Companies no Depending on the level of taxable income earned in a tax year, the Company may three September 30, 2023 2022, nine September 30, 2023 2022, The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than- not” 740, Income Taxes 946. not not no September 30, 2023 December 31, 2022 2022, 2021 2020 Distributions Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may may The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not may Stockholders Equity On August 2, 2021, “2021 2021 may On September 22, 2023, 2021 “2023 2021 2023 may may 415 During the three September 30, 2023 2023 2021 During the three September 30, 2022 2021 During the nine September 30, 2023 2023 2021 During the nine September 30, 2022, 2021 The Company generally uses net proceeds from these sales to make investments, to pay down liabilities and for general corporate purposes. As of September 30, 2023 2023 On March 14, 2022, On June 2, 2023, Stock Repurchase Program On April 28, 2023, may, not 10b‑18 1934, 1940 June 30, 2024 $5.0 three nine September 30, 2023 2022 not September 30, 2023 Transfers of financial assets Assets related to transactions that do not 860, Transfers and Servicing not Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when ( 1 2 3 not Recently issued accounting pronouncement In June 2022, No. 2022 03, 2022 03” 2022 03 2022 03 December 15, 2023, 2022 03 |
Note 3 - Related Party Transact
Note 3 - Related Party Transactions | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | Note 3. Investment Management Agreement On October 28, 2022, March 7, 2019 ( “2019 May 25, 2023 June 28, 2023, June 30, 2023 ( 2019 2019 June 30, 2023. 2019 The Advisor’s services under the Investment Management Agreement are not not two The base management is calculated at an annual rate of 2.00% of the Company’s gross assets (less cash and cash equivalents) including any assets acquired with the proceeds of leverage; provided, that, to the extent the Company’s gross assets (less cash and cash equivalents) exceed $250 $250 The base management fee payable at September 30, 2023 December 31, 2022 three September 30, 2023 2022 nine September 30, 2023 2022 The incentive fee has two The first zero not no 1.75%, 2.1875% 20.00% not Pre-Incentive Fee Net Investment Income does not may 2.00% three The incentive fee on Pre-Incentive Fee Net Investment Income is subject to a fee cap and deferral mechanism which is determined based upon a look-back period of up to three 11 may 20.00% zero not three The second 20.00% not There was no performance based incentive fee expense for the three September 30, 2023. three September 30, 2022. nine September 30, 2023 2022 three nine September 30, 2023, not may three September 30, 2023 December 31, 2025, March 31, 2026, June 30, 2026, September 30, 2026, not three nine September 30, 2022. September 30, 2023. December 31, 2022 December 31, 2022 one Administration Agreement The Company entered into an administration agreement (the “Administration Agreement”) with the Advisor to provide administrative services to the Company. For providing these services, facilities and personnel, the Company reimburses the Advisor for the Company’s allocable portion of overhead and other expenses incurred by the Advisor in performing its obligations under the Administration Agreement, including rent, the fees and expenses associated with performing compliance functions and the Company’s allocable portion of the costs of compensation and related expenses of the Company’s Chief Financial Officer and Chief Compliance Officer and their respective staffs. The administrative fee expense was $0.4 million for the three September 30, 2023 2022 nine September 30, 2023 2022 |
Note 4 - Investments
Note 4 - Investments | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Investment Holdings [Text Block] | Note 4. The following table shows the Company’s investments as of September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 Cost Fair Value Cost Fair Value (In thousands) Investments Debt $ 716,655 $ 679,838 $ 701,074 $ 686,458 Warrants 15,783 26,189 14,790 29,712 Other 7,354 7,254 1,200 1,300 Equity 15,022 15,772 4,184 2,556 Total investments $ 754,814 $ 729,053 $ 721,248 $ 720,026 The following table shows the Company’s investments by industry sector as of September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 Cost Fair Value Cost Fair Value (In thousands) Life Science Biotechnology $ 158,953 $ 139,935 $ 193,372 $ 195,006 Medical Device 140,172 139,039 132,803 135,960 Technology Communications 21,057 24,317 22,892 26,176 Consumer-Related 110,245 106,559 121,961 114,050 Data Storage 417 1,070 476 1,316 Internet and Media 329 1,615 329 1,159 Networking 6,671 6,558 11,831 11,710 Power Management 1,585 2,901 1,585 2,610 Semiconductors 56 — 56 — Software 164,903 161,258 120,157 118,716 Sustainability Energy Efficiency 111 36 8 27 Other Sustainability 89,395 83,476 84,633 85,524 Healthcare Information and Services Diagnostics 9,971 9,939 9,851 9,858 Other 102 1,379 7,559 3,870 Software 50,847 50,971 13,735 14,044 Total investments $ 754,814 $ 729,053 $ 721,248 $ 720,026 |
Note 5 - Transactions With Affi
Note 5 - Transactions With Affiliated Companies | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Investments in and Advances to Affiliates, Schedule of Investments [Text Block] | Note 5. A non-controlled affiliated company is generally a portfolio company in which the Company owns 5% not 25% Transactions related to investments in non-controlled affiliated companies for the three September 30, 2023 Three months ended September 30, 2023 Fair value at Transfers Net Fair value at Portfolio June 30, Principal in/(out) at Discount unrealized Net realized September 30, Interest Company 2023 Purchases Payments fair value accretion gain/(loss) gain/(loss) 2023 income (In thousands) Aulea Medical, Inc. $ — $ — $ — $ — $ — $ — $ — $ — $ — Cadrenal Therapeutics, Inc. (1) 906 — — (906 ) — — — — — Evelo Biosciences, Inc. — — — 7,665 8 (5,007 ) — 2,666 277 — — — 11,496 11 (7,510 ) — 3,997 415 — — — 4,612 5 (3,013 ) — 1,604 166 — — — 4,598 3 (3,004 ) — 1,597 163 — — — 3,067 4 (2,003 ) — 1,068 114 — — — 3,067 4 (2,003 ) — 1,068 111 — — — 5,000 — 3,485 — 8,485 — Total non-controlled affiliates $ 906 $ — $ — $ 38,599 $ 35 $ (19,055 ) $ — $ 20,485 $ 1,246 ( 1 As of September 30, 2023, no Transactions related to investments in non-controlled affiliated companies for the nine September 30, 2023 Nine months ended September 30, 2023 Fair value at Transfers Net Fair value at Portfolio December 31, Principal in/(out) at Discount unrealized Net realized September 30, Interest Company 2022 Purchases Payments fair value accretion gain/(loss) gain/(loss) 2023 income (In thousands) Aulea Medical, Inc. $ — $ — $ — $ — $ — $ — $ — $ — $ — Cadrenal Therapeutics, Inc. (1) — — — (906 ) — 906 — — — Evelo Biosciences, Inc. — — — 7,665 8 (5,007 ) — 2,666 277 — — — 11,496 11 (7,510 ) — 3,997 415 — — — 4,612 5 (3,013 ) — 1,604 166 — — — 4,598 3 (3,004 ) — 1,597 163 — — — 3,067 4 (2,003 ) — 1,068 114 — — — 3,067 4 (2,003 ) — 1,068 111 — — — 5,000 — 3,485 — 8,485 — Total non-controlled affiliates $ — $ — $ — $ 38,599 $ 35 $ (18,149 ) $ — $ 20,485 $ 1,246 ( 1 As of September 30, 2023, no 5% Transactions related to investments in non-controlled affiliated companies for the three September 30, 2022 Three months ended September 30, 2022 Fair value at Transfers Net Fair value at Portfolio June 30, in/(out) at Discount unrealized Net realized September 30, Interest Company 2022 Purchases Sales fair value Accretion gain/(loss) gain/(loss) 2022 income (In thousands) MVI (ABC) LLC fka StereoVision, Inc. — — (30 ) — — — 30 — — Total non-controlled affiliates $ — $ — $ (30 ) $ — $ — $ — $ 30 $ — $ — Transactions related to investments in non-controlled affiliated companies for the nine September 30, 2022 Nine months ended September 30, 2022 Fair value at Transfers Net Fair value at Portfolio December 31, in/(out) at Discount unrealized Net realized September 30, Interest Company 2021 Purchases Sales fair value Accretion gain/(loss) gain/(loss) 2022 income (In thousands) MVI (ABC) LLC fka StereoVision, Inc. — — (30 ) — — — 30 — — Total non-controlled affiliates $ — $ — $ (30 ) $ — $ — $ — $ 30 $ — $ — A controlled affiliated company is generally a portfolio company in which the Company owns more than 25% Transactions related to investments in controlled affiliated companies for the three September 30, 2023 Three months ended September 30, 2023 Fair value at Transfers Net Fair value at Portfolio June 30, Principal in/(out) at Discount unrealized Net realized September 30, Interest Company 2023 Purchases Payments PIK fair value accretion gain/(loss) gain/(loss) 2023 income (In thousands) Better Place Forests Co. $ — $ 59 $ — $ 105 $ 1,759 $ 2 $ 1,080 $ — $ 3,005 $ 111 — — — 53 844 1 536 — 1,434 55 — — — — 2,061 — — — 2,061 — — 750 — — — — (259 ) — 491 — HIMV LLC — — — — 6,154 — — — 6,154 — Total controlled affiliates $ — $ 809 $ — $ 158 $ 10,818 $ 3 $ 1,357 $ — $ 13,145 $ 166 Transactions related to investments in controlled affiliated companies for the nine September 30, 2023 Nine months ended September 30, 2023 Fair value at Transfers Net Fair value at Portfolio December 31, Principal in/(out) at Discount unrealized Net realized September 30, Interest Company 2022 Purchases Payments PIK fair value accretion gain/(loss) gain/(loss) 2023 income (In thousands) Better Place Forests Co. $ — $ 59 $ — $ 105 $ 1,759 $ 2 $ 1,080 $ — $ 3,005 $ 111 — — — 53 844 1 536 — 1,434 55 — — — — 2,061 — — — 2,061 — — 750 — — — — (259 ) — 491 — HIMV LLC — — — — 6,154 — — — 6,154 — Total controlled affiliates $ — $ 809 $ — $ 158 $ 10,818 $ 3 $ 1,357 $ — $ 13,145 $ 166 Transactions related to investments in controlled affiliated companies for the three September 30, 2022 Three months ended September 30, 2022 Fair value at Transfers Net Fair value at Portfolio June 30, in/(out) at Discount unrealized Net realized September 30, Interest Company 2022 Purchases Sales fair value Accretion gain/(loss) gain/(loss) 2022 income (In thousands) HESP LLC — — (50 ) — — — 50 — — Total controlled affiliates $ — $ — $ (50 ) $ — $ — $ — $ 50 $ — $ — Transactions related to investments in controlled affiliated companies for the nine September 30, 2022 Nine months ended September 30, 2022 Fair value at Transfers Net Fair value at Portfolio December 31, in/(out) at Discount unrealized Net realized September 30, Interest Company 2021 Purchases Sales fair value accretion gain/(loss) gain/(loss) 2022 income (In thousands) HESP LLC — — (300 ) — — 1,450 (1,150 ) — — Total controlled affiliates $ — $ — $ (300 ) $ — $ — $ 1,450 $ (1,150 ) $ — $ — |
Note 6 - Fair Value
Note 6 - Fair Value | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | Note 6. Prior to July 30, 2022, 2a 5 1940 July 29, 2022, twelve The Company uses fair value measurements made by the valuation designee to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in certain instances, there are no not may not Fair value measurements focus on exit prices in an orderly transaction (that is, not may The Company’s fair value measurements are classified into a fair value hierarchy in accordance with ASC Topic 820, Fair Value Measurement three Level 1 Quoted prices in active markets for identical assets and liabilities. Level 2 Observable inputs other than Level 1 not Level 3 Unobservable inputs that are supported by little or no 3 Due to the inherent uncertainty of determining the fair value of investments that do not may may may may Cash and interest receivable: not 1 Money market funds: 2 Debt investments: 3 Under certain circumstances, the Company may Warrant investments: ● Underlying asset value of the issuer is estimated based on information available, including any information regarding the most recent rounds of borrower funding. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement. ● Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant price, is based on indices of publicly traded companies similar in nature to the underlying company issuing the warrant. A total of seven ● The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining life of the warrant. ● Other adjustments, including a marketability discount on private company warrants, are estimated based on management’s judgment about the general industry environment. ● Historical portfolio experience on cancellations and exercises of the Company’s warrants are utilized as the basis for determining the estimated time to exit of the warrants in each financial reporting period. Warrants may Under certain circumstances the Company may may The fair value of the Company’s warrants held in publicly traded companies is determined based on inputs that are readily available in public markets or can be derived from information available in public markets. Therefore, the Company has categorized these warrants as Level 2 3 Equity investments: third may 3 1 Other investments: 3 The following tables detail the investments that are carried at fair value and measured at fair value on a recurring basis as of September 30, 2023 December 31, 2022 September 30, 2023 Level 1 Level 2 Level 3 Total (In thousands) Debt investments $ — $ — $ 679,838 $ 679,838 Warrant investments — 956 25,233 26,189 Other investments — — 7,254 7,254 Equity investments 8,962 — 6,810 15,772 Total investments $ 8,962 $ 956 $ 719,135 $ 729,053 December 31, 2022 Level 1 Level 2 Level 3 Total (In thousands) Debt investments $ — $ — $ 686,458 $ 686,458 Warrant investments — 3,567 26,145 29,712 Other investments — — 1,300 1,300 Equity investments 140 — 2,416 2,556 Total investments $ 140 $ 3,567 $ 716,319 $ 720,026 The following tables provide a summary of quantitative information about the Company’s Level 3 September 30, 2023 December 31, 2022 may The following table is not 3 September 30, 2023 September 30, 2023 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average(1) (Dollars in thousands, except per share data) Debt investments $ 607,193 Discounted Expected Future Cash Flows Hypothetical Market Yield 11% – 20% 14 % 72,645 Multiple Probability Weighted Cash Flow Model Probability Weighting 20% - 100% 50 % Warrant investments 25,171 Black-Scholes Valuation Model Price Per Share 0.000 –1,89999 $ 58.11 Average Industry Volatility 28% 28 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 5 3 62 Expected Proceeds Price Per Share $0.25 $ 0.25 Other investments 7,254 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 30% – 100% 83 % Equity investments 6,810 Last Equity Financing Price Per Share 0.03 215.03 $ 18.30 Total Level 3 investments $ 719,135 ( 1 Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) ( 1 2 The following table is not 3 December 31, 2022 December 31, 2022 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average(1) (Dollars in thousands, except per share data) Debt investments $ 669,617 Discounted Expected Future Cash Flows Hypothetical Market Yield 3% – 22% 14 % 16,545 Multiple Probability Weighted Cash Flow Model Probability Weighting 10% - 75% 31 % 296 Convertible Note Analysis Price Per Share $168.93 $ 168.93 Warrant investments 26,145 Black-Scholes Valuation Model Price Per Share 0.000 –1.8989 $ 58.52 Average Industry Volatility 28% 28 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 5 3 Other investments 1,300 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 100% 100 % Equity investments 2,416 Last Equity Financing Price Per Share $1.00– $215.03 $ 26.93 Total Level 3 investments $ 716,319 ( 1 Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) ( 1 2 Borrowings: 2 2026 7 September 30, 2023 2026 1 2027 7 September 30, 2023 2027 1 September 30, 2023 2019 3 September 30, 2023 2022 3 not Off-balance-sheet instruments: 3 The following table shows a reconciliation of the beginning and ending balances for Level 3 three September 30, 2023 Three months ended September 30, 2023 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 683,309 $ 24,376 $ 4,259 $ 1,300 $ 713,244 Purchase of investments 66,185 — 750 — 66,935 Warrants received and classified as Level 3 — 1,294 — — 1,294 Principal payments received on investments (25,726 ) — — — (25,726 ) Payment-in-kind interest on investments 3,934 — — — 3,934 Proceeds from sale of investments (2,528 ) (23 ) (6 ) — (2,557 ) Net realized (loss) gain on investments (11,440 ) (118 ) 6 — (11,552 ) Unrealized depreciation included in earnings (18,877 ) (296 ) (1,349 ) (200 ) (20,722 ) Transfer out of Level 3 (5,000 ) — — — (5,000 ) Transfer out of debt investments (9,304 ) — 3,150 6,154 — Other (715 ) — — — (715 ) Level 3 assets, end of period $ 679,838 $ 25,233 $ 6,810 $ 7,254 $ 719,135 During the three September 30, 2023 one 3. one 3 one 1 The following table shows a reconciliation of the beginning and ending balances for Level 3 three September 30, 2022 Three months ended September 30, 2022 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 551,560 $ 25,167 $ 453 $ 200 $ 577,380 Purchase of investments 94,627 — — — 94,627 Warrants received and classified as Level 3 — 964 — — 964 Principal payments received on investments (26,929 ) — — (31 ) (26,960 ) Proceeds from sale of investments (6,088 ) (38 ) — — (6,126 ) Net realized (loss) gain on investments (8,492 ) 266 — 31 (8,195 ) Unrealized appreciation (depreciation) included in earnings 8,095 (3,348 ) (420 ) (100 ) 4,227 Transfer out of Level 3 — (1,117 ) — — (1,117 ) Transfer out of debt investments (3,200 ) — 2,000 1,200 — Other (541 ) — — — (541 ) Level 3 assets, end of period $ 609,032 $ 21,894 $ 2,033 $ 1,300 $ 634,259 During the three September 30, 2022 two 3 . 3 one 2 3 one 1 The following table shows a reconciliation of the beginning and ending balances for Level 3 nine September 30, 2023 Nine months ended September 30, 2023 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 686,458 $ 26,145 $ 2,416 $ 1,300 $ 716,319 Purchase of investments 153,728 — 760 — 154,488 Warrants and equity received and classified as Level 3 — 1,950 89 — 2,039 Principal payments received on investments (90,222 ) — — — (90,222 ) Payment-in-kind interest on investments 6,088 — — — 6,088 Proceeds from sale of investments (9,564 ) (1,493 ) (6 ) — (11,063 ) Net realized (loss) gain on investments (29,105 ) 1,028 (121 ) — (28,198 ) Unrealized depreciation included in earnings (21,325 ) (2,392 ) (2,467 ) (200 ) (26,384 ) Transfer out of Level 3 (5,000 ) — (111 ) — (5,111 ) Transfer out of debt investments (12,399 ) (5 ) 6,250 6,154 — Other 1,179 — — — 1,179 Level 3 assets, end of period $ 679,838 $ 25,233 $ 6,810 $ 7,254 $ 719,135 During the nine September 30, 2023 two 3. 3 one 1 one 1 The change in unrealized depreciation included in the consolidated statement of operations attributable to Level 3 September 30, 2023 The following table shows a reconciliation of the beginning and ending balances for Level 3 nine September 30, 2022 Nine months ended September 30, 2022 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 437,317 $ 19,837 $ 203 $ 200 $ 457,557 Purchase of investments 348,097 — 250 — 348,347 Warrants received and classified as Level 3 — 2,441 — — 2,441 Principal payments received on investments (114,120 ) — — (313 ) (114,433 ) Proceeds from sale of investments (49,088 ) (464 ) — — (49,552 ) Net realized (loss) gain on investments (8,492 ) 535 — (1,137 ) (9,094 ) Unrealized appreciation (depreciation) included in earnings 1,128 662 (420 ) 1,350 2,720 Transfer out of Level 3 — (1,117 ) — — (1,117 ) Transfer out of debt investments (3,200 ) — 2,000 1,200 — Other (2,610 ) — — — (2,610 ) Level 3 assets, end of period $ 609,032 $ 21,894 $ 2,033 $ 1,300 $ 634,259 During the nine September 30, 2022 two 3 . 3 one 2 3 one 1 The change in unrealized appreciation included in the consolidated statement of operations attributable to Level 3 September 30, 2022 The Company discloses fair value information about financial instruments, whether or not not The fair value amounts have been measured as of the reporting date and have not may As of September 30, 2023 December 31, 2022 Market risk The Company assumes interest rate risk (the risk that general interest rate levels will change) as a result of its normal operations. As a result, the fair values of the Company’s financial instruments will change when interest rate levels change, and that change may |
Note 7 - Borrowings
Note 7 - Borrowings | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | Note 7. The following table shows the Company’s borrowings as of September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 Total Balance Unused Total Balance Unused Commitment Outstanding Commitment Commitment Outstanding Commitment (In thousands) Key Facility $ 150,000 $ 25,000 $ 125,000 $ 125,000 $ 5,000 $ 120,000 NYL Facility 250,000 181,000 69,000 200,000 176,750 23,250 2019 Asset-Backed Notes 18,696 18,696 — 42,573 42,573 — 2022 Asset-Backed Notes 100,000 100,000 — 100,000 100,000 — 2027 Notes 57,500 57,500 — 57,500 57,500 — 2026 Notes 57,500 57,500 — 57,500 57,500 — Total before debt issuance costs 633,696 439,696 194,000 582,573 439,323 143,250 Unamortized debt issuance costs attributable to term borrowings — (4,196 ) — — (5,245 ) — Total borrowings outstanding, net $ 633,696 $ 435,500 $ 194,000 $ 582,573 $ 434,078 $ 143,250 As of September 30, 2023 1940 September 30, 2023 Credit Facilities Key Facility The Company entered into the Key Facility with Key effective November 4, 2013. June 29, 2023, may June 22, 2024 June 22, 2026. September 30, 2023 December 31, 2022 three September 30, 2023 2022 nine September 30, 2023 2022 September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 NYL Facility On April 21, 2020, June 1, 2018, three On February 25, 2022, three On May 24, 2023, June 2024 June 2029. May 24, 2023, 4.60% 3.50%, There were $181.0 million and $176.8 million in advances made by the NYL Noteholders as of September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 Under the terms of the NYL Facility, the Company is required to maintain a reserve cash balance, which may September 30, 2023 December 31, 2022 Securitizations 2019 On August 13, 2019, 2019 2019 no August 13, 2019. The 2019 2019‑1 August 13, 2019, 2019 2019 July 15, 2021 September 15, 2027. As of September 30, 2023 December 31, 2022 2019 Under the terms of the 2019 2019 may 2019 September 30, 2023 December 31, 2022 2022 On November 9, 2022, 2022 2022 no November 9, 2022. The 2022 2022‑1 November 9, 2022, 2022 2022 November 15, 2024 November 15, 2030. As of September 30, 2023 December 31, 2022 2022 $100.0 Under the terms of the 2022 2022 may 2022 September 30, 2023 December 31, 2022 Unsecured Notes 2026 On March 30, 2021, 2026 “2026 2026 2026 March 30, 2026 may March 30, 2023 2026 4.875% March 30, June 30, September 30 December 30 2026 2026 September 30, 2023 2026 2026 2027 On June 15, 2022, 2027 July 11, 2022, 30 “2027 2027 June 15, 2027 may June 15, 2024 2027 6.25% March 30, June 30, September 30 December 30 September 30, 2022. 2027 2027 September 30, 2023 2027 2027 |
Note 8 - Financial Instruments
Note 8 - Financial Instruments With Off-balance-sheet Risk | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Financial Instruments Disclosure [Text Block] | Note 8. In the normal course of business, the Company is party to financial instruments with off-balance-sheet risk to meet the financing needs of its borrowers. These financial instruments include commitments to extend credit and involve, to varying degrees, elements of credit risk in excess of the amount recognized in the consolidated statement of assets and liabilities. The Company attempts to limit its credit risk by conducting extensive due diligence and obtaining collateral where appropriate. The balance of unfunded commitments to extend credit was $181.8 million and $190.0 million as of September 30, 2023 December 31, 2022 may not The following table provides the Company’s unfunded commitments by portfolio company as of September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 Fair Value of Fair Value of Unfunded Unfunded Principal Commitment Principal Commitment Balance Liability Balance Liability (In thousands) (In thousands) BrightInsight, Inc. $ 18,250 $ 241 $ 21,000 $ 278 Britecore Holdings, Inc. 5,000 72 5,000 66 Candesant Biomedical Corporation 10,000 151 — — Castle Creek Biosciences 4,000 72 4,000 72 Divergent Technologies, Inc. 11,250 118 22,500 236 Elligo Healthcare Research, Inc. 15,000 194 — — Engage3, LLC — — 8,000 40 Groundspeed Analytics, Inc. — — 15,000 150 Hound Labs, Inc. — — 7,500 88 KSQ Therapeutics, Inc. — — 10,000 100 Lytics, Inc. 4,000 52 5,000 65 Mirantis, Inc. 15,000 136 — — Native Microbials, Inc. — — 7,500 72 Noodle Partners, Inc. 5,000 61 — — Optoro, Inc. 6,250 — 15,000 38 PDS Biotechnology Corporation — — 10,000 158 Robin Healthcare, Inc. — — 10,000 100 SafelyYou, Inc. 20,000 270 — — Scientia Vascular, Inc. 5,000 55 10,000 110 Slingshot Aerospace, Inc. — — 5,000 64 Sonex Health, Inc. 15,000 176 — — Supply Network Visibility Holdings, LLC 10,000 35 — — Swift Health Systems Inc. 11,500 — 25,500 105 Tallac Therapeutics, Inc. 10,000 229 — — Temperpack Technologies, Inc. 6,500 14 9,000 19 Viken Detection Corporation 10,000 160 — — Total $ 181,750 $ 2,036 $ 190,000 $ 1,761 The table above also provides the fair value of the Company’s unfunded commitment liability as of September 30, 2023 December 31, 2022, |
Note 9 - Concentrations of Cred
Note 9 - Concentrations of Credit Risk | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Concentration Risk Disclosure [Text Block] | Note 9. The Company’s debt investments consist primarily of loans to development-stage companies at various stages of development in the technology, life science, healthcare information and services and sustainability industries. Many of these companies may may The Company’s largest debt investments may five September 30, 2023 December 31, 2022 five September 30, 2023 December 31, 2022, No 10% September 30, 2023 December 31, 2022 five three September 30, 2023 2022 five three September 30, 2023 2022, five nine September 30, 2023 2022 five nine September 30, 2023 2022, |
Note 10 - Distributions
Note 10 - Distributions | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Equity [Text Block] | Note 10. The Company’s distributions are recorded on the declaration date. The following table summarizes the Company’s distribution activity for the nine September 30, 2023 December 31, 2022 DRIP DRIP Date Amount Cash Shares Share Declared Record Date Payment Date Per Share Distribution Issued Value (In thousands, except share and per share data) Nine Months Ended September 30, 2023 7/28/2023 11/17/23 12/15/23 $ 0.11 $ — — $ — 7/28/2023 10/18/23 11/15/23 0.11 — — — 7/28/2023 9/19/23 10/16/23 0.11 3,445 15,067 184 4/28/2023 8/17/23 9/15/23 0.11 3,458 8,665 106 4/28/2023 7/18/23 8/15/23 0.11 3,427 8,307 105 4/28/2023 6/16/23 7/14/23 0.11 3,434 7,424 96 2/23/2023 5/18/23 6/14/23 0.11 3,087 7,128 86 2/23/2023 4/18/23 5/16/23 0.11 3,068 6,705 84 2/23/2023 3/17/23 4/14/23 0.11 3,035 6,894 81 $ 0.99 $ 22,954 60,190 $ 742 Year Ended December 31, 2022 10/28/2022 2/17/23 3/15/23 $ 0.11 $ 3,040 6,764 $ 75 10/28/2022 1/18/23 2/15/23 0.11 3,021 5,754 74 10/28/2022 12/19/22 1/13/23 0.11 2,978 5,618 69 10/28/2022 11/17/22 12/15/22 0.05 1,319 2,171 27 7/29/2022 11/17/22 12/15/22 0.10 2,638 4,341 57 7/29/2022 10/18/22 11/15/22 0.10 2,580 4,621 60 7/29/2022 9/19/22 10/14/22 0.10 2,558 7,703 81 4/29/2022 8/18/22 9/15/22 0.10 2,528 4,925 60 4/29/2022 7/19/22 8/16/22 0.10 2,484 3,939 55 4/29/2022 6/17/22 7/15/22 0.10 2,434 4,286 51 2/25/2022 5/18/22 6/15/22 0.10 2,378 4,428 50 2/25/2022 4/19/22 5/16/22 0.10 2,349 4,088 49 2/25/2022 3/18/22 4/14/22 0.10 2,352 3,221 46 $ 1.28 $ 32,659 61,859 $ 754 On October 27, 2023, Monthly distributions Ex-Dividend Date Record Date Payment Date Distributions Declared February 15, 2024 February 16, 2024 March 15, 2024 $ 0.11 January 17, 2024 January 18, 2024 February 14, 2024 $ 0.11 December 18, 2023 December 19, 2023 January 16, 2024 $ 0.11 Special distribution Ex-Dividend Date Record Date Payment Date Distributions Declared November 16, 2023 November 17, 2023 December 15, 2023 $ 0.05 After paying distributions of $0.33 per share and earning net investment income of $0.53 per share for the quarter, the Company’s undistributed spillover income as of September 30, 2023 not |
Note 11 - Financial Highlights
Note 11 - Financial Highlights | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Investment Company, Financial Highlights [Text Block] | Note 11. The following table shows financial highlights for the Company: Nine months ended September 30, 2023 2022 (In thousands, except share and per share data) Per share data: Net asset value at beginning of period $ 11.47 $ 11.56 Net investment income 1.54 1.06 Realized loss (0.95 ) (0.40 ) Unrealized (depreciation) appreciation on investments (0.81 ) 0.05 Net increase in net assets resulting from operations (0.22 ) 0.71 Distributions declared (1) (0.99 ) (0.90 ) From net investment income (0.99 ) (0.90 ) From net realized gain on investments — — Return of capital — — Other (2) 0.15 0.29 Net asset value at end of period $ 10.41 $ 11.66 Per share market value, beginning of period $ 11.60 $ 15.92 Per share market value, end of period $ 11.88 $ 10.01 Total return based on a market value (3) 10.9 % (31.5 )% Shares outstanding at end of period 33,306,958 26,393,773 Ratios to average net assets: Expenses without incentive value (4) 14.0 % 11.4 % Incentive fees (4) 1.2 % 3.0 % Net expenses (4) 15.2 % 14.4 % Net investment income with incentive fees (4) 18.5 % 12.1 % Net assets at the end of the period $ 346,575 $ 307,687 Average net asset value $ 335,531 $ 280,904 Average debt per share $ 14.29 $ 13.32 Portfolio turnover ratio 10.0 % (5) 14.9 % (5) ( 1 Distributions are determined based on taxable income calculated in accordance with income tax regulations, which may ( 2 Includes the impact of the different share amounts as a result of calculating per share data based on the weighted average basic shares outstanding during the period and certain per share data based on the shares outstanding as of a period end or transaction date. The issuance of common stock on a per share basis reflects the incremental net asset value changes as a result of the issuance of common stock in the Company’s continuous public offering and pursuant to the Company’s distribution reinvestment plan. The issuance of common stock at an offering price, net of sales commissions and dealer manager fees, that is greater than the net asset value per share results in an increase in net asset value per share. ( 3 The total return equals the change in the ending market value over the beginning of period price per share plus distributions paid per share during the period, divided by the beginning price. ( 4 Annualized. ( 5 Calculated by dividing the lesser of purchases or the sum of ( 1 2 |
Note 12 - Subsequent Events
Note 12 - Subsequent Events | 9 Months Ended |
Sep. 30, 2023 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | Note 12. On October 27, 2023 , $11.0 December 15, 2022, As of October 30, 2023, September 30, 2023 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2023 | |
Accounting Policies [Abstract] | |
Consolidation, Policy [Policy Text Block] | Principles of consolidation As required under GAAP and Regulation S- X, Assets related to transactions that do not 860, Transfers and Servicing 2019‑1 2022 1 not |
Use of Estimates, Policy [Policy Text Block] | Use of estimates In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments. |
Fair Value Measurement, Policy [Policy Text Block] | Fair value The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three 6. not The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3. See Note 6 |
Segment Reporting, Policy [Policy Text Block] | Segments The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment. |
Investment, Policy [Policy Text Block] | Investments Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a 5 1940 July 29, 2022, Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 not may may September 30, 2023 three December 31, 2022 three three nine September 30, 2023 2022, not The Company has a limited number of debt investments in its portfolio that contain a PIK provision. Contractual PIK interest, which represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on an accrual basis to the extent such amounts are expected to be collected. The Company will generally cease accruing PIK interest if there is insufficient value to support the accrual or management does not three nine September 30, 2023 three nine September 30, 2022 The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not not three September 30, 2023 2022 not nine September 30, 2023 2022 In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments. Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not |
Debt, Policy [Policy Text Block] | Debt issuance costs Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of September 30, 2023 December 31, 2022 September 30, 2023 December 31, 2022 three September 30, 2023 2022 nine September 30, 2023 2022 |
Income Tax, Policy [Policy Text Block] | Income taxes As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% no 946, Financial Services Investment Companies no Depending on the level of taxable income earned in a tax year, the Company may three September 30, 2023 2022, nine September 30, 2023 2022, The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than- not” 740, Income Taxes 946. not not no September 30, 2023 December 31, 2022 2022, 2021 2020 |
Distributions [Policy Text Block] | Distributions Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may may The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not may |
Stockholders' Equity, Policy [Policy Text Block] | Stockholders Equity On August 2, 2021, “2021 2021 may On September 22, 2023, 2021 “2023 2021 2023 may may 415 During the three September 30, 2023 2023 2021 During the three September 30, 2022 2021 During the nine September 30, 2023 2023 2021 During the nine September 30, 2022, 2021 The Company generally uses net proceeds from these sales to make investments, to pay down liabilities and for general corporate purposes. As of September 30, 2023 2023 On March 14, 2022, On June 2, 2023, |
Stock Repurchase Program [Policy Text Block] | Stock Repurchase Program On April 28, 2023, may, not 10b‑18 1934, 1940 June 30, 2024 $5.0 three nine September 30, 2023 2022 not September 30, 2023 |
Transfers and Servicing of Financial Assets, Policy [Policy Text Block] | Transfers of financial assets Assets related to transactions that do not 860, Transfers and Servicing not Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when ( 1 2 3 not |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently issued accounting pronouncement In June 2022, No. 2022 03, 2022 03” 2022 03 2022 03 December 15, 2023, 2022 03 |
Consolidated Schedule of Inve_2
Consolidated Schedule of Investments (Unaudited) (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Notes Tables | |
Investment [Table Text Block] | Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Investments — 200.7% Non-Affiliate Debt Investments — 191.4% Non-Affiliate Debt Investments — Life Science — 69.7% Castle Creek Biosciences, Inc. (2)(12) Biotechnology Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,903 4,903 Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,975 4,975 Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,985 2,985 Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,975 4,975 Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,975 4,975 Term Loan 13.25 % Prime 4.75 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,985 2,985 Emalex Biosciences, Inc. (2)(12) Biotechnology Term Loan 13.22 % Prime 4.72 % 9.75 % - 5.00 % June 1, 2024 1,979 1,971 1,971 Term Loan 13.22 % Prime 4.72 % 9.75 % - 5.00 % June 1, 2024 1,979 1,972 1,972 Term Loan 13.22 % Prime 4.72 % 9.75 % - 5.00 % November 1, 2025 5,000 4,943 4,943 Term Loan 13.22 % Prime 4.72 % 9.75 % - 5.00 % May 1, 2026 5,000 4,939 4,939 Greenlight Biosciences, Inc. (2)(12) Biotechnology Term Loan 14.25 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 3,500 3,399 3,365 Term Loan 14.25 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 1,750 1,699 1,684 KSQ Therapeutics, Inc. (2)(12) Biotechnology Term Loan 13.25 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,193 6,193 Term Loan 13.25 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,193 6,193 Native Microbials, Inc (2)(12) Biotechnology Term Loan 13.75 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 3,750 3,716 3,716 Term Loan 13.75 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 2,500 2,478 2,478 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Term Loan 14.25 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 10,000 9,898 9,898 Term Loan 14.25 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,712 3,712 Term Loan 14.25 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,712 3,712 Provivi, Inc. (2)(12) Biotechnology Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 4,667 4,594 4,594 Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 4,667 4,594 4,594 Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,286 2,286 Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,286 2,286 Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,282 2,282 Term Loan 13.86 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,282 2,282 Stealth Biotherapeutics Inc. (2)(12) Biotechnology Term Loan 14.00 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 4,500 4,434 4,434 Term Loan 14.00 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 2,250 2,217 2,217 Tallac Therapeutics, Inc. (2)(12) Biotechnology Term Loan 12.75 % Prime 4.25 % 12.25 % - 4.00 % August 1, 2027 2,500 2,226 2,226 Term Loan 12.75 % Prime 4.25 % 12.25 % - 4.00 % August 1, 2027 2,500 2,455 2,455 Aerobiotix, LLC (2)(12) Medical Device Term Loan 9.00 % Fixed - - - 18.00 % April 1, 2028 2,500 2,466 2,344 Term Loan 9.00 % Fixed - - - 18.00 % April 1, 2028 2,500 2,466 2,344 Term Loan 9.00 % Fixed - - - 18.00 % June 30, 2024 200 200 190 Candesant Biomedical, Inc. (2)(12) Medical Device Term Loan 12.00 % Prime 3.50 % 11.50 % - 5.00 % September 1, 2027 5,000 4,751 4,751 Term Loan 12.00 % Prime 3.50 % 11.50 % - 5.00 % September 1, 2027 2,500 2,451 2,451 Term Loan 12.00 % Prime 3.50 % 11.50 % - 5.00 % September 1, 2027 2,500 2,451 2,451 Ceribell, Inc. (2)(12) Medical Device Term Loan 12.00 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 5,000 4,985 4,985 Term Loan 12.00 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 5,000 4,985 4,985 Term Loan 12.00 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 2,500 2,488 2,488 Term Loan 12.00 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 2,500 2,488 2,488 Cognoa, Inc. (2)(12) Medical Device Term Loan 14.00 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 4,722 4,678 4,678 Term Loan 14.00 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 2,361 2,339 2,339 Conventus Orthopaedics, Inc. (2)(12) Medical Device Term Loan 13.32 % Prime 4.82 % 9.25 % - 10.36 % July 1, 2025 3,960 3,916 3,916 Term Loan 13.32 % Prime 4.82 % 9.25 % - 10.36 % July 1, 2025 3,960 3,916 3,916 CSA Medical, Inc. (2)(12) Medical Device Term Loan 13.59 % Prime 5.09 % 10.00 % - 5.00 % January 1, 2024 750 739 739 Term Loan 13.59 % Prime 5.09 % 10.00 % - 5.00 % January 1, 2024 50 49 49 Term Loan 13.59 % Prime 5.09 % 10.00 % - 5.00 % March 1, 2024 1,067 1,052 1,052 InfoBionic, Inc. (2)(12) Medical Device Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % October 1, 2024 2,771 2,733 2,733 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % June 1, 2025 1,000 982 982 Magnolia Medical Technologies, Inc. (2)(12) Medical Device Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,960 4,960 Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,960 4,960 Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,956 4,956 Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,956 4,956 Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % January 1, 2027 5,000 4,934 4,934 Term Loan 13.50 % Prime 5.00 % 9.75 % - 4.00 % January 1, 2027 5,000 4,934 4,934 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Robin Healthcare, Inc. (2)(12)(13) Medical Device Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % November 1, 2026 3,500 3,468 1,749 Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % November 1, 2026 3,500 3,468 1,749 Scientia Vascular, Inc. (2)(12) Medical Device Term Loan 13.25 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,663 3,663 Term Loan 13.25 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,718 3,718 Term Loan 13.75 % Prime 5.25 % 9.00 % - 5.00 % March 1, 2027 5,000 4,938 4,938 Sonex Health, Inc. (2)(12) Medical Device Term Loan 12.00 % Prime 3.50 % 11.75 % - 8.00 % September 1, 2027 2,500 2,295 2,295 Term Loan 12.00 % Prime 3.50 % 11.75 % - 8.00 % September 1, 2027 2,500 2,471 2,471 Term Loan 12.00 % Prime 3.50 % 11.75 % - 8.00 % September 1, 2027 5,000 4,943 4,943 Term Loan 12.00 % Prime 3.50 % 11.75 % - 8.00 % September 1, 2027 5,000 4,943 4,943 Spineology, Inc. (2)(12) Medical Device Term Loan 15.50 % Prime 7.00 % 10.25 % - 1.00 % October 1, 2025 5,000 4,975 4,975 Term Loan 15.50 % Prime 7.00 % 10.25 % - 1.00 % April 1, 2026 2,500 2,487 2,487 Swift Health Systems Inc. (2)(12) Medical Device Term Loan 13.75 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,464 3,464 Term Loan 13.75 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,464 3,464 Term Loan 13.75 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,453 3,453 Term Loan 13.75 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,453 3,453 Total Non-Affiliate Debt Investments — Life Science 245,317 241,576 Non-Affiliate Debt Investments — Sustainability — 23.8% New Aerofarms, Inc. assignee of Aerofarms, Inc. (2)(12)(15) Other Sustainability Term Loan 15.25 % Prime 6.75 % 10.00 % - 4.33 % December 1, 2026 3,750 3,675 3,675 Term Loan 15.25 % Prime 6.75 % 10.00 % - 4.33 % December 1, 2026 3,750 3,675 3,675 Nexii Building Solutions, Inc. (2)(12)(14) Other Sustainability Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 8,102 8,009 6,754 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 8,102 8,009 6,754 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 1, 2025 8,102 8,009 6,754 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % July 1, 2026 5,402 5,332 4,496 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % July 1, 2026 5,402 5,332 4,496 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 30, 2023 707 707 596 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 30, 2023 564 564 475 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 30, 2023 281 281 237 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 30, 2023 279 279 235 Term Loan 15.50 % (11) Prime 7.00 % 10.25 % - 2.50 % September 30, 2023 167 167 141 Soli Organic, Inc. (2)(12) Other Sustainability Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 5,000 4,951 4,951 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 2,500 2,475 2,475 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 5,000 4,948 4,948 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 2,500 2,474 2,474 Term Loan 14.00 % Prime 5.50 % 11.75 % - 2.75 % December 1, 2026 5,000 4,926 4,926 Term Loan 14.00 % Prime 5.50 % 11.75 % - 2.75 % December 1, 2026 2,500 2,463 2,463 Temperpack Technologies, Inc. (2)(12) Other Sustainability Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.50 % April 1, 2028 3,750 3,678 3,678 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.50 % April 1, 2028 3,750 3,692 3,692 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.50 % April 1, 2028 7,500 7,374 7,374 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.50 % April 1, 2028 3,750 3,687 3,687 Term Loan 15.25 % Prime 6.75 % 10.00 % - 2.50 % April 1, 2028 3,750 3,687 3,687 Total Non-Affiliate Debt Investments — Sustainability 88,394 82,643 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Debt Investments — Technology — 80.5% Axiom Space, Inc. (2)(12) Communications Term Loan 14.50 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 6,875 6,840 6,840 Term Loan 14.50 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 6,875 6,840 6,840 Term Loan 14.50 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 6,875 6,840 6,840 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Term Loan 15.75 % Prime 7.25 % 10.50 % - 3.00 % May 1, 2026 3,500 3,470 3,470 Clara Foods Co. (2)(12) Consumer-related Technologies Term Loan 14.25 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 1,833 1,821 1,821 Term Loan 14.25 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 1,833 1,821 1,821 Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,605 3,605 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,241 1,241 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,723 3,723 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,241 1,241 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,723 3,723 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,241 1,241 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % January 1, 2028 3,750 3,709 3,709 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % January 1, 2028 3,750 3,703 3,703 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % April 1, 2028 3,750 3,709 3,709 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2028 3,750 3,705 3,705 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2028 3,750 3,705 3,705 Havenly, Inc. (2)(12) Consumer-related Technologies Term Loan 13.50 % Prime 5.00 % 5.00 % - 4.00 % March 1, 2027 2,000 1,335 1,335 Term Loan 13.50 % Prime 5.00 % 5.00 % - 4.00 % March 1, 2027 3,000 2,003 2,003 Term Loan 12.00 % Prime 3.50 % 10.50 % - 7.78 % February 1, 2028 2,813 2,813 2,813 Term Loan 12.00 % Prime 3.50 % 10.50 % - 7.78 % February 1, 2028 2,813 2,813 2,813 Lyrical Foods, Inc. (2)(12) Consumer-related Technologies Term Loan 11.00 % Prime 2.50 % 8.00 % - - September 1, 2027 2,598 2,589 2,351 MyForest Foods Co. (2)(12) Consumer-related Technologies Term Loan 15.25 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 4,000 3,975 3,975 Term Loan 15.25 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 2,000 1,987 1,987 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 5,547 5,505 4,894 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,219 2,204 1,960 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,774 2,759 2,453 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 3,328 3,310 2,943 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,774 2,747 2,443 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,774 2,747 2,443 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 5,547 5,493 4,884 Term Loan 14.25 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,774 2,746 2,441 Optoro, Inc. (2)(12) Consumer-related Technologies Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % August 1, 2027 2,500 2,408 2,408 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % July 1, 2028 1,875 1,783 1,783 Primary Kids, Inc. (2)(12) Consumer-related Technologies Term Loan 15.75 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 1,700 1,683 1,683 Term Loan 15.75 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 1,700 1,683 1,683 Term Loan 15.75 % Prime 7.25 % 10.50 % - 3.00 % September 1, 2025 2,300 2,277 2,277 Unagi, Inc. (2)(12)(13) Consumer-related Technologies Term Loan 16.25 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 1,108 1,086 872 Term Loan 16.25 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 554 543 436 Term Loan 16.25 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 554 543 436 Liqid, Inc. (2)(12) Networking Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,833 1,807 1,807 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,833 1,807 1,807 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 917 903 903 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 917 903 903 Term Loan 14.75 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 917 887 887 BriteCore Holdings, Inc. (2)(12) Software Term Loan 14.00 % Prime 5.50 % 14.00 % - 3.00 % October 1, 2028 5,000 4,857 4,857 Term Loan 14.00 % Prime 5.50 % 14.00 % - 3.00 % October 1, 2028 2,500 2,464 2,464 Term Loan 14.00 % Prime 5.50 % 14.00 % - 3.00 % October 1, 2028 2,500 2,464 2,464 Term Loan 14.00 % Prime 5.50 % 14.00 % - 3.00 % October 1, 2028 2,500 2,464 2,464 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Dropoff, Inc. (2)(12) Software Term Loan 15.00 % (11) Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,550 6,432 6,377 Term Loan 15.00 % (11) Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,046 5,937 5,886 Term Loan 15.00 % (11) Prime 6.50 % 9.75 % - 3.50 % August 1, 2026 2,519 2,472 2,451 Engage3, LLC (2)(12) Software Term Loan 14.75 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,726 3,726 Term Loan 14.75 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,726 3,726 Kodiak Robotics, Inc. (2)(12) Software Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,877 9,877 Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,877 9,877 Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,939 4,939 Term Loan 14.00 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,939 4,939 Lemongrass Holdings, Inc. (2)(12) Software Term Loan 15.00 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 5,000 4,965 4,965 Term Loan 15.00 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 2,500 2,483 2,483 Lytics, Inc. (2)(12) Software Term Loan 14.50 % Prime 6.00 % 14.25 % - 4.00 % November 1, 2026 2,500 2,418 2,350 Term Loan 14.50 % Prime 6.00 % 14.25 % - 4.00 % December 1, 2026 1,250 1,236 1,201 Term Loan 14.50 % Prime 6.00 % 14.25 % - 4.00 % April 1, 2027 1,000 993 966 Mirantis, Inc. (2)(12) Software Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2028 5,000 4,774 4,774 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2028 5,000 4,910 4,910 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2028 5,000 4,910 4,910 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2028 5,000 4,910 4,910 Noodle Partners, Inc. (2)(12) Software Term Loan 13.50 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 10,000 9,814 9,814 Term Loan 13.50 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 5,000 4,938 4,938 Term Loan 13.50 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 5,000 4,939 4,939 Reputation Institute, Inc. (2)(12) Software Term Loan 15.75 % Prime 7.25 % 10.50 % - 3.00 % August 1, 2025 3,833 3,785 3,785 Slingshot Aerospace, Inc. (2)(12) Software Term Loan 14.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,952 4,952 Term Loan 14.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,952 4,952 Term Loan 14.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,952 4,952 Term Loan 14.25 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,952 4,952 Supply Network Visibility Holdings LLC (2)(12) Software Term Loan 12.75 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 2,500 2,457 2,457 Term Loan 12.75 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 3,500 3,489 3,489 Term Loan 12.75 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 2,500 2,492 2,492 Term Loan 12.75 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 1,500 1,495 1,495 Viken Detection Corporation (2)(12) Software Term Loan 12.50 % Prime 4.00 % 11.75 % - 3.50 % June 1, 2027 5,000 4,768 4,768 Term Loan 12.50 % Prime 4.00 % 11.75 % - 3.50 % June 1, 2027 2,500 2,464 2,464 Term Loan 12.50 % Prime 4.00 % 11.75 % - 3.50 % June 1, 2027 2,500 2,464 2,464 Total Non-Affiliate Debt Investments — Technology 282,962 278,989 Non-Affiliate Debt Investments — Healthcare information and services — 17.4% Hound Labs inc. (2) (12) Diagnostics Term Loan 14.50 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,481 2,481 Term Loan 14.50 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,481 2,481 Term Loan 14.50 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 5,000 4,962 4,962 BrightInsight, Inc. (2)(12) Software Term Loan 14.00 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 7,000 6,677 6,677 Term Loan 14.00 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,459 3,459 Term Loan 14.00 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,459 3,459 Term Loan 14.00 % Prime 5.50 % 9.50 % - 3.00 % April 1, 2028 2,750 2,708 2,708 Elligo Health Research, Inc. (2)(12) Software Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2027 10,000 9,647 9,647 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2027 5,000 4,921 4,921 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2027 5,000 4,921 4,921 Term Loan 12.00 % Prime 3.50 % 11.75 % - 4.00 % October 1, 2027 5,000 4,921 4,921 SafelyYou, Inc. (2)(12) Software Term Loan 11.75 % Prime 3.25 % 11.00 % - 5.00 % June 1, 2027 5,000 4,642 4,642 Term Loan 11.75 % Prime 3.25 % 11.00 % - 5.00 % June 1, 2027 5,000 4,912 4,912 Total Non-Affiliate Debt Investments — Healthcare information and services 60,191 60,191 Total Non- Affiliate Debt Investments 676,864 663,399 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrant Investments — 7.6% Non-Affiliate Warrants — Life Science — 2.0% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 26,444 311 — Castle Creek Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 7,404 214 348 Emalex Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 110,402 176 269 Imunon, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 19,671 65 — KSQ Therapeutics, Inc. (2) (12) Biotechnology Preferred Stock Warrant 48,076 50 60 Mustang Bio, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 16,611 146 — Native Microbials, Inc (2)(12) Biotechnology Preferred Stock Warrant 103,679 64 165 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Common Stock Warrant 299,848 162 667 Provivi, Inc. (2)(12) Biotechnology Preferred Stock Warrant 345,327 487 205 Stealth Biotherapeutics Inc. (2)(12) Biotechnology Common Stock Warrant 318,181 264 127 Tallac Therapeutics, Inc. (2)(12) Biotechnology Preferred Stock Warrant 1,600,002 194 194 vTv Therapeutics Inc. (2)(5)(12) Biotechnology Common Stock Warrant 95,293 44 — Xeris Pharmaceuticals, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 126,000 72 17 AccuVein Inc. (2)(12) Medical Device Common Stock Warrant 1,175 24 — Aerin Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,818,183 66 1,210 Aerobiotix, LLC (2)(12) Medical Device Preferred Stock Warrant 8,800 48 10 Canary Medical Inc. (2)(12) Medical Device Preferred Stock Warrant 12,153 86 1,307 Candesant Biomedical, Inc. (2)(12) Medical Device Preferred Stock Warrant 93,336 152 152 Ceribell, Inc. (2)(12) Medical Device Preferred Stock Warrant 145,483 69 213 Cognoa, Inc. (2)(12) Medical Device Preferred Stock Warrant 4,106,174 148 184 Conventus Orthopaedics, Inc. (2)(12) Medical Device Preferred Stock Warrant 7,972,222 218 236 CSA Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,730,746 172 176 CVRx, Inc. (2)(5)(12) Medical Device Common Stock Warrant 47,410 76 272 Infobionic, Inc. (2)(12) Medical Device Preferred Stock Warrant 317,647 124 59 Magnolia Medical Technologies, Inc. (2)(12) Medical Device Preferred Stock Warrant 809,931 194 395 Meditrina, Inc. (2)(12) Medical Device Preferred Stock Warrant 233,993 83 104 Robin Healthcare, Inc. (2)(12) Medical Device Preferred Stock Warrant 86,066 16 — Scientia Vascular, Inc (2)(12) Medical Device Preferred Stock Warrant 27,036 59 230 Sonex Health, Inc. (2)(12) Medical Device Preferred Stock Warrant 2,637,043 275 304 VERO Biotech LLC (2)(12) Medical Device Preferred Stock Warrant 408 53 1 Swift Health Systems Inc. (2)(12) Medical Device Preferred Stock Warrant 135,484 71 40 Total Non-Affiliate Warrants — Life Science 4,183 6,945 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrants — Sustainability — 0.2% New Aerofarms, Inc. assignee of Aerofarms, Inc. (2)(12)(15) Other Sustainability Preferred Stock Warrant 400,000 81 81 LiquiGlide, Inc. (2)(12) Other Sustainability Common Stock Warrant 61,359 41 59 Nexii Building Solutions, Inc. (2)(12)(14) Other Sustainability Common Stock Warrant 217,726 490 — Soli Organic, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 681 214 371 Temperpack Technologies, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 46,311 175 322 Total Non-Affiliate Warrants — Sustainability 1,001 833 Non-Affiliate Warrants — Technology — 4.7% Axiom Space, Inc. (2)(12) Communications Common Stock Warrant 1,991 46 69 Intelepeer Holdings, Inc. (2)(12) Communications Preferred Stock Warrant 2,936,535 138 3,283 PebblePost, Inc. (2)(12) Communications Preferred Stock Warrant 598,850 92 139 Alula Holdings, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 20,000 93 — Aterian, Inc. (2)(5)(12) Consumer-related Technologies Common Stock Warrant 76,923 195 — Caastle, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 268,591 68 1,060 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 75,997 22 30 Clara Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 46,745 31 128 CZV, Inc. (2)(12) Consumer-related Technologies Common Stock Warrant 65,569 81 81 Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 37,294 92 279 Havenly, Inc. (2)(12) Consumer-related Technologies Common Stock Warrant 1,312,500 2,945 2,676 MyForest Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 250 29 63 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Preferred and Common Stock Warrant 1,237,370 197 — Optoro, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 11,550 182 182 Primary Kids, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 553,778 57 596 Quip NYC Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 6,191 325 538 Unagi, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 171,081 32 — Updater, Inc.(2)(12) Consumer-related Technologies Common Stock Warrant 108,333 34 — CPG Beyond, Inc. (2)(12) Data Storage Preferred Stock Warrant 500,000 242 917 Silk, Inc. (2)(12) Data Storage Preferred Stock Warrant 394,110 175 153 Global Worldwide LLC (2)(12) Internet and Media Preferred Stock Warrant 245,810 75 63 Rocket Lawyer Incorporated (2)(12) Internet and Media Preferred Stock Warrant 261,721 92 336 Skillshare, Inc. (2)(12) Internet and Media Preferred Stock Warrant 139,074 162 1,216 Liqid, Inc. (2)(12) Networking Preferred Stock Warrant 344,102 364 251 Halio, Inc. (2)(12) Power Management Preferred Stock Warrant 5,002,574 1,585 2,901 Avalanche Technology, Inc. (2)(12) Semiconductors Preferred and Common Stock Warrant 6,081 56 — BriteCore Holdings, Inc. (2)(12) Software Preferred Stock Warrant 161,215 98 147 Dropoff, Inc. (2)(12) Software Common Stock Warrant 516,732 455 54 Mirantis, Inc. (2)(12) Software Common Stock Warrant 948,275 223 223 E La Carte, Inc. (2)(5)(12) Software Common Stock Warrant 147,361 60 — Everstream Holdings, LLC (2)(12) Software Preferred Stock Warrant 350,000 70 71 Kodiak Robotics, Inc. (2)(12) Software Preferred Stock Warrant 639,918 273 124 Lemongrass Holdings, Inc. (2)(12) Software Preferred Stock Warrant 101,308 32 43 Lotame Solutions, Inc. (2)(12) Software Preferred Stock Warrant 71,305 18 44 Lytics, Inc. (2)(12) Software Preferred Stock Warrant 85,543 43 1 Noodle Partners, Inc. (2)(12) Software Preferred Stock Warrant 84,037 115 79 Reputation Institute, Inc. (2)(12) Software Preferred Stock Warrant 3,731 56 48 Revinate Holdings, Inc. (2)(12) Software Preferred Stock Warrant 682,034 44 103 SIGNiX, Inc. (12) Software Preferred Stock Warrant 186,235 225 — Slingshot Aerospace, Inc. (2)(12) Software Preferred Stock Warrant 309,208 123 135 Supply Network Visibility Holdings LLC (2)(12) Software Preferred Stock Warrant 682 64 146 Topia Mobility, Inc. (2)(12) Software Preferred Stock Warrant 3,049,607 138 — Viken Detection Corporation (2)(12) Software Preferred Stock Warrant 345,443 120 122 xAd, Inc. (2)(12) Software Preferred Stock Warrant 4,343,348 177 12 Total Non-Affiliate Warrants — Technology 9,744 16,313 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrants — Healthcare information and services — 0.6% Hound Labs, Inc (2) (12) Diagnostics Preferred Stock Warrant 171,370 47 15 Kate Farms, Inc. (2)(12) Other Healthcare Preferred Stock Warrant 82,965 102 1,379 BrightInsight, Inc. (2)(12) Software Preferred Stock Warrant 85,066 167 — Elligo Health Research, Inc. (2)(12) Software Preferred Stock Warrant 652,250 189 191 Medsphere Systems Corporation (2)(12) Software Preferred Stock Warrant 7,097,792 61 346 SafelyYou, Inc. (2)(12) Software Preferred Stock Warrant 150,353 163 167 Total Non-Affiliate Warrants — Healthcare information and services 729 2,098 Total Non-Affiliate Warrants 15,657 26,189 Non-Affiliate Other Investments — Life Science — 0.3% Lumithera, Inc. (12) Medical Device Royalty Agreement 1,200 1,100 ZetrOZ, Inc. (12) Medical Device Royalty Agreement — — Total Non-Affiliate Other Investments 1,200 1,100 Non-Affiliate Equity — 1.4% Cadrenal Therapeutics, Inc. (5) Biotechnology Common Stock 600,000 — 408 Castle Creek Biosciences, Inc. (12) Biotechnology Common Stock 1,162 250 250 Emalex Biosciences, Inc. (12) Biotechnology Common Stock 32,831 355 356 Getaround, Inc. (2)(5) Consumer-related Technologies Common Stock 87,082 253 30 NextCar Holding Company, Inc. (2)(12) Technology Preferred Stock 2,688,971 89 89 SnagAJob.com, Inc. (12) Consumer-related Technologies Common Stock 82,974 9 83 Lumithera, Inc. (12) Medical Device Common Stock 392,651 2,000 1,700 Tigo Energy, Inc. (5) Other Sustainability Common Stock 5,205 111 36 Branded Online, Inc. (2)(5) Software Common Stock 5,398 1,079 3 Decisyon, Inc. (12) Software Preferred Stock 280,000 2,800 1,281 Lotame, Inc. (12) Software Preferred Stock 66,127 4 193 Axiom Space, Inc. (12) Technology Preferred Stock 1,810 261 306 Total Non-Affiliate Equity 7,211 4,735 Total Non-Affiliate Portfolio Investment Assets $ 700,932 $ 695,423 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Controlled Affiliate Investments — 5.9% Non-Controlled Affiliate Debt Investments — Life Sciences — 3.5% Evelo Biosciences, Inc. (2)(5)(12)(13) Biotechnology Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 7,778 7,672 2,666 Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 11,667 11,509 3,997 Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 4,681 4,618 1,604 Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 4,667 4,603 1,597 Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 3,111 3,069 1,068 Term Loan 12.75 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 3,111 3,069 1,068 Total Non-Controlled Affiliate Debt Investments 34,540 12,000 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-controlled Affiliate Equity — Life Sciences — 2.4% Aulea Medical, Inc. (12)(16) Medical Device Common Stock 660,537 — — Evelo Biosciences, Inc. (5) Biotechnology Common Stock 2,164,502 5,000 8,485 Total Non-Controlled Affiliate Equity 5,000 8,485 Non-controlled Affiliate Warrants — Life Sciences — 0.0% Evelo Biosciences, Inc. (2)(5)(12) Biotechnology Common Stock 23,196 126 — Total Non-Controlled Affiliate Warrants 126 — Total Non-Controlled Affiliate Portfolio Investment Assets $ 39,666 $ 20,485 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Controlled Affiliate Investments — 3.8% Controlled Affiliate Debt Investments — Technology — 1.3% Better Place Forests Co. (12) Consumer-related Technologies Term Loan 12.25 % (11) Prime 3.75 % 12.00 % - 2.78 % August 1, 2029 3,604 3,556 3,006 Term Loan 12.25 % (11) Prime 3.75 % 12.00 % - 2.78 % August 1, 2029 1,719 1,695 1,433 Total Controlled Affiliate Debt Investments 5,251 4,439 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Controlled Affiliate Equity — Technology — 0.7% Better Place Forests Co. (12) Technology Preferred and Common Stock 2,551,596 2,811 2,552 Total Controlled Affiliate Equity 2,811 2,552 Controlled Affiliate Other Investments — Life Sciences — 1.8% HIMV LLC (12)(17) Biotechnology Other Investment 6,154 6,154 Total Controlled Affiliate Equity 6,154 6,154 Total Controlled Affiliate Portfolio Investment Assets $ 14,216 $ 13,145 Total Portfolio Investment Assets — 210.4% $ 754,814 $ 729,053 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Investments — 226.1% Non-Affiliate Debt Investments — 215.5% Non-Affiliate Debt Investments — Life Science — 99.7% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 $ 2,885 $ 2,853 $ 2,777 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 2,885 2,823 2,750 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 1,442 1,411 1,374 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,885 2,821 2,748 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,885 2,821 2,748 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,442 1,408 1,371 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,442 1,408 1,371 Castle Creek Biosciences, Inc. (2)(12) Biotechnology Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,891 4,891 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,963 4,963 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,978 2,978 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,963 4,963 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,963 4,963 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,978 2,978 Emalex Biosciences, Inc. (2)(12) Biotechnology Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 1,979 1,962 1,962 Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 1,979 1,963 1,963 Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % November 1, 2025 5,0 |
Note 4 - Investments (Tables)
Note 4 - Investments (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Notes Tables | |
Investment Holdings, Schedule of Investments [Table Text Block] | September 30, 2023 December 31, 2022 Cost Fair Value Cost Fair Value (In thousands) Investments Debt $ 716,655 $ 679,838 $ 701,074 $ 686,458 Warrants 15,783 26,189 14,790 29,712 Other 7,354 7,254 1,200 1,300 Equity 15,022 15,772 4,184 2,556 Total investments $ 754,814 $ 729,053 $ 721,248 $ 720,026 September 30, 2023 December 31, 2022 Cost Fair Value Cost Fair Value (In thousands) Life Science Biotechnology $ 158,953 $ 139,935 $ 193,372 $ 195,006 Medical Device 140,172 139,039 132,803 135,960 Technology Communications 21,057 24,317 22,892 26,176 Consumer-Related 110,245 106,559 121,961 114,050 Data Storage 417 1,070 476 1,316 Internet and Media 329 1,615 329 1,159 Networking 6,671 6,558 11,831 11,710 Power Management 1,585 2,901 1,585 2,610 Semiconductors 56 — 56 — Software 164,903 161,258 120,157 118,716 Sustainability Energy Efficiency 111 36 8 27 Other Sustainability 89,395 83,476 84,633 85,524 Healthcare Information and Services Diagnostics 9,971 9,939 9,851 9,858 Other 102 1,379 7,559 3,870 Software 50,847 50,971 13,735 14,044 Total investments $ 754,814 $ 729,053 $ 721,248 $ 720,026 |
Note 5 - Transactions With Af_2
Note 5 - Transactions With Affiliated Companies (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Notes Tables | |
Investments in and Advances to Affiliates [Table Text Block] | Three months ended September 30, 2023 Fair value at Transfers Net Fair value at Portfolio June 30, Principal in/(out) at Discount unrealized Net realized September 30, Interest Company 2023 Purchases Payments fair value accretion gain/(loss) gain/(loss) 2023 income (In thousands) Aulea Medical, Inc. $ — $ — $ — $ — $ — $ — $ — $ — $ — Cadrenal Therapeutics, Inc. (1) 906 — — (906 ) — — — — — Evelo Biosciences, Inc. — — — 7,665 8 (5,007 ) — 2,666 277 — — — 11,496 11 (7,510 ) — 3,997 415 — — — 4,612 5 (3,013 ) — 1,604 166 — — — 4,598 3 (3,004 ) — 1,597 163 — — — 3,067 4 (2,003 ) — 1,068 114 — — — 3,067 4 (2,003 ) — 1,068 111 — — — 5,000 — 3,485 — 8,485 — Total non-controlled affiliates $ 906 $ — $ — $ 38,599 $ 35 $ (19,055 ) $ — $ 20,485 $ 1,246 Nine months ended September 30, 2023 Fair value at Transfers Net Fair value at Portfolio December 31, Principal in/(out) at Discount unrealized Net realized September 30, Interest Company 2022 Purchases Payments fair value accretion gain/(loss) gain/(loss) 2023 income (In thousands) Aulea Medical, Inc. $ — $ — $ — $ — $ — $ — $ — $ — $ — Cadrenal Therapeutics, Inc. (1) — — — (906 ) — 906 — — — Evelo Biosciences, Inc. — — — 7,665 8 (5,007 ) — 2,666 277 — — — 11,496 11 (7,510 ) — 3,997 415 — — — 4,612 5 (3,013 ) — 1,604 166 — — — 4,598 3 (3,004 ) — 1,597 163 — — — 3,067 4 (2,003 ) — 1,068 114 — — — 3,067 4 (2,003 ) — 1,068 111 — — — 5,000 — 3,485 — 8,485 — Total non-controlled affiliates $ — $ — $ — $ 38,599 $ 35 $ (18,149 ) $ — $ 20,485 $ 1,246 Three months ended September 30, 2022 Fair value at Transfers Net Fair value at Portfolio June 30, in/(out) at Discount unrealized Net realized September 30, Interest Company 2022 Purchases Sales fair value Accretion gain/(loss) gain/(loss) 2022 income (In thousands) MVI (ABC) LLC fka StereoVision, Inc. — — (30 ) — — — 30 — — Total non-controlled affiliates $ — $ — $ (30 ) $ — $ — $ — $ 30 $ — $ — Nine months ended September 30, 2022 Fair value at Transfers Net Fair value at Portfolio December 31, in/(out) at Discount unrealized Net realized September 30, Interest Company 2021 Purchases Sales fair value Accretion gain/(loss) gain/(loss) 2022 income (In thousands) MVI (ABC) LLC fka StereoVision, Inc. — — (30 ) — — — 30 — — Total non-controlled affiliates $ — $ — $ (30 ) $ — $ — $ — $ 30 $ — $ — Three months ended September 30, 2023 Fair value at Transfers Net Fair value at Portfolio June 30, Principal in/(out) at Discount unrealized Net realized September 30, Interest Company 2023 Purchases Payments PIK fair value accretion gain/(loss) gain/(loss) 2023 income (In thousands) Better Place Forests Co. $ — $ 59 $ — $ 105 $ 1,759 $ 2 $ 1,080 $ — $ 3,005 $ 111 — — — 53 844 1 536 — 1,434 55 — — — — 2,061 — — — 2,061 — — 750 — — — — (259 ) — 491 — HIMV LLC — — — — 6,154 — — — 6,154 — Total controlled affiliates $ — $ 809 $ — $ 158 $ 10,818 $ 3 $ 1,357 $ — $ 13,145 $ 166 Nine months ended September 30, 2023 Fair value at Transfers Net Fair value at Portfolio December 31, Principal in/(out) at Discount unrealized Net realized September 30, Interest Company 2022 Purchases Payments PIK fair value accretion gain/(loss) gain/(loss) 2023 income (In thousands) Better Place Forests Co. $ — $ 59 $ — $ 105 $ 1,759 $ 2 $ 1,080 $ — $ 3,005 $ 111 — — — 53 844 1 536 — 1,434 55 — — — — 2,061 — — — 2,061 — — 750 — — — — (259 ) — 491 — HIMV LLC — — — — 6,154 — — — 6,154 — Total controlled affiliates $ — $ 809 $ — $ 158 $ 10,818 $ 3 $ 1,357 $ — $ 13,145 $ 166 Three months ended September 30, 2022 Fair value at Transfers Net Fair value at Portfolio June 30, in/(out) at Discount unrealized Net realized September 30, Interest Company 2022 Purchases Sales fair value Accretion gain/(loss) gain/(loss) 2022 income (In thousands) HESP LLC — — (50 ) — — — 50 — — Total controlled affiliates $ — $ — $ (50 ) $ — $ — $ — $ 50 $ — $ — Nine months ended September 30, 2022 Fair value at Transfers Net Fair value at Portfolio December 31, in/(out) at Discount unrealized Net realized September 30, Interest Company 2021 Purchases Sales fair value accretion gain/(loss) gain/(loss) 2022 income (In thousands) HESP LLC — — (300 ) — — 1,450 (1,150 ) — — Total controlled affiliates $ — $ — $ (300 ) $ — $ — $ 1,450 $ (1,150 ) $ — $ — |
Note 6 - Fair Value (Tables)
Note 6 - Fair Value (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Notes Tables | |
Fair Value, Assets Measured on Recurring Basis [Table Text Block] | September 30, 2023 Level 1 Level 2 Level 3 Total (In thousands) Debt investments $ — $ — $ 679,838 $ 679,838 Warrant investments — 956 25,233 26,189 Other investments — — 7,254 7,254 Equity investments 8,962 — 6,810 15,772 Total investments $ 8,962 $ 956 $ 719,135 $ 729,053 December 31, 2022 Level 1 Level 2 Level 3 Total (In thousands) Debt investments $ — $ — $ 686,458 $ 686,458 Warrant investments — 3,567 26,145 29,712 Other investments — — 1,300 1,300 Equity investments 140 — 2,416 2,556 Total investments $ 140 $ 3,567 $ 716,319 $ 720,026 |
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] | September 30, 2023 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average(1) (Dollars in thousands, except per share data) Debt investments $ 607,193 Discounted Expected Future Cash Flows Hypothetical Market Yield 11% – 20% 14 % 72,645 Multiple Probability Weighted Cash Flow Model Probability Weighting 20% - 100% 50 % Warrant investments 25,171 Black-Scholes Valuation Model Price Per Share 0.000 –1,89999 $ 58.11 Average Industry Volatility 28% 28 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 5 3 62 Expected Proceeds Price Per Share $0.25 $ 0.25 Other investments 7,254 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 30% – 100% 83 % Equity investments 6,810 Last Equity Financing Price Per Share 0.03 215.03 $ 18.30 Total Level 3 investments $ 719,135 December 31, 2022 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average(1) (Dollars in thousands, except per share data) Debt investments $ 669,617 Discounted Expected Future Cash Flows Hypothetical Market Yield 3% – 22% 14 % 16,545 Multiple Probability Weighted Cash Flow Model Probability Weighting 10% - 75% 31 % 296 Convertible Note Analysis Price Per Share $168.93 $ 168.93 Warrant investments 26,145 Black-Scholes Valuation Model Price Per Share 0.000 –1.8989 $ 58.52 Average Industry Volatility 28% 28 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 5 3 Other investments 1,300 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 100% 100 % Equity investments 2,416 Last Equity Financing Price Per Share $1.00– $215.03 $ 26.93 Total Level 3 investments $ 716,319 |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | Three months ended September 30, 2023 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 683,309 $ 24,376 $ 4,259 $ 1,300 $ 713,244 Purchase of investments 66,185 — 750 — 66,935 Warrants received and classified as Level 3 — 1,294 — — 1,294 Principal payments received on investments (25,726 ) — — — (25,726 ) Payment-in-kind interest on investments 3,934 — — — 3,934 Proceeds from sale of investments (2,528 ) (23 ) (6 ) — (2,557 ) Net realized (loss) gain on investments (11,440 ) (118 ) 6 — (11,552 ) Unrealized depreciation included in earnings (18,877 ) (296 ) (1,349 ) (200 ) (20,722 ) Transfer out of Level 3 (5,000 ) — — — (5,000 ) Transfer out of debt investments (9,304 ) — 3,150 6,154 — Other (715 ) — — — (715 ) Level 3 assets, end of period $ 679,838 $ 25,233 $ 6,810 $ 7,254 $ 719,135 Three months ended September 30, 2022 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 551,560 $ 25,167 $ 453 $ 200 $ 577,380 Purchase of investments 94,627 — — — 94,627 Warrants received and classified as Level 3 — 964 — — 964 Principal payments received on investments (26,929 ) — — (31 ) (26,960 ) Proceeds from sale of investments (6,088 ) (38 ) — — (6,126 ) Net realized (loss) gain on investments (8,492 ) 266 — 31 (8,195 ) Unrealized appreciation (depreciation) included in earnings 8,095 (3,348 ) (420 ) (100 ) 4,227 Transfer out of Level 3 — (1,117 ) — — (1,117 ) Transfer out of debt investments (3,200 ) — 2,000 1,200 — Other (541 ) — — — (541 ) Level 3 assets, end of period $ 609,032 $ 21,894 $ 2,033 $ 1,300 $ 634,259 Nine months ended September 30, 2023 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 686,458 $ 26,145 $ 2,416 $ 1,300 $ 716,319 Purchase of investments 153,728 — 760 — 154,488 Warrants and equity received and classified as Level 3 — 1,950 89 — 2,039 Principal payments received on investments (90,222 ) — — — (90,222 ) Payment-in-kind interest on investments 6,088 — — — 6,088 Proceeds from sale of investments (9,564 ) (1,493 ) (6 ) — (11,063 ) Net realized (loss) gain on investments (29,105 ) 1,028 (121 ) — (28,198 ) Unrealized depreciation included in earnings (21,325 ) (2,392 ) (2,467 ) (200 ) (26,384 ) Transfer out of Level 3 (5,000 ) — (111 ) — (5,111 ) Transfer out of debt investments (12,399 ) (5 ) 6,250 6,154 — Other 1,179 — — — 1,179 Level 3 assets, end of period $ 679,838 $ 25,233 $ 6,810 $ 7,254 $ 719,135 Nine months ended September 30, 2022 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 437,317 $ 19,837 $ 203 $ 200 $ 457,557 Purchase of investments 348,097 — 250 — 348,347 Warrants received and classified as Level 3 — 2,441 — — 2,441 Principal payments received on investments (114,120 ) — — (313 ) (114,433 ) Proceeds from sale of investments (49,088 ) (464 ) — — (49,552 ) Net realized (loss) gain on investments (8,492 ) 535 — (1,137 ) (9,094 ) Unrealized appreciation (depreciation) included in earnings 1,128 662 (420 ) 1,350 2,720 Transfer out of Level 3 — (1,117 ) — — (1,117 ) Transfer out of debt investments (3,200 ) — 2,000 1,200 — Other (2,610 ) — — — (2,610 ) Level 3 assets, end of period $ 609,032 $ 21,894 $ 2,033 $ 1,300 $ 634,259 |
Note 7 - Borrowings (Tables)
Note 7 - Borrowings (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | September 30, 2023 December 31, 2022 Total Balance Unused Total Balance Unused Commitment Outstanding Commitment Commitment Outstanding Commitment (In thousands) Key Facility $ 150,000 $ 25,000 $ 125,000 $ 125,000 $ 5,000 $ 120,000 NYL Facility 250,000 181,000 69,000 200,000 176,750 23,250 2019 Asset-Backed Notes 18,696 18,696 — 42,573 42,573 — 2022 Asset-Backed Notes 100,000 100,000 — 100,000 100,000 — 2027 Notes 57,500 57,500 — 57,500 57,500 — 2026 Notes 57,500 57,500 — 57,500 57,500 — Total before debt issuance costs 633,696 439,696 194,000 582,573 439,323 143,250 Unamortized debt issuance costs attributable to term borrowings — (4,196 ) — — (5,245 ) — Total borrowings outstanding, net $ 633,696 $ 435,500 $ 194,000 $ 582,573 $ 434,078 $ 143,250 |
Note 8 - Financial Instrument_2
Note 8 - Financial Instruments With Off-balance-sheet Risk (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Notes Tables | |
Schedule of Fair Value, off-Balance-Sheet Risks [Table Text Block] | September 30, 2023 December 31, 2022 Fair Value of Fair Value of Unfunded Unfunded Principal Commitment Principal Commitment Balance Liability Balance Liability (In thousands) (In thousands) BrightInsight, Inc. $ 18,250 $ 241 $ 21,000 $ 278 Britecore Holdings, Inc. 5,000 72 5,000 66 Candesant Biomedical Corporation 10,000 151 — — Castle Creek Biosciences 4,000 72 4,000 72 Divergent Technologies, Inc. 11,250 118 22,500 236 Elligo Healthcare Research, Inc. 15,000 194 — — Engage3, LLC — — 8,000 40 Groundspeed Analytics, Inc. — — 15,000 150 Hound Labs, Inc. — — 7,500 88 KSQ Therapeutics, Inc. — — 10,000 100 Lytics, Inc. 4,000 52 5,000 65 Mirantis, Inc. 15,000 136 — — Native Microbials, Inc. — — 7,500 72 Noodle Partners, Inc. 5,000 61 — — Optoro, Inc. 6,250 — 15,000 38 PDS Biotechnology Corporation — — 10,000 158 Robin Healthcare, Inc. — — 10,000 100 SafelyYou, Inc. 20,000 270 — — Scientia Vascular, Inc. 5,000 55 10,000 110 Slingshot Aerospace, Inc. — — 5,000 64 Sonex Health, Inc. 15,000 176 — — Supply Network Visibility Holdings, LLC 10,000 35 — — Swift Health Systems Inc. 11,500 — 25,500 105 Tallac Therapeutics, Inc. 10,000 229 — — Temperpack Technologies, Inc. 6,500 14 9,000 19 Viken Detection Corporation 10,000 160 — — Total $ 181,750 $ 2,036 $ 190,000 $ 1,761 |
Note 10 - Distributions (Tables
Note 10 - Distributions (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Notes Tables | |
Dividends Declared [Table Text Block] | DRIP DRIP Date Amount Cash Shares Share Declared Record Date Payment Date Per Share Distribution Issued Value (In thousands, except share and per share data) Nine Months Ended September 30, 2023 7/28/2023 11/17/23 12/15/23 $ 0.11 $ — — $ — 7/28/2023 10/18/23 11/15/23 0.11 — — — 7/28/2023 9/19/23 10/16/23 0.11 3,445 15,067 184 4/28/2023 8/17/23 9/15/23 0.11 3,458 8,665 106 4/28/2023 7/18/23 8/15/23 0.11 3,427 8,307 105 4/28/2023 6/16/23 7/14/23 0.11 3,434 7,424 96 2/23/2023 5/18/23 6/14/23 0.11 3,087 7,128 86 2/23/2023 4/18/23 5/16/23 0.11 3,068 6,705 84 2/23/2023 3/17/23 4/14/23 0.11 3,035 6,894 81 $ 0.99 $ 22,954 60,190 $ 742 Year Ended December 31, 2022 10/28/2022 2/17/23 3/15/23 $ 0.11 $ 3,040 6,764 $ 75 10/28/2022 1/18/23 2/15/23 0.11 3,021 5,754 74 10/28/2022 12/19/22 1/13/23 0.11 2,978 5,618 69 10/28/2022 11/17/22 12/15/22 0.05 1,319 2,171 27 7/29/2022 11/17/22 12/15/22 0.10 2,638 4,341 57 7/29/2022 10/18/22 11/15/22 0.10 2,580 4,621 60 7/29/2022 9/19/22 10/14/22 0.10 2,558 7,703 81 4/29/2022 8/18/22 9/15/22 0.10 2,528 4,925 60 4/29/2022 7/19/22 8/16/22 0.10 2,484 3,939 55 4/29/2022 6/17/22 7/15/22 0.10 2,434 4,286 51 2/25/2022 5/18/22 6/15/22 0.10 2,378 4,428 50 2/25/2022 4/19/22 5/16/22 0.10 2,349 4,088 49 2/25/2022 3/18/22 4/14/22 0.10 2,352 3,221 46 $ 1.28 $ 32,659 61,859 $ 754 Ex-Dividend Date Record Date Payment Date Distributions Declared February 15, 2024 February 16, 2024 March 15, 2024 $ 0.11 January 17, 2024 January 18, 2024 February 14, 2024 $ 0.11 December 18, 2023 December 19, 2023 January 16, 2024 $ 0.11 Ex-Dividend Date Record Date Payment Date Distributions Declared November 16, 2023 November 17, 2023 December 15, 2023 $ 0.05 |
Note 11 - Financial Highlights
Note 11 - Financial Highlights (Tables) | 9 Months Ended |
Sep. 30, 2023 | |
Notes Tables | |
Investment Company, Financial Highlights [Table Text Block] | Nine months ended September 30, 2023 2022 (In thousands, except share and per share data) Per share data: Net asset value at beginning of period $ 11.47 $ 11.56 Net investment income 1.54 1.06 Realized loss (0.95 ) (0.40 ) Unrealized (depreciation) appreciation on investments (0.81 ) 0.05 Net increase in net assets resulting from operations (0.22 ) 0.71 Distributions declared (1) (0.99 ) (0.90 ) From net investment income (0.99 ) (0.90 ) From net realized gain on investments — — Return of capital — — Other (2) 0.15 0.29 Net asset value at end of period $ 10.41 $ 11.66 Per share market value, beginning of period $ 11.60 $ 15.92 Per share market value, end of period $ 11.88 $ 10.01 Total return based on a market value (3) 10.9 % (31.5 )% Shares outstanding at end of period 33,306,958 26,393,773 Ratios to average net assets: Expenses without incentive value (4) 14.0 % 11.4 % Incentive fees (4) 1.2 % 3.0 % Net expenses (4) 15.2 % 14.4 % Net investment income with incentive fees (4) 18.5 % 12.1 % Net assets at the end of the period $ 346,575 $ 307,687 Average net asset value $ 335,531 $ 280,904 Average debt per share $ 14.29 $ 13.32 Portfolio turnover ratio 10.0 % (5) 14.9 % (5) |
Consolidated Schedule of Inve_3
Consolidated Schedule of Investments (Unaudited) (Details Textual) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 | Nov. 09, 2022 | Aug. 13, 2019 |
Debt Instrument, Face Amount | $ 633,696 | $ 582,573 | ||
Percentage of Nonqualifying Assets on a Cost Basis | 4.50% | 6.50% | ||
Percentage of Nonqualifying Assets on a Fair Value Basis | 3.90% | 6.60% | ||
Asset-backed Notes 2019 [Member] | ||||
Debt Instrument, Face Amount | $ 18,696 | $ 42,573 | $ 160,000 | |
Asset-backed Notes 2019 [Member] | Affiliated Entity [Member] | ||||
Debt Instrument, Face Amount | $ 100,000 | |||
Asset-backed Notes 2022 [Member] | ||||
Debt Instrument, Face Amount | $ 100,000 | $ 100,000 | $ 157,800 | |
Asset-backed Notes 2022 [Member] | Affiliated Entity [Member] | ||||
Debt Instrument, Face Amount | $ 100,000 |
Consolidated Schedule of Inve_4
Consolidated Schedule of Investments (Unaudited) - Investments (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Jun. 30, 2023 | Dec. 31, 2022 | Sep. 30, 2022 | Jun. 30, 2022 | Dec. 31, 2021 | |
Investments at cost | $ 754,814 | $ 721,248 | |||||
Investments at fair value | 729,053 | 720,026 | |||||
Biotechnology Sector [Member] | |||||||
Investments at cost | 158,953 | 193,372 | |||||
Investments at fair value | 139,935 | 195,006 | |||||
Medical Device Sector [Member] | |||||||
Investments at cost | 140,172 | 132,803 | |||||
Investments at fair value | 139,039 | 135,960 | |||||
Communications Sector [Member] | |||||||
Investments at cost | 21,057 | 22,892 | |||||
Investments at fair value | 24,317 | 26,176 | |||||
Software Sector [Member] | |||||||
Investments at cost | 164,903 | 120,157 | |||||
Investments at fair value | 161,258 | 118,716 | |||||
Other Sustainability Sector [Member] | |||||||
Investments at cost | 89,395 | 84,633 | |||||
Investments at fair value | 83,476 | 85,524 | |||||
Diagnostics Sector [Member] | |||||||
Investments at cost | 9,971 | 9,851 | |||||
Investments at fair value | 9,939 | 9,858 | |||||
Other Healthcare Sector [Member] | |||||||
Investments at cost | 102 | 7,559 | |||||
Investments at fair value | 1,379 | 3,870 | |||||
Data Storage Sector [Member] | |||||||
Investments at cost | 417 | 476 | |||||
Investments at fair value | 1,070 | 1,316 | |||||
Internet and Media Sector [Member] | |||||||
Investments at cost | 329 | 329 | |||||
Investments at fair value | 1,615 | 1,159 | |||||
Networking Sector [Member] | |||||||
Investments at cost | 6,671 | 11,831 | |||||
Investments at fair value | 6,558 | 11,710 | |||||
Power Management Sector [Member] | |||||||
Investments at cost | 1,585 | 1,585 | |||||
Investments at fair value | 2,901 | 2,610 | |||||
Semiconductor Sector [Member] | |||||||
Investments at cost | 56 | 56 | |||||
Investments at fair value | 0 | 0 | |||||
Software, Healthcare Information and Service [Member] | |||||||
Investments at cost | 50,847 | 13,735 | |||||
Investments at fair value | 50,971 | 14,044 | |||||
Evelo Biosciences, Inc. [Member] | |||||||
Investments at fair value | 8,500 | ||||||
Investment, Unaffiliated Issuer [Member] | |||||||
Investments at cost | 700,932 | 721,248 | |||||
Investments at fair value | 695,423 | 720,026 | |||||
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | |||||||
Investments at cost | 676,864 | 701,074 | |||||
Investments at fair value | 663,399 | 686,458 | |||||
Investment, Unaffiliated Issuer [Member] | Equity Securities [Member] | |||||||
Investments at cost | 7,211 | 4,184 | |||||
Investments at fair value | 4,735 | 2,556 | |||||
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | |||||||
Investments at cost | 15,657 | 14,790 | |||||
Investments at fair value | 26,189 | 29,712 | |||||
Investment, Unaffiliated Issuer [Member] | Other Long-Term Investments [Member] | |||||||
Investments at cost | 1,200 | 1,200 | |||||
Investments at fair value | 1,100 | 1,300 | |||||
Investment, Unaffiliated Issuer [Member] | Other Sustainability Sector [Member] | Debt Securities [Member] | |||||||
Investments at cost | 88,394 | ||||||
Investments at fair value | 82,643 | ||||||
Investment, Unaffiliated Issuer [Member] | Other Sustainability Sector [Member] | Warrant [Member] | |||||||
Investments at cost | 1,001 | ||||||
Investments at fair value | $ 833 | ||||||
Number of Shares (in shares) | |||||||
Investment, Unaffiliated Issuer [Member] | Technology Sector [Member] | Debt Securities [Member] | |||||||
Ceiling | |||||||
Investments at cost | $ 282,962 | 268,468 | |||||
Investments at fair value | 278,989 | 259,366 | |||||
Investment, Unaffiliated Issuer [Member] | Technology Sector [Member] | Warrant [Member] | |||||||
Investments at cost | 9,744 | 9,249 | |||||
Investments at fair value | 16,313 | 16,148 | |||||
Investment, Unaffiliated Issuer [Member] | Life Science [Member] | Debt Securities [Member] | |||||||
Investments at cost | 245,317 | 318,172 | |||||
Investments at fair value | 241,576 | 317,568 | |||||
Investment, Unaffiliated Issuer [Member] | Life Science [Member] | Warrant [Member] | |||||||
Investments at cost | 4,197 | ||||||
Investments at fair value | $ 9,792 | ||||||
Number of Shares (in shares) | |||||||
Investment, Unaffiliated Issuer [Member] | Healthcare Sector [Member] | Debt Securities [Member] | |||||||
Investments at cost | 60,191 | $ 30,729 | |||||
Investments at fair value | 60,191 | 25,819 | |||||
Investment, Unaffiliated Issuer [Member] | Healthcare Sector [Member] | Warrant [Member] | |||||||
Investments at cost | 729 | 416 | |||||
Investments at fair value | 2,098 | 1,953 | |||||
Investment, Unaffiliated Issuer [Member] | Life Science Segment [Member] | Warrant [Member] | |||||||
Investments at cost | 4,183 | ||||||
Investments at fair value | $ 6,945 | ||||||
Investment, Unaffiliated Issuer [Member] | Sustainability Segment [Member] | Debt Securities [Member] | |||||||
Investments at cost | 83,705 | ||||||
Investments at fair value | 83,705 | ||||||
Investment, Unaffiliated Issuer [Member] | Sustainability Segment [Member] | Warrant [Member] | |||||||
Investments at cost | 928 | ||||||
Investments at fair value | $ 1,819 | ||||||
Number of Shares (in shares) | |||||||
Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 13.25% | 12.50% | |||||
Margin | 4.75% | 6.05% | |||||
Floor | 9.55% | 9.55% | |||||
Ceiling | 13.50% | 13.50% | |||||
ETP | 5.50% | 5.50% | |||||
Maturity Date | May 01, 2026 | May 01, 2026 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,903 | 4,891 | |||||
Investments at fair value | $ 4,903 | $ 4,891 | |||||
Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 13.25% | 12.50% | |||||
Margin | 4.75% | 6.05% | |||||
Floor | 9.55% | 9.55% | |||||
Ceiling | 13.50% | 13.50% | |||||
ETP | 5.50% | 5.50% | |||||
Maturity Date | May 01, 2026 | May 01, 2026 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,975 | 4,963 | |||||
Investments at fair value | 4,975 | 4,963 | |||||
Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 214 | 214 | |||||
Investments at fair value | $ 348 | $ 335 | |||||
Number of Shares (in shares) | 7,404 | 7,404 | |||||
Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Common Stock [Member] | |||||||
Investments at cost | $ 250 | $ 250 | |||||
Investments at fair value | $ 250 | $ 250 | |||||
Number of Shares (in shares) | 1,162 | 1,162 | |||||
Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 13.25% | 12.50% | |||||
Margin | 4.75% | 6.05% | |||||
Floor | 9.55% | 9.55% | |||||
Ceiling | 13.50% | 13.50% | |||||
ETP | 5.50% | 5.50% | |||||
Maturity Date | May 01, 2026 | May 01, 2026 | |||||
Principal Amount | $ 3,000 | $ 3,000 | |||||
Investments at cost | 2,985 | 2,978 | |||||
Investments at fair value | $ 2,985 | $ 2,978 | |||||
Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 13.25% | 12.50% | |||||
Margin | 4.75% | 6.05% | |||||
Floor | 9.55% | 9.55% | |||||
Ceiling | 13.50% | 13.50% | |||||
ETP | 5.50% | 5.50% | |||||
Maturity Date | May 01, 2026 | May 01, 2026 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,975 | 4,963 | |||||
Investments at fair value | $ 4,975 | $ 4,963 | |||||
Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Five [Member] | |||||||
Cash Rate | 13.25% | 12.50% | |||||
Margin | 4.75% | 6.05% | |||||
Floor | 9.55% | 9.55% | |||||
Ceiling | 13.50% | 13.50% | |||||
ETP | 5.50% | 5.50% | |||||
Maturity Date | May 01, 2026 | May 01, 2026 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,975 | 4,963 | |||||
Investments at fair value | $ 4,975 | $ 4,963 | |||||
Investment, Unaffiliated Issuer [Member] | Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Six [Member] | |||||||
Cash Rate | 13.25% | 12.50% | |||||
Margin | 4.75% | 6.05% | |||||
Floor | 9.55% | 9.55% | |||||
Ceiling | 13.50% | 13.50% | |||||
ETP | 5.50% | 5.50% | |||||
Maturity Date | May 01, 2026 | May 01, 2026 | |||||
Principal Amount | $ 3,000 | $ 3,000 | |||||
Investments at cost | 2,985 | 2,978 | |||||
Investments at fair value | $ 2,985 | $ 2,978 | |||||
Investment, Unaffiliated Issuer [Member] | Robin Healthcare, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 14% | 13% | |||||
Margin | 5.50% | 5.50% | |||||
Floor | 10.25% | 10.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 4% | |||||
Maturity Date | Nov. 01, 2026 | Nov. 01, 2026 | |||||
Principal Amount | $ 3,500 | $ 3,500 | |||||
Investments at cost | 3,468 | 3,360 | |||||
Investments at fair value | $ 1,749 | $ 3,360 | |||||
Investment, Unaffiliated Issuer [Member] | Robin Healthcare, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 14% | 13% | |||||
Margin | 5.50% | 5.50% | |||||
Floor | 10.25% | 10.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 4% | |||||
Maturity Date | Nov. 01, 2026 | Nov. 01, 2026 | |||||
Principal Amount | $ 3,500 | $ 3,500 | |||||
Investments at cost | 3,468 | 3,460 | |||||
Investments at fair value | 1,749 | 3,460 | |||||
Investment, Unaffiliated Issuer [Member] | Robin Healthcare, Inc. [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 16 | 16 | |||||
Investments at fair value | $ 0 | $ 16 | |||||
Number of Shares (in shares) | 86,066 | 86,066 | |||||
Investment, Unaffiliated Issuer [Member] | Axiom Space, Inc [Member] | Communications Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 14.50% | 13% | |||||
Margin | 6% | 6% | |||||
Floor | 9.25% | 9.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.50% | 2.50% | |||||
Maturity Date | Jun. 01, 2026 | Jun. 01, 2026 | |||||
Principal Amount | $ 6,875 | $ 7,500 | |||||
Investments at cost | 6,840 | 7,455 | |||||
Investments at fair value | $ 6,840 | $ 7,455 | |||||
Investment, Unaffiliated Issuer [Member] | Axiom Space, Inc [Member] | Communications Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 14.50% | 13% | |||||
Margin | 6% | 6% | |||||
Floor | 9.25% | 9.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.50% | 2.50% | |||||
Maturity Date | Jun. 01, 2026 | Jun. 01, 2026 | |||||
Principal Amount | $ 6,875 | $ 7,500 | |||||
Investments at cost | 6,840 | 7,455 | |||||
Investments at fair value | 6,840 | 7,455 | |||||
Investment, Unaffiliated Issuer [Member] | Axiom Space, Inc [Member] | Communications Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | 46 | 46 | |||||
Investments at fair value | $ 69 | $ 67 | |||||
Number of Shares (in shares) | 1,991 | 1,991 | |||||
Investment, Unaffiliated Issuer [Member] | Axiom Space, Inc [Member] | Communications Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 14.50% | 13% | |||||
Margin | 6% | 6% | |||||
Floor | 9.25% | 9.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.50% | 2.50% | |||||
Maturity Date | Jun. 01, 2026 | Jun. 01, 2026 | |||||
Principal Amount | $ 6,875 | $ 7,500 | |||||
Investments at cost | 6,840 | 7,455 | |||||
Investments at fair value | 6,840 | $ 7,455 | |||||
Investment, Unaffiliated Issuer [Member] | Axiom Space, Inc [Member] | Communications Sector [Member] | Convertible Debt Securities [Member] | |||||||
Cash Rate | 3% | ||||||
Maturity Date | Jul. 01, 2023 | ||||||
Principal Amount | $ 250 | ||||||
Investments at cost | 250 | ||||||
Investments at fair value | $ 306 | ||||||
Investment, Unaffiliated Issuer [Member] | Axiom Space, Inc [Member] | Technology Sector [Member] | Preferred Stock [Member] | |||||||
Investments at cost | 261 | ||||||
Investments at fair value | $ 306 | ||||||
Number of Shares (in shares) | 1,810 | ||||||
Investment, Unaffiliated Issuer [Member] | DropOff, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 15% | 14% | |||||
Margin | 6.50% | 6.50% | |||||
Floor | 9.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 3.50% | 3.50% | |||||
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |||||
Principal Amount | $ 6,550 | $ 6,500 | |||||
Investments at cost | 6,432 | 6,347 | |||||
Investments at fair value | $ 6,377 | $ 6,347 | |||||
Investment, Unaffiliated Issuer [Member] | DropOff, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 15% | 14% | |||||
Margin | 6.50% | 6.50% | |||||
Floor | 9.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 3.50% | 3.50% | |||||
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |||||
Principal Amount | $ 6,046 | $ 6,000 | |||||
Investments at cost | 5,937 | 5,859 | |||||
Investments at fair value | 5,886 | 5,859 | |||||
Investment, Unaffiliated Issuer [Member] | DropOff, Inc. [Member] | Software Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | 455 | 455 | |||||
Investments at fair value | $ 54 | $ 197 | |||||
Number of Shares (in shares) | 516,732 | 516,732 | |||||
Investment, Unaffiliated Issuer [Member] | DropOff, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 15% | 14% | |||||
Margin | 6.50% | 6.50% | |||||
Floor | 9.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 3.50% | 3.50% | |||||
Maturity Date | Aug. 01, 2026 | Aug. 01, 2026 | |||||
Principal Amount | $ 2,519 | $ 2,500 | |||||
Investments at cost | 2,472 | 2,436 | |||||
Investments at fair value | 2,451 | $ 2,436 | |||||
Investment, Unaffiliated Issuer [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 11.75% | ||||||
Margin | 4.75% | ||||||
Floor | 11% | ||||||
Ceiling | 0% | ||||||
ETP | 4.25% | ||||||
Maturity Date | Jan. 01, 2028 | ||||||
Principal Amount | $ 10,000 | ||||||
Investments at cost | 9,872 | ||||||
Investments at fair value | $ 9,872 | ||||||
Investment, Unaffiliated Issuer [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 11.75% | ||||||
Margin | 4.75% | ||||||
Floor | 11% | ||||||
Ceiling | 0% | ||||||
ETP | 4.25% | ||||||
Maturity Date | Jan. 01, 2028 | ||||||
Principal Amount | $ 15,000 | ||||||
Investments at cost | 14,808 | ||||||
Investments at fair value | 14,808 | ||||||
Investment, Unaffiliated Issuer [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | 126 | ||||||
Investments at fair value | $ 125 | ||||||
Number of Shares (in shares) | 463,915 | ||||||
Investment, Unaffiliated Issuer [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 11.75% | ||||||
Margin | 4.75% | ||||||
Floor | 11% | ||||||
Ceiling | 0% | ||||||
ETP | 4.25% | ||||||
Maturity Date | Jan. 01, 2028 | ||||||
Principal Amount | $ 6,000 | ||||||
Investments at cost | 5,923 | ||||||
Investments at fair value | $ 5,923 | ||||||
Investment, Unaffiliated Issuer [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 11.75% | ||||||
Margin | 4.75% | ||||||
Floor | 11% | ||||||
Ceiling | 0% | ||||||
ETP | 4.25% | ||||||
Maturity Date | Jan. 01, 2028 | ||||||
Principal Amount | $ 6,000 | ||||||
Investments at cost | 5,923 | ||||||
Investments at fair value | $ 5,923 | ||||||
Investment, Unaffiliated Issuer [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Five [Member] | |||||||
Cash Rate | 11.75% | ||||||
Margin | 4.75% | ||||||
Floor | 11% | ||||||
Ceiling | 0% | ||||||
ETP | 4.25% | ||||||
Maturity Date | Jan. 01, 2028 | ||||||
Principal Amount | $ 4,000 | ||||||
Investments at cost | 3,949 | ||||||
Investments at fair value | $ 3,949 | ||||||
Investment, Unaffiliated Issuer [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Six [Member] | |||||||
Cash Rate | 11.75% | ||||||
Margin | 4.75% | ||||||
Floor | 11% | ||||||
Ceiling | 0% | ||||||
ETP | 4.25% | ||||||
Maturity Date | Jan. 01, 2028 | ||||||
Principal Amount | $ 4,000 | ||||||
Investments at cost | 3,949 | ||||||
Investments at fair value | $ 3,949 | ||||||
Investment, Unaffiliated Issuer [Member] | Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 13.75% | ||||||
Margin | 6.25% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 1.85% | ||||||
Maturity Date | Jul. 01, 2025 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,951 | ||||||
Investments at fair value | $ 3,834 | ||||||
Investment, Unaffiliated Issuer [Member] | Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 13.75% | ||||||
Margin | 6.25% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 1.85% | ||||||
Maturity Date | Oct. 01, 2025 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,474 | ||||||
Investments at fair value | 1,916 | ||||||
Investment, Unaffiliated Issuer [Member] | Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 26 | ||||||
Investments at fair value | $ 0 | ||||||
Number of Shares (in shares) | 10,690 | ||||||
Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 13.75% | ||||||
Margin | 6.25% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Jan. 01, 2025 | ||||||
Principal Amount | $ 2,885 | ||||||
Investments at cost | 2,853 | ||||||
Investments at fair value | $ 2,777 | ||||||
Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 13.75% | ||||||
Margin | 6.25% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Jan. 01, 2025 | ||||||
Principal Amount | $ 2,885 | ||||||
Investments at cost | 2,823 | ||||||
Investments at fair value | 2,750 | ||||||
Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | 311 | 311 | |||||
Investments at fair value | $ 0 | $ 0 | |||||
Number of Shares (in shares) | 26,444 | 26,442 | |||||
Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 13.75% | ||||||
Margin | 6.25% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Jan. 01, 2025 | ||||||
Principal Amount | $ 1,442 | ||||||
Investments at cost | 1,411 | ||||||
Investments at fair value | $ 1,374 | ||||||
Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 13.75% | ||||||
Margin | 6.25% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Feb. 01, 2025 | ||||||
Principal Amount | $ 2,885 | ||||||
Investments at cost | 2,821 | ||||||
Investments at fair value | $ 2,748 | ||||||
Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Five [Member] | |||||||
Cash Rate | 13.75% | ||||||
Margin | 6.25% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Feb. 01, 2025 | ||||||
Principal Amount | $ 2,885 | ||||||
Investments at cost | 2,821 | ||||||
Investments at fair value | $ 2,748 | ||||||
Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Six [Member] | |||||||
Cash Rate | 13.75% | ||||||
Margin | 6.25% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Apr. 01, 2025 | ||||||
Principal Amount | $ 1,442 | ||||||
Investments at cost | 1,408 | ||||||
Investments at fair value | $ 1,371 | ||||||
Investment, Unaffiliated Issuer [Member] | Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Seven [Member] | |||||||
Cash Rate | 13.75% | ||||||
Margin | 6.25% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Apr. 01, 2025 | ||||||
Principal Amount | $ 1,442 | ||||||
Investments at cost | 1,408 | ||||||
Investments at fair value | $ 1,371 | ||||||
Investment, Unaffiliated Issuer [Member] | Corinth Medtech, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 12.25% | ||||||
Margin | 5.25% | ||||||
Floor | 8.50% | ||||||
Ceiling | 0% | ||||||
ETP | 20% | ||||||
Maturity Date | Sep. 15, 2022 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,500 | ||||||
Investments at fair value | $ 2,500 | ||||||
Investment, Unaffiliated Issuer [Member] | Corinth Medtech, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 12.25% | ||||||
Margin | 5.25% | ||||||
Floor | 8.50% | ||||||
Ceiling | 0% | ||||||
ETP | 20% | ||||||
Maturity Date | Sep. 15, 2022 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,500 | ||||||
Investments at fair value | $ 2,500 | ||||||
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 11.25% | 11.25% | |||||
Margin | 6% | 6% | |||||
Floor | 9.50% | 9.50% | |||||
Ceiling | 11.25% | 11.25% | |||||
ETP | 3% | 3% | |||||
Maturity Date | Jul. 01, 2027 | Jul. 01, 2027 | |||||
Principal Amount | $ 3,750 | $ 3,750 | |||||
Investments at cost | 3,605 | 3,478 | |||||
Investments at fair value | $ 3,605 | $ 3,478 | |||||
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 11.25% | 11.25% | |||||
Margin | 6% | 6% | |||||
Floor | 9.50% | 9.50% | |||||
Ceiling | 11.25% | 11.25% | |||||
ETP | 3% | 3% | |||||
Maturity Date | Jul. 01, 2027 | Jul. 01, 2027 | |||||
Principal Amount | $ 1,250 | $ 1,250 | |||||
Investments at cost | 1,241 | 1,238 | |||||
Investments at fair value | 1,241 | 1,238 | |||||
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 92 | 56 | |||||
Investments at fair value | $ 279 | $ 233 | |||||
Number of Shares (in shares) | 37,294 | 31,966 | |||||
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 11.25% | 11.25% | |||||
Margin | 6% | 6% | |||||
Floor | 9.50% | 9.50% | |||||
Ceiling | 11.25% | 11.25% | |||||
ETP | 3% | 3% | |||||
Maturity Date | Jul. 01, 2027 | Jul. 01, 2027 | |||||
Principal Amount | $ 3,750 | $ 3,750 | |||||
Investments at cost | 3,723 | 3,715 | |||||
Investments at fair value | $ 3,723 | $ 3,715 | |||||
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 11.25% | 11.25% | |||||
Margin | 6% | 6% | |||||
Floor | 9.50% | 9.50% | |||||
Ceiling | 11.25% | 11.25% | |||||
ETP | 3% | 3% | |||||
Maturity Date | Jul. 01, 2027 | Jul. 01, 2027 | |||||
Principal Amount | $ 1,250 | $ 1,250 | |||||
Investments at cost | 1,241 | 1,238 | |||||
Investments at fair value | $ 1,241 | $ 1,238 | |||||
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Five [Member] | |||||||
Cash Rate | 11.25% | 11.25% | |||||
Margin | 6% | 6% | |||||
Floor | 9.50% | 9.50% | |||||
Ceiling | 11.25% | 11.25% | |||||
ETP | 3% | 3% | |||||
Maturity Date | Jul. 01, 2027 | Jul. 01, 2027 | |||||
Principal Amount | $ 3,750 | $ 3,750 | |||||
Investments at cost | 3,723 | 3,715 | |||||
Investments at fair value | $ 3,723 | $ 3,715 | |||||
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Six [Member] | |||||||
Cash Rate | 11.25% | 11.25% | |||||
Margin | 6% | 6% | |||||
Floor | 9.50% | 9.50% | |||||
Ceiling | 11.25% | 11.25% | |||||
ETP | 3% | 3% | |||||
Maturity Date | Jul. 01, 2027 | Jul. 01, 2027 | |||||
Principal Amount | $ 1,250 | $ 1,250 | |||||
Investments at cost | 1,241 | 1,238 | |||||
Investments at fair value | $ 1,241 | $ 1,238 | |||||
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Seven [Member] | |||||||
Cash Rate | 11.25% | 11.25% | |||||
Margin | 6% | 6% | |||||
Floor | 9.50% | 9.50% | |||||
Ceiling | 11.25% | 11.25% | |||||
ETP | 3% | 3% | |||||
Maturity Date | Jan. 01, 2028 | Jan. 01, 2028 | |||||
Principal Amount | $ 3,750 | $ 3,750 | |||||
Investments at cost | 3,709 | 3,698 | |||||
Investments at fair value | $ 3,709 | $ 3,698 | |||||
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Eight [Member] | |||||||
Cash Rate | 11.25% | 11.25% | |||||
Margin | 6% | 6% | |||||
Floor | 9.50% | 9.50% | |||||
Ceiling | 11.25% | 11.25% | |||||
ETP | 3% | 3% | |||||
Maturity Date | Jan. 01, 2028 | Jan. 01, 2028 | |||||
Principal Amount | $ 3,750 | $ 3,750 | |||||
Investments at cost | 3,703 | 3,698 | |||||
Investments at fair value | $ 3,703 | $ 3,698 | |||||
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Nine [Member] | |||||||
Cash Rate | 11.25% | ||||||
Margin | 6% | ||||||
Floor | 9.50% | ||||||
Ceiling | 11.25% | ||||||
ETP | 3% | ||||||
Maturity Date | Apr. 01, 2028 | ||||||
Principal Amount | $ 3,750 | ||||||
Investments at cost | 3,709 | ||||||
Investments at fair value | $ 3,709 | ||||||
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Ten [Member] | |||||||
Cash Rate | 11.25% | ||||||
Margin | 6% | ||||||
Floor | 9.50% | ||||||
Ceiling | 11.25% | ||||||
ETP | 3% | ||||||
Maturity Date | Jul. 01, 2028 | ||||||
Principal Amount | $ 3,750 | ||||||
Investments at cost | 3,705 | ||||||
Investments at fair value | $ 3,705 | ||||||
Investment, Unaffiliated Issuer [Member] | Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Eleven [Member] | |||||||
Cash Rate | 11.25% | ||||||
Margin | 6% | ||||||
Floor | 9.50% | ||||||
Ceiling | 11.25% | ||||||
ETP | 3% | ||||||
Maturity Date | Jul. 01, 2028 | ||||||
Principal Amount | $ 3,750 | ||||||
Investments at cost | 3,705 | ||||||
Investments at fair value | $ 3,705 | ||||||
Investment, Unaffiliated Issuer [Member] | New Aerofarms, Inc. assignee of Aerofarms, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 15.25% | ||||||
Margin | 6.75% | ||||||
Floor | 10% | ||||||
Ceiling | 0% | ||||||
ETP | 4.33% | ||||||
Maturity Date | Dec. 01, 2026 | ||||||
Principal Amount | $ 3,750 | ||||||
Investments at cost | 3,675 | ||||||
Investments at fair value | $ 3,675 | ||||||
Investment, Unaffiliated Issuer [Member] | New Aerofarms, Inc. assignee of Aerofarms, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 15.25% | ||||||
Margin | 6.75% | ||||||
Floor | 10% | ||||||
Ceiling | 0% | ||||||
ETP | 4.33% | ||||||
Maturity Date | Dec. 01, 2026 | ||||||
Principal Amount | $ 3,750 | ||||||
Investments at cost | 3,675 | ||||||
Investments at fair value | 3,675 | ||||||
Investment, Unaffiliated Issuer [Member] | New Aerofarms, Inc. assignee of Aerofarms, Inc [Member] | Other Sustainability Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 81 | ||||||
Investments at fair value | $ 81 | ||||||
Number of Shares (in shares) | 400,000 | ||||||
Investment, Unaffiliated Issuer [Member] | Hound Labs, Inc. [Member] | Diagnostics Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 14.50% | 13.50% | |||||
Margin | 6% | 6% | |||||
Floor | 9.25% | 9.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 3.50% | 3.50% | |||||
Maturity Date | Jun. 01, 2026 | Jun. 01, 2026 | |||||
Principal Amount | $ 2,500 | $ 2,500 | |||||
Investments at cost | 2,481 | 2,385 | |||||
Investments at fair value | $ 2,481 | $ 2,385 | |||||
Investment, Unaffiliated Issuer [Member] | Hound Labs, Inc. [Member] | Diagnostics Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 14.50% | 13.50% | |||||
Margin | 6% | 6% | |||||
Floor | 9.25% | 9.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 3.50% | 3.50% | |||||
Maturity Date | Jun. 01, 2026 | Jun. 01, 2026 | |||||
Principal Amount | $ 2,500 | $ 2,500 | |||||
Investments at cost | 2,481 | 2,473 | |||||
Investments at fair value | 2,481 | 2,473 | |||||
Investment, Unaffiliated Issuer [Member] | Hound Labs, Inc. [Member] | Diagnostics Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 47 | 47 | |||||
Investments at fair value | $ 15 | $ 54 | |||||
Number of Shares (in shares) | 171,370 | 159,893 | |||||
Investment, Unaffiliated Issuer [Member] | Hound Labs, Inc. [Member] | Diagnostics Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 14.50% | 13.50% | |||||
Margin | 6% | 6% | |||||
Floor | 9.25% | 9.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 3.50% | 3.50% | |||||
Maturity Date | Jun. 01, 2026 | Jun. 01, 2026 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,962 | 4,946 | |||||
Investments at fair value | $ 4,962 | $ 4,946 | |||||
Investment, Unaffiliated Issuer [Member] | Scientia Vascular, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 13.25% | 11.75% | |||||
Margin | 4.75% | 4.75% | |||||
Floor | 8.50% | 8.50% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5% | 5% | |||||
Maturity Date | Jan. 01, 2027 | Jan. 01, 2027 | |||||
Principal Amount | $ 3,750 | $ 3,750 | |||||
Investments at cost | 3,663 | 3,597 | |||||
Investments at fair value | $ 3,663 | $ 3,597 | |||||
Investment, Unaffiliated Issuer [Member] | Scientia Vascular, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 13.25% | 11.75% | |||||
Margin | 4.75% | 4.75% | |||||
Floor | 8.50% | 8.50% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5% | 5% | |||||
Maturity Date | Jan. 01, 2027 | Jan. 01, 2027 | |||||
Principal Amount | $ 3,750 | $ 3,750 | |||||
Investments at cost | 3,718 | 3,706 | |||||
Investments at fair value | 3,718 | 3,706 | |||||
Investment, Unaffiliated Issuer [Member] | Scientia Vascular, Inc. [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 59 | 40 | |||||
Investments at fair value | $ 230 | $ 46 | |||||
Number of Shares (in shares) | 27,036 | 19,662 | |||||
Investment, Unaffiliated Issuer [Member] | Scientia Vascular, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 13.75% | ||||||
Margin | 5.25% | ||||||
Floor | 9% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Mar. 01, 2027 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,938 | ||||||
Investments at fair value | 4,938 | ||||||
Investment, Unaffiliated Issuer [Member] | LiquiGlide, Inc [Member] | Other Sustainability Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | 41 | $ 39 | |||||
Investments at fair value | $ 59 | $ 55 | |||||
Number of Shares (in shares) | 61,359 | 61,539 | |||||
Investment, Unaffiliated Issuer [Member] | Kate Farms, Inc [Member] | Other Healthcare Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | $ 102 | $ 102 | |||||
Investments at fair value | $ 1,379 | $ 1,370 | |||||
Number of Shares (in shares) | 82,965 | 82,965 | |||||
Investment, Unaffiliated Issuer [Member] | CSA Medical, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 13.59% | ||||||
Margin | 5.09% | ||||||
Floor | 10% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Jan. 01, 2024 | ||||||
Principal Amount | $ 750 | ||||||
Investments at cost | 739 | ||||||
Investments at fair value | $ 739 | ||||||
Investment, Unaffiliated Issuer [Member] | CSA Medical, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 13.59% | ||||||
Margin | 5.09% | ||||||
Floor | 10% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Jan. 01, 2024 | ||||||
Principal Amount | $ 50 | ||||||
Investments at cost | 49 | ||||||
Investments at fair value | 49 | ||||||
Investment, Unaffiliated Issuer [Member] | CSA Medical, Inc [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 172 | $ 153 | |||||
Investments at fair value | $ 176 | $ 150 | |||||
Number of Shares (in shares) | 1,730,746 | 1,375,727 | |||||
Investment, Unaffiliated Issuer [Member] | CSA Medical, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 13.59% | ||||||
Margin | 5.09% | ||||||
Floor | 10% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Mar. 01, 2024 | ||||||
Principal Amount | $ 1,067 | ||||||
Investments at cost | 1,052 | ||||||
Investments at fair value | 1,052 | ||||||
Investment, Unaffiliated Issuer [Member] | CSA Medical, Inc [Member] | Medical Device Sector [Member] | Term Loan, LIBOR Index, One [Member] | |||||||
Cash Rate | 12.37% | ||||||
Margin | 8.20% | ||||||
Floor | 10% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Jan. 01, 2024 | ||||||
Principal Amount | $ 1,625 | ||||||
Investments at cost | 1,610 | ||||||
Investments at fair value | $ 1,610 | ||||||
Investment, Unaffiliated Issuer [Member] | CSA Medical, Inc [Member] | Medical Device Sector [Member] | Term Loan, LIBOR Index, Two [Member] | |||||||
Cash Rate | 12.37% | ||||||
Margin | 8.20% | ||||||
Floor | 10% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Jan. 01, 2024 | ||||||
Principal Amount | $ 108 | ||||||
Investments at cost | 107 | ||||||
Investments at fair value | $ 107 | ||||||
Investment, Unaffiliated Issuer [Member] | CSA Medical, Inc [Member] | Medical Device Sector [Member] | Term Loan, LIBOR Index, Three [Member] | |||||||
Cash Rate | 12.37% | ||||||
Margin | 8.20% | ||||||
Floor | 10% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Mar. 01, 2024 | ||||||
Principal Amount | $ 2,000 | ||||||
Investments at cost | 1,983 | ||||||
Investments at fair value | 1,983 | ||||||
Investment, Unaffiliated Issuer [Member] | Intelepeer Holdings, Inc [Member] | Communications Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 138 | 139 | |||||
Investments at fair value | $ 3,283 | $ 3,265 | |||||
Number of Shares (in shares) | 2,936,535 | 2,936,535 | |||||
Investment, Unaffiliated Issuer [Member] | CAMP NYC, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 15.75% | 14.75% | |||||
Margin | 7.25% | 7.25% | |||||
Floor | 10.50% | 10.50% | |||||
Ceiling | 0% | 0% | |||||
ETP | 3% | 3% | |||||
Maturity Date | May 01, 2026 | May 01, 2026 | |||||
Principal Amount | $ 3,500 | $ 3,500 | |||||
Investments at cost | 3,470 | 3,461 | |||||
Investments at fair value | 3,470 | 3,461 | |||||
Investment, Unaffiliated Issuer [Member] | CAMP NYC, Inc [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 22 | 20 | |||||
Investments at fair value | $ 30 | $ 61 | |||||
Number of Shares (in shares) | 75,997 | 17,605 | |||||
Investment, Unaffiliated Issuer [Member] | Engage3, LLC [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 14.75% | 13.25% | |||||
Margin | 6.25% | 6.25% | |||||
Floor | 9.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4.50% | 4.50% | |||||
Maturity Date | Jul. 01, 2027 | Jul. 01, 2027 | |||||
Principal Amount | $ 3,750 | $ 3,750 | |||||
Investments at cost | 3,726 | 3,678 | |||||
Investments at fair value | $ 3,726 | $ 3,678 | |||||
Investment, Unaffiliated Issuer [Member] | Engage3, LLC [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 14.75% | 13.25% | |||||
Margin | 6.25% | 6.25% | |||||
Floor | 9.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4.50% | 4.50% | |||||
Maturity Date | Jul. 01, 2027 | Jul. 01, 2027 | |||||
Principal Amount | $ 3,750 | $ 3,750 | |||||
Investments at cost | 3,726 | 3,718 | |||||
Investments at fair value | $ 3,726 | 3,718 | |||||
Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 13.22% | ||||||
Margin | 4.72% | ||||||
Floor | 9.75% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Jun. 01, 2024 | ||||||
Principal Amount | $ 1,979 | ||||||
Investments at cost | 1,971 | ||||||
Investments at fair value | $ 1,971 | ||||||
Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 13.22% | ||||||
Margin | 4.72% | ||||||
Floor | 9.75% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Jun. 01, 2024 | ||||||
Principal Amount | $ 1,979 | ||||||
Investments at cost | 1,972 | ||||||
Investments at fair value | 1,972 | ||||||
Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 176 | 176 | |||||
Investments at fair value | $ 269 | $ 263 | |||||
Number of Shares (in shares) | 110,402 | 110,402 | |||||
Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Common Stock [Member] | |||||||
Investments at cost | $ 355 | $ 356 | |||||
Investments at fair value | $ 356 | $ 356 | |||||
Number of Shares (in shares) | 32,831 | 32,831 | |||||
Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 13.22% | ||||||
Margin | 4.72% | ||||||
Floor | 9.75% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Nov. 01, 2025 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,943 | ||||||
Investments at fair value | $ 4,943 | ||||||
Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, LIBOR Index, One [Member] | |||||||
Cash Rate | 12.07% | ||||||
Margin | 7.90% | ||||||
Floor | 9.75% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Jun. 01, 2024 | ||||||
Principal Amount | $ 1,979 | ||||||
Investments at cost | 1,962 | ||||||
Investments at fair value | $ 1,962 | ||||||
Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 13.22% | ||||||
Margin | 4.72% | ||||||
Floor | 9.75% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | May 01, 2026 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,939 | ||||||
Investments at fair value | 4,939 | ||||||
Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, LIBOR Index, Two [Member] | |||||||
Cash Rate | 12.07% | ||||||
Margin | 7.90% | ||||||
Floor | 9.75% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Jun. 01, 2024 | ||||||
Principal Amount | $ 1,979 | ||||||
Investments at cost | 1,963 | ||||||
Investments at fair value | $ 1,963 | ||||||
Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, LIBOR Index, Three [Member] | |||||||
Cash Rate | 12.07% | ||||||
Margin | 7.90% | ||||||
Floor | 9.75% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Nov. 01, 2025 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,923 | ||||||
Investments at fair value | $ 4,923 | ||||||
Investment, Unaffiliated Issuer [Member] | Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, LIBOR Index, Four [Member] | |||||||
Cash Rate | 12.07% | ||||||
Margin | 7.90% | ||||||
Floor | 9.75% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | May 01, 2026 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,912 | ||||||
Investments at fair value | $ 4,912 | ||||||
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc [Member] | Other Sustainability Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | 490 | ||||||
Investments at fair value | $ 0 | ||||||
Number of Shares (in shares) | 217,726 | ||||||
Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 14% | ||||||
Margin | 5.50% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Aug. 01, 2027 | ||||||
Principal Amount | $ 7,000 | ||||||
Investments at cost | 6,677 | ||||||
Investments at fair value | $ 6,677 | ||||||
Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 14% | ||||||
Margin | 5.50% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Aug. 01, 2027 | ||||||
Principal Amount | $ 3,500 | ||||||
Investments at cost | 3,459 | ||||||
Investments at fair value | 3,459 | ||||||
Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 167 | ||||||
Investments at fair value | $ 0 | ||||||
Number of Shares (in shares) | 85,066 | ||||||
Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 14% | ||||||
Margin | 5.50% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Aug. 01, 2027 | ||||||
Principal Amount | $ 3,500 | ||||||
Investments at cost | 3,459 | ||||||
Investments at fair value | $ 3,459 | ||||||
Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 14% | ||||||
Margin | 5.50% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Apr. 01, 2028 | ||||||
Principal Amount | $ 2,750 | ||||||
Investments at cost | 2,708 | ||||||
Investments at fair value | 2,708 | ||||||
Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 12.50% | ||||||
Margin | 5.50% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Aug. 01, 2027 | ||||||
Principal Amount | $ 7,000 | ||||||
Investments at cost | 6,619 | ||||||
Investments at fair value | $ 6,619 | ||||||
Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 12.50% | ||||||
Margin | 5.50% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Aug. 01, 2027 | ||||||
Principal Amount | $ 3,500 | ||||||
Investments at cost | 3,448 | ||||||
Investments at fair value | 3,448 | ||||||
Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 160 | ||||||
Investments at fair value | $ 170 | ||||||
Number of Shares (in shares) | 80,544 | ||||||
Investment, Unaffiliated Issuer [Member] | BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 12.50% | ||||||
Margin | 5.50% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Aug. 01, 2027 | ||||||
Principal Amount | $ 3,500 | ||||||
Investments at cost | 3,448 | ||||||
Investments at fair value | 3,448 | ||||||
Investment, Unaffiliated Issuer [Member] | Corvium, Inc [Member] | Biotechnology Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 53 | ||||||
Investments at fair value | $ 0 | ||||||
Number of Shares (in shares) | 661,956 | ||||||
Investment, Unaffiliated Issuer [Member] | PebblePost, Inc [Member] | Communications Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 92 | $ 92 | |||||
Investments at fair value | $ 139 | $ 173 | |||||
Number of Shares (in shares) | 598,850 | 598,850 | |||||
Investment, Unaffiliated Issuer [Member] | Clara Foods Co [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 14.25% | 12.75% | |||||
Margin | 5.75% | 5.75% | |||||
Floor | 9% | 9% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5.50% | 5.50% | |||||
Maturity Date | Aug. 01, 2025 | Aug. 01, 2025 | |||||
Principal Amount | $ 1,833 | $ 2,500 | |||||
Investments at cost | 1,821 | 2,482 | |||||
Investments at fair value | $ 1,821 | $ 2,482 | |||||
Investment, Unaffiliated Issuer [Member] | Clara Foods Co [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 14.25% | 12.75% | |||||
Margin | 5.75% | 5.75% | |||||
Floor | 9% | 9% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5.50% | 5.50% | |||||
Maturity Date | Aug. 01, 2025 | Aug. 01, 2025 | |||||
Principal Amount | $ 1,833 | $ 2,500 | |||||
Investments at cost | 1,821 | 2,482 | |||||
Investments at fair value | 1,821 | 2,482 | |||||
Investment, Unaffiliated Issuer [Member] | Clara Foods Co [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 31 | 30 | |||||
Investments at fair value | $ 128 | $ 125 | |||||
Number of Shares (in shares) | 46,745 | 46,745 | |||||
Investment, Unaffiliated Issuer [Member] | Imunon, Inc [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | $ 65 | $ 66 | |||||
Investments at fair value | $ 0 | $ 0 | |||||
Number of Shares (in shares) | 19,671 | 16,502 | |||||
Investment, Unaffiliated Issuer [Member] | Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 15.25% | 14.25% | |||||
Margin | 6.75% | 6.75% | |||||
Floor | 10% | 10% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.75% | 2.75% | |||||
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |||||
Principal Amount | $ 5,000 | $ 2,500 | |||||
Investments at cost | 4,951 | 2,463 | |||||
Investments at fair value | $ 4,951 | $ 2,463 | |||||
Investment, Unaffiliated Issuer [Member] | Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 15.25% | 14.25% | |||||
Margin | 6.75% | 6.75% | |||||
Floor | 10% | 10% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.75% | 2.75% | |||||
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |||||
Principal Amount | $ 2,500 | $ 5,000 | |||||
Investments at cost | 2,475 | 4,927 | |||||
Investments at fair value | 2,475 | 4,927 | |||||
Investment, Unaffiliated Issuer [Member] | Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 214 | 214 | |||||
Investments at fair value | $ 371 | $ 361 | |||||
Number of Shares (in shares) | 681 | 681 | |||||
Investment, Unaffiliated Issuer [Member] | Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 15.25% | 14.25% | |||||
Margin | 6.75% | 6.75% | |||||
Floor | 10% | 10% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.75% | 2.75% | |||||
Maturity Date | May 01, 2026 | May 01, 2026 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,948 | 4,924 | |||||
Investments at fair value | $ 4,948 | $ 4,924 | |||||
Investment, Unaffiliated Issuer [Member] | Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 15.25% | 14.25% | |||||
Margin | 6.75% | 6.75% | |||||
Floor | 10% | 10% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.75% | 2.75% | |||||
Maturity Date | May 01, 2026 | May 01, 2026 | |||||
Principal Amount | $ 2,500 | $ 2,500 | |||||
Investments at cost | 2,474 | 2,462 | |||||
Investments at fair value | $ 2,474 | $ 2,462 | |||||
Investment, Unaffiliated Issuer [Member] | Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Five [Member] | |||||||
Cash Rate | 14% | 13% | |||||
Margin | 5.50% | 5.50% | |||||
Floor | 11.75% | 10% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.75% | 2.75% | |||||
Maturity Date | Dec. 01, 2026 | Dec. 01, 2026 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,926 | 4,900 | |||||
Investments at fair value | $ 4,926 | $ 4,900 | |||||
Investment, Unaffiliated Issuer [Member] | Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Six [Member] | |||||||
Cash Rate | 14% | 13% | |||||
Margin | 5.50% | 5.50% | |||||
Floor | 11.75% | 10% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.75% | 2.75% | |||||
Maturity Date | Dec. 01, 2026 | Dec. 01, 2026 | |||||
Principal Amount | $ 2,500 | $ 2,500 | |||||
Investments at cost | 2,463 | 2,450 | |||||
Investments at fair value | $ 2,463 | $ 2,450 | |||||
Investment, Unaffiliated Issuer [Member] | Elligo Health Research, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 12% | ||||||
Margin | 3.50% | ||||||
Floor | 11.75% | ||||||
Ceiling | 0% | ||||||
ETP | 4% | ||||||
Maturity Date | Oct. 01, 2027 | ||||||
Principal Amount | $ 10,000 | ||||||
Investments at cost | 9,647 | ||||||
Investments at fair value | $ 9,647 | ||||||
Investment, Unaffiliated Issuer [Member] | Elligo Health Research, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 12% | ||||||
Margin | 3.50% | ||||||
Floor | 11.75% | ||||||
Ceiling | 0% | ||||||
ETP | 4% | ||||||
Maturity Date | Oct. 01, 2027 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,921 | ||||||
Investments at fair value | 4,921 | ||||||
Investment, Unaffiliated Issuer [Member] | Elligo Health Research, Inc [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 189 | ||||||
Investments at fair value | $ 191 | ||||||
Number of Shares (in shares) | 652,250 | ||||||
Investment, Unaffiliated Issuer [Member] | Elligo Health Research, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 12% | ||||||
Margin | 3.50% | ||||||
Floor | 11.75% | ||||||
Ceiling | 0% | ||||||
ETP | 4% | ||||||
Maturity Date | Oct. 01, 2027 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,921 | ||||||
Investments at fair value | $ 4,921 | ||||||
Investment, Unaffiliated Issuer [Member] | Elligo Health Research, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 12% | ||||||
Margin | 3.50% | ||||||
Floor | 11.75% | ||||||
Ceiling | 0% | ||||||
ETP | 4% | ||||||
Maturity Date | Oct. 01, 2027 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,921 | ||||||
Investments at fair value | 4,921 | ||||||
Investment, Unaffiliated Issuer [Member] | Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 13.75% | ||||||
Margin | 6.75% | ||||||
Floor | 10% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Jan. 01, 2025 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,966 | ||||||
Investments at fair value | $ 4,966 | ||||||
Investment, Unaffiliated Issuer [Member] | Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 13.75% | ||||||
Margin | 6.75% | ||||||
Floor | 10% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Jan. 01, 2025 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,966 | ||||||
Investments at fair value | 4,966 | ||||||
Investment, Unaffiliated Issuer [Member] | Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 93 | 93 | |||||
Investments at fair value | $ 0 | $ 64 | |||||
Number of Shares (in shares) | 20,000 | 20,000 | |||||
Investment, Unaffiliated Issuer [Member] | Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 13.75% | ||||||
Margin | 6.75% | ||||||
Floor | 10% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Jan. 01, 2025 | ||||||
Principal Amount | $ 3,000 | ||||||
Investments at cost | 2,979 | ||||||
Investments at fair value | $ 2,979 | ||||||
Investment, Unaffiliated Issuer [Member] | Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 13.75% | ||||||
Margin | 6.75% | ||||||
Floor | 10% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Dec. 01, 2025 | ||||||
Principal Amount | $ 1,000 | ||||||
Investments at cost | 976 | ||||||
Investments at fair value | $ 976 | ||||||
Investment, Unaffiliated Issuer [Member] | Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Five [Member] | |||||||
Cash Rate | 13.75% | ||||||
Margin | 6.75% | ||||||
Floor | 10% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Feb. 01, 2026 | ||||||
Principal Amount | $ 1,000 | ||||||
Investments at cost | 977 | ||||||
Investments at fair value | $ 977 | ||||||
Investment, Unaffiliated Issuer [Member] | Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 12% | 13.50% | |||||
Margin | 3.50% | 6.50% | |||||
Floor | 11.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 8% | 8% | |||||
Maturity Date | Sep. 01, 2027 | Jun. 01, 2025 | |||||
Principal Amount | $ 2,500 | $ 2,500 | |||||
Investments at cost | 2,295 | 2,476 | |||||
Investments at fair value | $ 2,295 | $ 2,476 | |||||
Investment, Unaffiliated Issuer [Member] | Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 12% | 13.50% | |||||
Margin | 3.50% | 6.50% | |||||
Floor | 11.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 8% | 8% | |||||
Maturity Date | Sep. 01, 2027 | Jun. 01, 2025 | |||||
Principal Amount | $ 2,500 | $ 2,500 | |||||
Investments at cost | 2,471 | 2,476 | |||||
Investments at fair value | 2,471 | 2,476 | |||||
Investment, Unaffiliated Issuer [Member] | Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 275 | 98 | |||||
Investments at fair value | $ 304 | $ 123 | |||||
Number of Shares (in shares) | 2,637,043 | 605,313 | |||||
Investment, Unaffiliated Issuer [Member] | Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 12% | 13.50% | |||||
Margin | 3.50% | 6.50% | |||||
Floor | 11.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 8% | 8% | |||||
Maturity Date | Sep. 01, 2027 | Jun. 01, 2025 | |||||
Principal Amount | $ 5,000 | $ 2,500 | |||||
Investments at cost | 4,943 | 2,476 | |||||
Investments at fair value | $ 4,943 | $ 2,476 | |||||
Investment, Unaffiliated Issuer [Member] | Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 12% | 13.50% | |||||
Margin | 3.50% | 6.50% | |||||
Floor | 11.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 8% | 8% | |||||
Maturity Date | Sep. 01, 2027 | Apr. 01, 2026 | |||||
Principal Amount | $ 5,000 | $ 2,500 | |||||
Investments at cost | 4,943 | 2,453 | |||||
Investments at fair value | $ 4,943 | $ 2,453 | |||||
Investment, Unaffiliated Issuer [Member] | Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, Five [Member] | |||||||
Cash Rate | 13.50% | ||||||
Margin | 6.50% | ||||||
Floor | 9.75% | ||||||
Ceiling | 0% | ||||||
ETP | 8% | ||||||
Maturity Date | May 01, 2026 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,455 | ||||||
Investments at fair value | $ 2,455 | ||||||
Investment, Unaffiliated Issuer [Member] | Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 14% | 13% | |||||
Margin | 5.50% | 5.50% | |||||
Floor | 10.25% | 10.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 4% | |||||
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |||||
Principal Amount | $ 10,000 | $ 10,000 | |||||
Investments at cost | 9,877 | 9,826 | |||||
Investments at fair value | $ 9,877 | $ 9,826 | |||||
Investment, Unaffiliated Issuer [Member] | Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 14% | 13% | |||||
Margin | 5.50% | 5.50% | |||||
Floor | 10.25% | 10.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 4% | |||||
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |||||
Principal Amount | $ 10,000 | $ 10,000 | |||||
Investments at cost | 9,877 | 9,826 | |||||
Investments at fair value | 9,877 | 9,826 | |||||
Investment, Unaffiliated Issuer [Member] | Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 273 | 273 | |||||
Investments at fair value | $ 124 | $ 296 | |||||
Number of Shares (in shares) | 639,918 | 639,918 | |||||
Investment, Unaffiliated Issuer [Member] | Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 14% | 13% | |||||
Margin | 5.50% | 5.50% | |||||
Floor | 10.25% | 10.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 4% | |||||
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,939 | 4,913 | |||||
Investments at fair value | $ 4,939 | $ 4,913 | |||||
Investment, Unaffiliated Issuer [Member] | Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 14% | 13% | |||||
Margin | 5.50% | 5.50% | |||||
Floor | 10.25% | 10.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 4% | |||||
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,939 | 4,913 | |||||
Investments at fair value | $ 4,939 | $ 4,913 | |||||
Investment, Unaffiliated Issuer [Member] | KSQ Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 13.25% | 12.25% | |||||
Margin | 4.75% | 4.75% | |||||
Floor | 8.50% | 8.50% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5.50% | 5.50% | |||||
Maturity Date | May 01, 2027 | May 01, 2027 | |||||
Principal Amount | $ 6,250 | $ 6,250 | |||||
Investments at cost | 6,193 | 6,077 | |||||
Investments at fair value | $ 6,193 | $ 6,077 | |||||
Investment, Unaffiliated Issuer [Member] | KSQ Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 13.25% | 12.25% | |||||
Margin | 4.75% | 4.75% | |||||
Floor | 8.50% | 8.50% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5.50% | 5.50% | |||||
Maturity Date | May 01, 2027 | May 01, 2027 | |||||
Principal Amount | $ 6,250 | $ 6,250 | |||||
Investments at cost | 6,193 | 6,177 | |||||
Investments at fair value | 6,193 | 6,177 | |||||
Investment, Unaffiliated Issuer [Member] | KSQ Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 50 | 51 | |||||
Investments at fair value | $ 60 | $ 60 | |||||
Number of Shares (in shares) | 48,076 | 48,077 | |||||
Investment, Unaffiliated Issuer [Member] | Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 15.25% | 14.25% | |||||
Margin | 6.75% | 6.75% | |||||
Floor | 10% | 10% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.50% | 2.50% | |||||
Maturity Date | Apr. 01, 2028 | Jun. 01, 2025 | |||||
Principal Amount | $ 3,750 | $ 3,750 | |||||
Investments at cost | 3,678 | 3,697 | |||||
Investments at fair value | $ 3,678 | $ 3,697 | |||||
Investment, Unaffiliated Issuer [Member] | Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 15.25% | 14.25% | |||||
Margin | 6.75% | 6.75% | |||||
Floor | 10% | 10% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.50% | 2.50% | |||||
Maturity Date | Apr. 01, 2028 | Jun. 01, 2025 | |||||
Principal Amount | $ 3,750 | $ 3,750 | |||||
Investments at cost | 3,692 | 3,717 | |||||
Investments at fair value | 3,692 | 3,717 | |||||
Investment, Unaffiliated Issuer [Member] | Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 175 | 126 | |||||
Investments at fair value | $ 322 | $ 268 | |||||
Number of Shares (in shares) | 46,311 | 35,906 | |||||
Investment, Unaffiliated Issuer [Member] | Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 15.25% | 14.25% | |||||
Margin | 6.75% | 6.75% | |||||
Floor | 10% | 10% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.50% | 2.50% | |||||
Maturity Date | Apr. 01, 2028 | Oct. 01, 2025 | |||||
Principal Amount | $ 7,500 | $ 7,500 | |||||
Investments at cost | 7,374 | 7,424 | |||||
Investments at fair value | $ 7,374 | $ 7,424 | |||||
Investment, Unaffiliated Issuer [Member] | Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 15.25% | 14.25% | |||||
Margin | 6.75% | 6.75% | |||||
Floor | 10% | 10% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.50% | 2.50% | |||||
Maturity Date | Apr. 01, 2028 | Oct. 01, 2025 | |||||
Principal Amount | $ 3,750 | $ 3,750 | |||||
Investments at cost | 3,687 | 3,712 | |||||
Investments at fair value | $ 3,687 | $ 3,712 | |||||
Investment, Unaffiliated Issuer [Member] | Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Five [Member] | |||||||
Cash Rate | 15.25% | 14.25% | |||||
Margin | 6.75% | 6.75% | |||||
Floor | 10% | 10% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.50% | 2.50% | |||||
Maturity Date | Apr. 01, 2028 | Oct. 01, 2025 | |||||
Principal Amount | $ 3,750 | $ 3,750 | |||||
Investments at cost | 3,687 | 3,712 | |||||
Investments at fair value | 3,687 | 3,712 | |||||
Investment, Unaffiliated Issuer [Member] | Medsphere Systems Corporation [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 61 | ||||||
Investments at fair value | $ 346 | ||||||
Number of Shares (in shares) | 7,097,792 | ||||||
Investment, Unaffiliated Issuer [Member] | Medsphere Systems Corporation [Member] | Software, Healthcare Information and Service [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 60 | ||||||
Investments at fair value | $ 359 | ||||||
Number of Shares (in shares) | 7,097,792 | ||||||
Investment, Unaffiliated Issuer [Member] | Embody, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 14% | ||||||
Margin | 6.50% | ||||||
Floor | 9.75% | ||||||
Ceiling | 0% | ||||||
ETP | 28% | ||||||
Maturity Date | Aug. 01, 2026 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,482 | ||||||
Investments at fair value | 2,482 | ||||||
Investment, Unaffiliated Issuer [Member] | Aterian, Inc [Member] | Consumer-related Technologies [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | $ 195 | 195 | |||||
Investments at fair value | $ 0 | $ 0 | |||||
Number of Shares (in shares) | 76,923 | 76,923 | |||||
Investment, Unaffiliated Issuer [Member] | Mustang Bio, Inc [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | $ 146 | $ 146 | |||||
Investments at fair value | $ 0 | $ 0 | |||||
Number of Shares (in shares) | 16,611 | 252,161 | |||||
Investment, Unaffiliated Issuer [Member] | SafelyYou, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 11.75% | ||||||
Margin | 3.25% | ||||||
Floor | 11% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Jun. 01, 2027 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,642 | ||||||
Investments at fair value | $ 4,642 | ||||||
Investment, Unaffiliated Issuer [Member] | SafelyYou, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 11.75% | ||||||
Margin | 3.25% | ||||||
Floor | 11% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Jun. 01, 2027 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,912 | ||||||
Investments at fair value | 4,912 | ||||||
Investment, Unaffiliated Issuer [Member] | SafelyYou, Inc [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 163 | ||||||
Investments at fair value | $ 167 | ||||||
Number of Shares (in shares) | 150,353 | ||||||
Investment, Unaffiliated Issuer [Member] | InfoBionic, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 14.75% | 13.25% | |||||
Margin | 6.25% | 6.25% | |||||
Floor | 9.50% | 9.50% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 4% | |||||
Maturity Date | Oct. 01, 2024 | Oct. 01, 2024 | |||||
Principal Amount | $ 2,771 | $ 3,208 | |||||
Investments at cost | 2,733 | 3,143 | |||||
Investments at fair value | $ 2,733 | $ 3,143 | |||||
Investment, Unaffiliated Issuer [Member] | InfoBionic, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 14.75% | 13.25% | |||||
Margin | 6.25% | 6.25% | |||||
Floor | 9.50% | 9.50% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 4% | |||||
Maturity Date | Jun. 01, 2025 | Jun. 01, 2025 | |||||
Principal Amount | $ 1,000 | $ 1,000 | |||||
Investments at cost | 982 | 974 | |||||
Investments at fair value | 982 | 974 | |||||
Investment, Unaffiliated Issuer [Member] | InfoBionic, Inc [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 124 | 124 | |||||
Investments at fair value | $ 59 | $ 113 | |||||
Number of Shares (in shares) | 317,647 | 317,647 | |||||
Investment, Unaffiliated Issuer [Member] | F-Star Therapeutics, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 13.25% | ||||||
Margin | 6.25% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 4% | ||||||
Maturity Date | Apr. 01, 2025 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,476 | ||||||
Investments at fair value | $ 2,476 | ||||||
Investment, Unaffiliated Issuer [Member] | F-Star Therapeutics, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 13.25% | ||||||
Margin | 6.25% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 4% | ||||||
Maturity Date | Jul. 01, 2025 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,473 | ||||||
Investments at fair value | 2,473 | ||||||
Investment, Unaffiliated Issuer [Member] | F-Star Therapeutics, Inc [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | 35 | ||||||
Investments at fair value | $ 0 | ||||||
Number of Shares (in shares) | 21,120 | ||||||
Investment, Unaffiliated Issuer [Member] | Native Microbials, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 13.75% | 12.75% | |||||
Margin | 5.25% | 5.25% | |||||
Floor | 8.50% | 8.50% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5% | 5% | |||||
Maturity Date | Nov. 01, 2026 | Nov. 01, 2026 | |||||
Principal Amount | $ 3,750 | $ 3,750 | |||||
Investments at cost | 3,716 | 3,630 | |||||
Investments at fair value | $ 3,716 | $ 3,630 | |||||
Investment, Unaffiliated Issuer [Member] | Native Microbials, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 13.75% | 12.75% | |||||
Margin | 5.25% | 5.25% | |||||
Floor | 8.50% | 8.50% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5% | 5% | |||||
Maturity Date | Nov. 01, 2026 | Nov. 01, 2026 | |||||
Principal Amount | $ 2,500 | $ 2,500 | |||||
Investments at cost | 2,478 | 2,469 | |||||
Investments at fair value | 2,478 | 2,469 | |||||
Investment, Unaffiliated Issuer [Member] | Native Microbials, Inc. [Member] | Biotechnology Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 64 | 64 | |||||
Investments at fair value | $ 165 | $ 162 | |||||
Number of Shares (in shares) | 103,679 | 103,679 | |||||
Investment, Unaffiliated Issuer [Member] | Greenlight Biosciences, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 14.25% | 13.25% | |||||
Margin | 5.75% | 5.75% | |||||
Floor | 9% | 9% | |||||
Ceiling | 0% | 0% | |||||
ETP | 3% | 3% | |||||
Maturity Date | Jul. 01, 2025 | Jul. 01, 2025 | |||||
Principal Amount | $ 3,500 | $ 5,000 | |||||
Investments at cost | 3,399 | 4,857 | |||||
Investments at fair value | $ 3,365 | $ 4,857 | |||||
Investment, Unaffiliated Issuer [Member] | Greenlight Biosciences, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 14.25% | 13.25% | |||||
Margin | 5.75% | 5.75% | |||||
Floor | 9% | 9% | |||||
Ceiling | 0% | 0% | |||||
ETP | 3% | 3% | |||||
Maturity Date | Jul. 01, 2025 | Jul. 01, 2025 | |||||
Principal Amount | $ 1,750 | $ 2,500 | |||||
Investments at cost | 1,699 | 2,430 | |||||
Investments at fair value | 1,684 | 2,430 | |||||
Investment, Unaffiliated Issuer [Member] | Greenlight Biosciences, Inc [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | 366 | ||||||
Investments at fair value | $ 0 | ||||||
Number of Shares (in shares) | 47,452 | ||||||
Investment, Unaffiliated Issuer [Member] | Caastle, Inc [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 68 | $ 68 | |||||
Investments at fair value | $ 1,060 | $ 1,069 | |||||
Number of Shares (in shares) | 268,591 | 268,591 | |||||
Investment, Unaffiliated Issuer [Member] | PDS Biotechnology Corporation [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 14.25% | 13.25% | |||||
Margin | 5.75% | 5.75% | |||||
Floor | 9.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 3.75% | 3.75% | |||||
Maturity Date | Sep. 01, 2026 | Sep. 01, 2026 | |||||
Principal Amount | $ 10,000 | $ 10,000 | |||||
Investments at cost | 9,898 | 9,701 | |||||
Investments at fair value | $ 9,898 | $ 9,701 | |||||
Investment, Unaffiliated Issuer [Member] | PDS Biotechnology Corporation [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 14.25% | 13.25% | |||||
Margin | 5.75% | 5.75% | |||||
Floor | 9.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 3.75% | 3.75% | |||||
Maturity Date | Sep. 01, 2026 | Sep. 01, 2026 | |||||
Principal Amount | $ 3,750 | $ 3,750 | |||||
Investments at cost | 3,712 | 3,697 | |||||
Investments at fair value | 3,712 | 3,697 | |||||
Investment, Unaffiliated Issuer [Member] | PDS Biotechnology Corporation [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | 162 | 160 | |||||
Investments at fair value | $ 667 | $ 3,024 | |||||
Number of Shares (in shares) | 299,848 | 299,848 | |||||
Investment, Unaffiliated Issuer [Member] | PDS Biotechnology Corporation [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 14.25% | 13.25% | |||||
Margin | 5.75% | 5.75% | |||||
Floor | 9.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 3.75% | 3.75% | |||||
Maturity Date | Sep. 01, 2026 | Sep. 01, 2026 | |||||
Principal Amount | $ 3,750 | $ 3,750 | |||||
Investments at cost | 3,712 | 3,697 | |||||
Investments at fair value | 3,712 | $ 3,697 | |||||
Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | |||||||
Investments at fair value | $ 4,934 | ||||||
Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 13.50% | 12% | |||||
Margin | 5% | 5% | |||||
Floor | 9.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 4% | |||||
Maturity Date | Mar. 01, 2025 | Mar. 01, 2025 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,960 | 4,939 | |||||
Investments at fair value | $ 4,960 | $ 4,939 | |||||
Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 13.50% | 12% | |||||
Margin | 5% | 5% | |||||
Floor | 9.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 4% | |||||
Maturity Date | Mar. 01, 2025 | Mar. 01, 2025 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,960 | 4,939 | |||||
Investments at fair value | 4,960 | 4,939 | |||||
Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 194 | 194 | |||||
Investments at fair value | $ 395 | $ 385 | |||||
Number of Shares (in shares) | 809,931 | 809,931 | |||||
Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 13.50% | 12% | |||||
Margin | 5% | 5% | |||||
Floor | 9.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 4% | |||||
Maturity Date | Mar. 01, 2025 | Mar. 01, 2025 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,956 | 4,933 | |||||
Investments at fair value | $ 4,956 | $ 4,933 | |||||
Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 13.50% | 12% | |||||
Margin | 5% | 5% | |||||
Floor | 9.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 4% | |||||
Maturity Date | Mar. 01, 2025 | Mar. 01, 2025 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,956 | 4,933 | |||||
Investments at fair value | $ 4,956 | $ 4,933 | |||||
Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, Five [Member] | |||||||
Cash Rate | 13.50% | 12.50% | |||||
Margin | 5% | 5% | |||||
Floor | 9.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 4% | |||||
Maturity Date | Jan. 01, 2027 | Jan. 01, 2027 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,934 | 4,913 | |||||
Investments at fair value | $ 4,934 | $ 4,913 | |||||
Investment, Unaffiliated Issuer [Member] | Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, Six [Member] | |||||||
Cash Rate | 13.50% | 12.50% | |||||
Margin | 5% | 5% | |||||
Floor | 9.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 4% | |||||
Maturity Date | Jan. 01, 2027 | Jan. 01, 2027 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | $ 4,934 | 4,913 | |||||
Investments at fair value | $ 4,913 | ||||||
Investment, Unaffiliated Issuer [Member] | Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 13.50% | 12.50% | |||||
Margin | 5% | 5% | |||||
Floor | 5% | 5% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 4% | |||||
Maturity Date | Mar. 01, 2027 | Mar. 01, 2027 | |||||
Principal Amount | $ 2,000 | $ 2,000 | |||||
Investments at cost | 1,335 | 1,082 | |||||
Investments at fair value | $ 1,335 | $ 1,082 | |||||
Investment, Unaffiliated Issuer [Member] | Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 13.50% | 12.50% | |||||
Margin | 5% | 5% | |||||
Floor | 5% | 5% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 4% | |||||
Maturity Date | Mar. 01, 2027 | Mar. 01, 2027 | |||||
Principal Amount | $ 3,000 | $ 3,000 | |||||
Investments at cost | 2,003 | 1,623 | |||||
Investments at fair value | 2,003 | 1,623 | |||||
Investment, Unaffiliated Issuer [Member] | Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | 2,945 | 2,947 | |||||
Investments at fair value | $ 2,676 | $ 2,947 | |||||
Number of Shares (in shares) | 1,312,500 | 1,312,500 | |||||
Investment, Unaffiliated Issuer [Member] | Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 12% | 11% | |||||
Margin | 3.50% | 3.50% | |||||
Floor | 10.50% | 10.50% | |||||
Ceiling | 0% | 0% | |||||
ETP | 7.78% | 7.78% | |||||
Maturity Date | Feb. 01, 2028 | Feb. 01, 2028 | |||||
Principal Amount | $ 2,813 | $ 2,813 | |||||
Investments at cost | 2,813 | 2,813 | |||||
Investments at fair value | $ 2,813 | $ 2,813 | |||||
Investment, Unaffiliated Issuer [Member] | Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 12% | 11% | |||||
Margin | 3.50% | 3.50% | |||||
Floor | 10.50% | 10.50% | |||||
Ceiling | 0% | 0% | |||||
ETP | 7.78% | 7.78% | |||||
Maturity Date | Feb. 01, 2028 | Feb. 01, 2028 | |||||
Principal Amount | $ 2,813 | $ 2,813 | |||||
Investments at cost | 2,813 | 2,813 | |||||
Investments at fair value | $ 2,813 | $ 2,813 | |||||
Investment, Unaffiliated Issuer [Member] | Spineology, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 15.50% | 14.50% | |||||
Margin | 7% | 7% | |||||
Floor | 10.25% | 10.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 1% | 1% | |||||
Maturity Date | Oct. 01, 2025 | Oct. 01, 2025 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,975 | 4,966 | |||||
Investments at fair value | $ 4,975 | $ 4,966 | |||||
Investment, Unaffiliated Issuer [Member] | Spineology, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 15.50% | 14.50% | |||||
Margin | 7% | 7% | |||||
Floor | 10.25% | 10.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 1% | 1% | |||||
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |||||
Principal Amount | $ 2,500 | $ 2,500 | |||||
Investments at cost | 2,487 | 2,481 | |||||
Investments at fair value | $ 2,487 | $ 2,481 | |||||
Investment, Unaffiliated Issuer [Member] | Lemongrass Holdings, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 15% | 14% | |||||
Margin | 6.50% | 6.50% | |||||
Floor | 9.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.50% | 2.50% | |||||
Maturity Date | Mar. 01, 2026 | Mar. 01, 2026 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,965 | 4,947 | |||||
Investments at fair value | $ 4,965 | $ 4,947 | |||||
Investment, Unaffiliated Issuer [Member] | Lemongrass Holdings, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 15% | 14% | |||||
Margin | 6.50% | 6.50% | |||||
Floor | 9.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.50% | 2.50% | |||||
Maturity Date | Mar. 01, 2026 | Mar. 01, 2026 | |||||
Principal Amount | $ 2,500 | $ 2,500 | |||||
Investments at cost | 2,483 | 2,474 | |||||
Investments at fair value | 2,483 | 2,474 | |||||
Investment, Unaffiliated Issuer [Member] | Lemongrass Holdings, Inc [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 32 | 34 | |||||
Investments at fair value | $ 43 | $ 41 | |||||
Number of Shares (in shares) | 101,308 | 101,308 | |||||
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 13.86% | ||||||
Margin | 5.36% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 5.50% | ||||||
Maturity Date | Dec. 01, 2024 | ||||||
Principal Amount | $ 4,667 | ||||||
Investments at cost | 4,594 | ||||||
Investments at fair value | $ 4,594 | ||||||
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 13.86% | ||||||
Margin | 5.36% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 5.50% | ||||||
Maturity Date | Dec. 01, 2024 | ||||||
Principal Amount | $ 4,667 | ||||||
Investments at cost | 4,594 | ||||||
Investments at fair value | 4,594 | ||||||
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 487 | $ 399 | |||||
Investments at fair value | $ 205 | $ 648 | |||||
Number of Shares (in shares) | 345,327 | 203,017 | |||||
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 13.86% | ||||||
Margin | 5.36% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 5.50% | ||||||
Maturity Date | Dec. 01, 2024 | ||||||
Principal Amount | $ 2,333 | ||||||
Investments at cost | 2,286 | ||||||
Investments at fair value | $ 2,286 | ||||||
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, LIBOR Index, One [Member] | |||||||
Cash Rate | 12.67% | ||||||
Margin | 8.50% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 5.50% | ||||||
Maturity Date | Dec. 01, 2024 | ||||||
Principal Amount | $ 4,667 | ||||||
Investments at cost | 4,597 | ||||||
Investments at fair value | $ 4,597 | ||||||
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 13.86% | ||||||
Margin | 5.36% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 5.50% | ||||||
Maturity Date | Dec. 01, 2024 | ||||||
Principal Amount | $ 2,333 | ||||||
Investments at cost | 2,286 | ||||||
Investments at fair value | $ 2,286 | ||||||
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, LIBOR Index, Two [Member] | |||||||
Cash Rate | 12.67% | ||||||
Margin | 8.50% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 5.50% | ||||||
Maturity Date | Dec. 01, 2024 | ||||||
Principal Amount | $ 4,667 | ||||||
Investments at cost | 4,597 | ||||||
Investments at fair value | $ 4,597 | ||||||
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Five [Member] | |||||||
Cash Rate | 13.86% | ||||||
Margin | 5.36% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 5.50% | ||||||
Maturity Date | Dec. 01, 2024 | ||||||
Principal Amount | $ 2,333 | ||||||
Investments at cost | 2,282 | ||||||
Investments at fair value | $ 2,282 | ||||||
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, LIBOR Index, Three [Member] | |||||||
Cash Rate | 12.67% | ||||||
Margin | 8.50% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 5.50% | ||||||
Maturity Date | Dec. 01, 2024 | ||||||
Principal Amount | $ 2,333 | ||||||
Investments at cost | 2,280 | ||||||
Investments at fair value | $ 2,280 | ||||||
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Six [Member] | |||||||
Cash Rate | 13.86% | ||||||
Margin | 5.36% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 5.50% | ||||||
Maturity Date | Dec. 01, 2024 | ||||||
Principal Amount | $ 2,333 | ||||||
Investments at cost | 2,282 | ||||||
Investments at fair value | 2,282 | ||||||
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, LIBOR Index, Four [Member] | |||||||
Cash Rate | 12.67% | ||||||
Margin | 8.50% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 5.50% | ||||||
Maturity Date | Dec. 01, 2024 | ||||||
Principal Amount | $ 2,333 | ||||||
Investments at cost | 2,280 | ||||||
Investments at fair value | $ 2,280 | ||||||
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, LIBOR Index, Five [Member] | |||||||
Cash Rate | 12.67% | ||||||
Margin | 8.50% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 5.50% | ||||||
Maturity Date | Dec. 01, 2024 | ||||||
Principal Amount | $ 2,333 | ||||||
Investments at cost | 2,274 | ||||||
Investments at fair value | $ 2,274 | ||||||
Investment, Unaffiliated Issuer [Member] | Provivi, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, LIBOR Index, Six [Member] | |||||||
Cash Rate | 12.67% | ||||||
Margin | 8.50% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 5.50% | ||||||
Maturity Date | Dec. 01, 2024 | ||||||
Principal Amount | $ 2,333 | ||||||
Investments at cost | 2,274 | ||||||
Investments at fair value | 2,274 | ||||||
Investment, Unaffiliated Issuer [Member] | Lumithera, Inc. [Member] | Medical Device Sector [Member] | Common Stock [Member] | |||||||
Investments at cost | 2,000 | 2,000 | |||||
Investments at fair value | $ 1,700 | $ 1,700 | |||||
Number of Shares (in shares) | 392,651 | 392,651 | |||||
Investment, Unaffiliated Issuer [Member] | Lumithera, Inc. [Member] | Medical Device Sector [Member] | Royalty Agreement [Member] | |||||||
Investments at cost | $ 1,200 | $ 1,200 | |||||
Investments at fair value | $ 1,100 | $ 1,100 | |||||
Investment, Unaffiliated Issuer [Member] | IMV Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 13.25% | ||||||
Margin | 5.75% | ||||||
Floor | 9% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Jul. 01, 2025 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,946 | ||||||
Investments at fair value | $ 4,946 | ||||||
Investment, Unaffiliated Issuer [Member] | IMV Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 13.25% | ||||||
Margin | 5.75% | ||||||
Floor | 9% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Jul. 01, 2025 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,473 | ||||||
Investments at fair value | 2,473 | ||||||
Investment, Unaffiliated Issuer [Member] | IMV Inc [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | 67 | ||||||
Investments at fair value | $ 0 | ||||||
Number of Shares (in shares) | 39,774 | ||||||
Investment, Unaffiliated Issuer [Member] | IMV Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 13.25% | ||||||
Margin | 5.75% | ||||||
Floor | 9% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Jan. 01, 2026 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,947 | ||||||
Investments at fair value | $ 4,947 | ||||||
Investment, Unaffiliated Issuer [Member] | IMV Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 13.25% | ||||||
Margin | 5.75% | ||||||
Floor | 9% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Jan. 01, 2026 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,947 | ||||||
Investments at fair value | $ 4,947 | ||||||
Investment, Unaffiliated Issuer [Member] | Stealth BioTherapeutics Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 14% | 13% | |||||
Margin | 5.50% | 5.50% | |||||
Floor | 8.75% | 8.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 6% | 6% | |||||
Maturity Date | Oct. 01, 2025 | Oct. 01, 2025 | |||||
Principal Amount | $ 4,500 | $ 5,000 | |||||
Investments at cost | 4,434 | 4,914 | |||||
Investments at fair value | $ 4,434 | $ 4,914 | |||||
Investment, Unaffiliated Issuer [Member] | Stealth BioTherapeutics Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 14% | 13% | |||||
Margin | 5.50% | 5.50% | |||||
Floor | 8.75% | 8.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 6% | 6% | |||||
Maturity Date | Oct. 01, 2025 | Oct. 01, 2025 | |||||
Principal Amount | $ 2,250 | $ 2,500 | |||||
Investments at cost | 2,217 | 2,457 | |||||
Investments at fair value | 2,217 | 2,457 | |||||
Investment, Unaffiliated Issuer [Member] | Stealth BioTherapeutics Inc. [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | 264 | 264 | |||||
Investments at fair value | $ 127 | $ 37 | |||||
Number of Shares (in shares) | 318,181 | 318,181 | |||||
Investment, Unaffiliated Issuer [Member] | ZetrOZ, Inc [Member] | Medical Device Sector [Member] | Royalty Agreement [Member] | |||||||
Investments at cost | $ 0 | $ 0 | |||||
Investments at fair value | $ 0 | $ 200 | |||||
Investment, Unaffiliated Issuer [Member] | Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 13.75% | 12.25% | |||||
Margin | 5.25% | 5.25% | |||||
Floor | 9% | 9% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5% | 5% | |||||
Maturity Date | Jul. 01, 2027 | Jul. 01, 2027 | |||||
Principal Amount | $ 3,500 | $ 3,500 | |||||
Investments at cost | 3,464 | 3,349 | |||||
Investments at fair value | $ 3,464 | $ 3,349 | |||||
Investment, Unaffiliated Issuer [Member] | Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 13.75% | 12.25% | |||||
Margin | 5.25% | 5.25% | |||||
Floor | 9% | 9% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5% | 5% | |||||
Maturity Date | Jul. 01, 2027 | Jul. 01, 2027 | |||||
Principal Amount | $ 3,500 | $ 3,500 | |||||
Investments at cost | 3,464 | 3,454 | |||||
Investments at fair value | 3,464 | 3,454 | |||||
Investment, Unaffiliated Issuer [Member] | Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 71 | 71 | |||||
Investments at fair value | $ 40 | $ 83 | |||||
Number of Shares (in shares) | 135,484 | 135,484 | |||||
Investment, Unaffiliated Issuer [Member] | Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 13.75% | ||||||
Margin | 5.25% | ||||||
Floor | 9% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Jul. 01, 2027 | ||||||
Principal Amount | $ 3,500 | ||||||
Investments at cost | 3,453 | ||||||
Investments at fair value | $ 3,453 | ||||||
Investment, Unaffiliated Issuer [Member] | Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 13.75% | ||||||
Margin | 5.25% | ||||||
Floor | 9% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Jul. 01, 2027 | ||||||
Principal Amount | $ 3,500 | ||||||
Investments at cost | 3,453 | ||||||
Investments at fair value | $ 3,453 | ||||||
Investment, Unaffiliated Issuer [Member] | Lytics, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 14.50% | 13% | |||||
Margin | 6% | 6% | |||||
Floor | 14.25% | 9.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 3% | |||||
Maturity Date | Nov. 01, 2026 | Jul. 01, 2025 | |||||
Principal Amount | $ 2,500 | $ 2,500 | |||||
Investments at cost | 2,418 | 2,396 | |||||
Investments at fair value | $ 2,350 | $ 2,396 | |||||
Investment, Unaffiliated Issuer [Member] | Lytics, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 14.50% | 13% | |||||
Margin | 6% | 6% | |||||
Floor | 14.25% | 12.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 3% | |||||
Maturity Date | Dec. 01, 2026 | Dec. 01, 2026 | |||||
Principal Amount | $ 1,250 | $ 1,250 | |||||
Investments at cost | 1,236 | 1,231 | |||||
Investments at fair value | 1,201 | 1,231 | |||||
Investment, Unaffiliated Issuer [Member] | Lytics, Inc. [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 43 | 40 | |||||
Investments at fair value | $ 1 | $ 44 | |||||
Number of Shares (in shares) | 85,543 | 80,197 | |||||
Investment, Unaffiliated Issuer [Member] | Lytics, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 14.50% | ||||||
Margin | 6% | ||||||
Floor | 14.25% | ||||||
Ceiling | 0% | ||||||
ETP | 4% | ||||||
Maturity Date | Apr. 01, 2027 | ||||||
Principal Amount | $ 1,000 | ||||||
Investments at cost | 993 | ||||||
Investments at fair value | $ 966 | ||||||
Investment, Unaffiliated Issuer [Member] | Tallac Therapeutics, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 12.75% | ||||||
Margin | 4.25% | ||||||
Floor | 12.25% | ||||||
Ceiling | 0% | ||||||
ETP | 4% | ||||||
Maturity Date | Aug. 01, 2027 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,226 | ||||||
Investments at fair value | $ 2,226 | ||||||
Investment, Unaffiliated Issuer [Member] | Tallac Therapeutics, Inc [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 12.75% | ||||||
Margin | 4.25% | ||||||
Floor | 12.25% | ||||||
Ceiling | 0% | ||||||
ETP | 4% | ||||||
Maturity Date | Aug. 01, 2027 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,455 | ||||||
Investments at fair value | 2,455 | ||||||
Investment, Unaffiliated Issuer [Member] | Tallac Therapeutics, Inc [Member] | Biotechnology Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 194 | ||||||
Investments at fair value | $ 194 | ||||||
Number of Shares (in shares) | 1,600,002 | ||||||
Investment, Unaffiliated Issuer [Member] | vTv Therapeutics Inc [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | $ 44 | $ 44 | |||||
Investments at fair value | $ 0 | $ 0 | |||||
Number of Shares (in shares) | 95,293 | 95,293 | |||||
Investment, Unaffiliated Issuer [Member] | Interior Define, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 13.50% | ||||||
Margin | 6.50% | ||||||
Floor | 9.75% | ||||||
Ceiling | 0% | ||||||
ETP | 4% | ||||||
Maturity Date | Jan. 01, 2026 | ||||||
Principal Amount | $ 3,210 | ||||||
Investments at cost | 3,151 | ||||||
Investments at fair value | $ 0 | ||||||
Investment, Unaffiliated Issuer [Member] | Interior Define, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 13.50% | ||||||
Margin | 6.50% | ||||||
Floor | 9.75% | ||||||
Ceiling | 0% | ||||||
ETP | 4% | ||||||
Maturity Date | Jan. 01, 2026 | ||||||
Principal Amount | $ 2,963 | ||||||
Investments at cost | 2,886 | ||||||
Investments at fair value | 0 | ||||||
Investment, Unaffiliated Issuer [Member] | Interior Define, Inc. [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 103 | ||||||
Investments at fair value | $ 0 | ||||||
Number of Shares (in shares) | 553,710 | ||||||
Investment, Unaffiliated Issuer [Member] | Xeris Pharmaceuticals, Inc [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | $ 72 | $ 72 | |||||
Investments at fair value | $ 17 | $ 3 | |||||
Number of Shares (in shares) | 126,000 | 126,000 | |||||
Investment, Unaffiliated Issuer [Member] | MyForest Foods Co [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 15.25% | 14.25% | |||||
Margin | 6.75% | 6.75% | |||||
Floor | 10% | 10% | |||||
Ceiling | 0% | 0% | |||||
ETP | 3% | 3% | |||||
Maturity Date | Oct. 01, 2025 | Oct. 01, 2025 | |||||
Principal Amount | $ 4,000 | $ 5,000 | |||||
Investments at cost | 3,975 | 4,954 | |||||
Investments at fair value | $ 3,975 | $ 4,954 | |||||
Investment, Unaffiliated Issuer [Member] | MyForest Foods Co [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 15.25% | 14.25% | |||||
Margin | 6.75% | 6.75% | |||||
Floor | 10% | 10% | |||||
Ceiling | 0% | 0% | |||||
ETP | 3% | 3% | |||||
Maturity Date | Oct. 01, 2025 | Oct. 01, 2025 | |||||
Principal Amount | $ 2,000 | $ 2,500 | |||||
Investments at cost | 1,987 | 2,477 | |||||
Investments at fair value | 1,987 | 2,477 | |||||
Investment, Unaffiliated Issuer [Member] | MyForest Foods Co [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 29 | 29 | |||||
Investments at fair value | $ 63 | $ 37 | |||||
Number of Shares (in shares) | 250 | 143 | |||||
Investment, Unaffiliated Issuer [Member] | Mirantis, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 12% | ||||||
Margin | 3.50% | ||||||
Floor | 11.75% | ||||||
Ceiling | 0% | ||||||
ETP | 4% | ||||||
Maturity Date | Oct. 01, 2028 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,774 | ||||||
Investments at fair value | $ 4,774 | ||||||
Investment, Unaffiliated Issuer [Member] | Mirantis, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 12% | ||||||
Margin | 3.50% | ||||||
Floor | 11.75% | ||||||
Ceiling | 0% | ||||||
ETP | 4% | ||||||
Maturity Date | Oct. 01, 2028 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,910 | ||||||
Investments at fair value | 4,910 | ||||||
Investment, Unaffiliated Issuer [Member] | Mirantis, Inc [Member] | Software Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | 223 | ||||||
Investments at fair value | $ 223 | ||||||
Number of Shares (in shares) | 948,275 | ||||||
Investment, Unaffiliated Issuer [Member] | Mirantis, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 12% | ||||||
Margin | 3.50% | ||||||
Floor | 11.75% | ||||||
Ceiling | 0% | ||||||
ETP | 4% | ||||||
Maturity Date | Oct. 01, 2028 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,910 | ||||||
Investments at fair value | $ 4,910 | ||||||
Investment, Unaffiliated Issuer [Member] | Mirantis, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 12% | ||||||
Margin | 3.50% | ||||||
Floor | 11.75% | ||||||
Ceiling | 0% | ||||||
ETP | 4% | ||||||
Maturity Date | Oct. 01, 2028 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,910 | ||||||
Investments at fair value | 4,910 | ||||||
Investment, Unaffiliated Issuer [Member] | AccuVein Inc [Member] | Medical Device Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | 24 | $ 24 | |||||
Investments at fair value | $ 0 | $ 0 | |||||
Number of Shares (in shares) | 1,175 | 1,175 | |||||
Investment, Unaffiliated Issuer [Member] | Lyrical Foods, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 11% | 10% | |||||
Margin | 2.50% | 6.75% | |||||
Floor | 8% | 10% | |||||
Ceiling | 0% | 0% | |||||
ETP | 0% | 0% | |||||
Maturity Date | Sep. 01, 2027 | Sep. 01, 2027 | |||||
Principal Amount | $ 2,598 | $ 2,500 | |||||
Investments at cost | 2,589 | 2,588 | |||||
Investments at fair value | $ 2,351 | $ 2,279 | |||||
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 14.25% | 12.75% | |||||
Margin | 5.75% | 5.75% | |||||
Floor | 9% | 9% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5.25% | 2% | |||||
Maturity Date | Oct. 31, 2023 | Dec. 30, 2022 | |||||
Principal Amount | $ 5,547 | $ 5,000 | |||||
Investments at cost | 5,505 | 4,943 | |||||
Investments at fair value | $ 4,894 | $ 4,715 | |||||
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 14.25% | 12.75% | |||||
Margin | 5.75% | 5.75% | |||||
Floor | 9% | 9% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5.25% | 2% | |||||
Maturity Date | Oct. 31, 2023 | Dec. 30, 2022 | |||||
Principal Amount | $ 2,219 | $ 2,000 | |||||
Investments at cost | 2,204 | 1,981 | |||||
Investments at fair value | 1,960 | 1,890 | |||||
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 197 | ||||||
Investments at fair value | $ 17 | ||||||
Number of Shares (in shares) | 1,261,253 | ||||||
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Preferred and Common Stock [Member] | |||||||
Investments at cost | 197 | ||||||
Investments at fair value | $ 0 | ||||||
Number of Shares (in shares) | 1,237,370 | ||||||
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 14.25% | 12.75% | |||||
Margin | 5.75% | 5.75% | |||||
Floor | 9% | 9% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5.25% | 2% | |||||
Maturity Date | Oct. 31, 2023 | Dec. 30, 2022 | |||||
Principal Amount | $ 2,774 | $ 2,500 | |||||
Investments at cost | 2,759 | 2,477 | |||||
Investments at fair value | $ 2,453 | $ 2,363 | |||||
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 14.25% | 12.75% | |||||
Margin | 5.75% | 5.75% | |||||
Floor | 9% | 9% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5.25% | 2% | |||||
Maturity Date | Oct. 31, 2023 | Dec. 30, 2022 | |||||
Principal Amount | $ 3,328 | $ 3,000 | |||||
Investments at cost | 3,310 | 2,971 | |||||
Investments at fair value | $ 2,943 | $ 2,835 | |||||
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Five [Member] | |||||||
Cash Rate | 14.25% | 12.75% | |||||
Margin | 5.75% | 5.75% | |||||
Floor | 9% | 9% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5.25% | 2% | |||||
Maturity Date | Oct. 31, 2023 | Dec. 30, 2022 | |||||
Principal Amount | $ 2,774 | $ 2,500 | |||||
Investments at cost | 2,747 | 2,459 | |||||
Investments at fair value | $ 2,443 | $ 2,345 | |||||
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Six [Member] | |||||||
Cash Rate | 14.25% | 12.75% | |||||
Margin | 5.75% | 5.75% | |||||
Floor | 9% | 9% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5.25% | 2% | |||||
Maturity Date | Oct. 31, 2023 | Dec. 30, 2022 | |||||
Principal Amount | $ 2,774 | $ 2,500 | |||||
Investments at cost | 2,747 | 2,459 | |||||
Investments at fair value | $ 2,443 | $ 2,345 | |||||
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Seven [Member] | |||||||
Cash Rate | 14.25% | 12.75% | |||||
Margin | 5.75% | 5.75% | |||||
Floor | 9% | 9% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5.25% | 2% | |||||
Maturity Date | Oct. 31, 2023 | Dec. 30, 2022 | |||||
Principal Amount | $ 5,547 | $ 5,000 | |||||
Investments at cost | 5,493 | 4,914 | |||||
Investments at fair value | $ 4,884 | $ 4,688 | |||||
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, Eight [Member] | |||||||
Cash Rate | 14.25% | 12.75% | |||||
Margin | 5.75% | 5.75% | |||||
Floor | 9% | 9% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5.25% | 2% | |||||
Maturity Date | Oct. 31, 2023 | Dec. 30, 2022 | |||||
Principal Amount | $ 2,774 | $ 2,500 | |||||
Investments at cost | 2,746 | 2,456 | |||||
Investments at fair value | 2,441 | 2,342 | |||||
Investment, Unaffiliated Issuer [Member] | NextCar Holding Company, Inc [Member] | Technology Sector [Member] | Preferred Stock [Member] | |||||||
Investments at cost | 89 | ||||||
Investments at fair value | $ 89 | ||||||
Number of Shares (in shares) | 2,688,971 | ||||||
Investment, Unaffiliated Issuer [Member] | Aerin Medical, Inc [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | $ 66 | 64 | |||||
Investments at fair value | $ 1,210 | $ 1,200 | |||||
Number of Shares (in shares) | 1,818,183 | 1,818,183 | |||||
Investment, Unaffiliated Issuer [Member] | CZV, Inc [Member] | Consumer-related Technologies [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | $ 81 | ||||||
Investments at fair value | $ 81 | ||||||
Number of Shares (in shares) | 65,569 | ||||||
Investment, Unaffiliated Issuer [Member] | Getaround, Inc [Member] | Consumer-related Technologies [Member] | Common Stock [Member] | |||||||
Investments at cost | $ 253 | $ 253 | |||||
Investments at fair value | $ 30 | $ 57 | |||||
Number of Shares (in shares) | 87,082 | 87,082 | |||||
Investment, Unaffiliated Issuer [Member] | Rocket Pharmaceuticals Corporation [Member] | Biotechnology Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | $ 17 | ||||||
Investments at fair value | $ 14 | ||||||
Number of Shares (in shares) | 7,051 | ||||||
Investment, Unaffiliated Issuer [Member] | Optoro, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 14.75% | 13.25% | |||||
Margin | 6.25% | 6.25% | |||||
Floor | 9.50% | 9.50% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 4% | |||||
Maturity Date | Aug. 01, 2027 | Aug. 01, 2027 | |||||
Principal Amount | $ 2,500 | $ 2,500 | |||||
Investments at cost | 2,408 | 2,347 | |||||
Investments at fair value | $ 2,408 | 2,347 | |||||
Investment, Unaffiliated Issuer [Member] | Optoro, Inc. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 14.75% | ||||||
Margin | 6.25% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 4% | ||||||
Maturity Date | Jul. 01, 2028 | ||||||
Principal Amount | $ 1,875 | ||||||
Investments at cost | 1,783 | ||||||
Investments at fair value | 1,783 | ||||||
Investment, Unaffiliated Issuer [Member] | Optoro, Inc. [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 182 | 104 | |||||
Investments at fair value | $ 182 | $ 104 | |||||
Number of Shares (in shares) | 11,550 | 6,600 | |||||
Investment, Unaffiliated Issuer [Member] | Aerobiotix, LLC [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 13.75% | ||||||
Margin | 6.25% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 6% | ||||||
Maturity Date | Apr. 01, 2026 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,463 | ||||||
Investments at fair value | $ 2,364 | ||||||
Investment, Unaffiliated Issuer [Member] | Aerobiotix, LLC [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 13.75% | ||||||
Margin | 6.25% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 6% | ||||||
Maturity Date | Apr. 01, 2026 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,463 | ||||||
Investments at fair value | 2,364 | ||||||
Investment, Unaffiliated Issuer [Member] | Aerobiotix, LLC [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | $ 48 | 48 | |||||
Investments at fair value | $ 10 | $ 31 | |||||
Number of Shares (in shares) | 8,800 | 27,330 | |||||
Investment, Unaffiliated Issuer [Member] | Aerobiotix, LLC [Member] | Medical Device Sector [Member] | Term Loan, Fixed Index One [Member] | |||||||
Cash Rate | 9% | ||||||
Margin | 0% | ||||||
Floor | 0% | ||||||
Ceiling | 0% | ||||||
ETP | 18% | ||||||
Maturity Date | Apr. 01, 2028 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,466 | ||||||
Investments at fair value | $ 2,344 | ||||||
Investment, Unaffiliated Issuer [Member] | Aerobiotix, LLC [Member] | Medical Device Sector [Member] | Term Loan, Fixed Index Two [Member] | |||||||
Cash Rate | 9% | ||||||
Margin | 0% | ||||||
Floor | 0% | ||||||
Ceiling | 0% | ||||||
ETP | 18% | ||||||
Maturity Date | Apr. 01, 2028 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,466 | ||||||
Investments at fair value | $ 2,344 | ||||||
Investment, Unaffiliated Issuer [Member] | Aerobiotix, LLC [Member] | Medical Device Sector [Member] | Term Loan, Fixed Index Three [Member] | |||||||
Cash Rate | 9% | ||||||
Margin | 0% | ||||||
Floor | 0% | ||||||
Ceiling | 0% | ||||||
ETP | 18% | ||||||
Maturity Date | Jun. 30, 2024 | ||||||
Principal Amount | $ 200 | ||||||
Investments at cost | 200 | ||||||
Investments at fair value | $ 190 | ||||||
Investment, Unaffiliated Issuer [Member] | Primary Kids, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 15.75% | 14.25% | |||||
Margin | 7.25% | 7.25% | |||||
Floor | 10.50% | 10.50% | |||||
Ceiling | 0% | 0% | |||||
ETP | 3% | 3% | |||||
Maturity Date | Mar. 01, 2025 | Mar. 01, 2025 | |||||
Principal Amount | $ 1,700 | $ 2,700 | |||||
Investments at cost | 1,683 | 2,673 | |||||
Investments at fair value | $ 1,683 | $ 2,673 | |||||
Investment, Unaffiliated Issuer [Member] | Primary Kids, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 15.75% | 14.25% | |||||
Margin | 7.25% | 7.25% | |||||
Floor | 10.50% | 10.50% | |||||
Ceiling | 0% | 0% | |||||
ETP | 3% | 3% | |||||
Maturity Date | Mar. 01, 2025 | Mar. 01, 2025 | |||||
Principal Amount | $ 1,700 | $ 2,700 | |||||
Investments at cost | 1,683 | 2,673 | |||||
Investments at fair value | 1,683 | 2,673 | |||||
Investment, Unaffiliated Issuer [Member] | Primary Kids, Inc [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 57 | 57 | |||||
Investments at fair value | $ 596 | $ 429 | |||||
Number of Shares (in shares) | 553,778 | 553,778 | |||||
Investment, Unaffiliated Issuer [Member] | Primary Kids, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 15.75% | 14.25% | |||||
Margin | 7.25% | 7.25% | |||||
Floor | 10.50% | 10.50% | |||||
Ceiling | 0% | 0% | |||||
ETP | 3% | 3% | |||||
Maturity Date | Sep. 01, 2025 | Sep. 01, 2025 | |||||
Principal Amount | $ 2,300 | $ 3,000 | |||||
Investments at cost | 2,277 | 2,967 | |||||
Investments at fair value | 2,277 | $ 2,967 | |||||
Investment, Unaffiliated Issuer [Member] | Canary Medical Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 12.75% | ||||||
Margin | 5.75% | ||||||
Floor | 9% | ||||||
Ceiling | 0% | ||||||
ETP | 7% | ||||||
Maturity Date | Nov. 01, 2024 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,475 | ||||||
Investments at fair value | $ 2,475 | ||||||
Investment, Unaffiliated Issuer [Member] | Canary Medical Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 12.75% | ||||||
Margin | 5.75% | ||||||
Floor | 9% | ||||||
Ceiling | 0% | ||||||
ETP | 7% | ||||||
Maturity Date | Nov. 01, 2024 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,489 | ||||||
Investments at fair value | 2,489 | ||||||
Investment, Unaffiliated Issuer [Member] | Canary Medical Inc. [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 86 | 84 | |||||
Investments at fair value | $ 1,307 | $ 1,864 | |||||
Number of Shares (in shares) | 12,153 | 12,153 | |||||
Investment, Unaffiliated Issuer [Member] | Canary Medical Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 12.75% | ||||||
Margin | 5.75% | ||||||
Floor | 9% | ||||||
Ceiling | 0% | ||||||
ETP | 7% | ||||||
Maturity Date | Nov. 01, 2024 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,473 | ||||||
Investments at fair value | 2,473 | ||||||
Investment, Unaffiliated Issuer [Member] | SnagAJob.com, Inc [Member] | Consumer-related Technologies [Member] | Common Stock [Member] | |||||||
Investments at cost | $ 9 | 8 | |||||
Investments at fair value | $ 83 | $ 83 | |||||
Number of Shares (in shares) | 82,974 | 82,974 | |||||
Investment, Unaffiliated Issuer [Member] | Quip NYC Inc [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | $ 325 | $ 325 | |||||
Investments at fair value | $ 538 | $ 534 | |||||
Number of Shares (in shares) | 6,191 | 6,191 | |||||
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 15.50% | 14.50% | |||||
Margin | 7% | 7% | |||||
Floor | 10.25% | 10.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.50% | 2.50% | |||||
Maturity Date | Sep. 01, 2025 | Sep. 01, 2025 | |||||
Principal Amount | $ 8,102 | $ 7,500 | |||||
Investments at cost | 8,009 | 7,371 | |||||
Investments at fair value | $ 6,754 | $ 7,371 | |||||
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 15.50% | 14.50% | |||||
Margin | 7% | 7% | |||||
Floor | 10.25% | 10.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.50% | 2.50% | |||||
Maturity Date | Sep. 01, 2025 | Sep. 01, 2025 | |||||
Principal Amount | $ 8,102 | $ 7,500 | |||||
Investments at cost | 8,009 | 7,371 | |||||
Investments at fair value | $ 6,754 | 7,371 | |||||
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | 488 | ||||||
Investments at fair value | $ 1,061 | ||||||
Number of Shares (in shares) | 204,832 | ||||||
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 15.50% | 14.50% | |||||
Margin | 7% | 7% | |||||
Floor | 10.25% | 10.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.50% | 2.50% | |||||
Maturity Date | Sep. 01, 2025 | Sep. 01, 2025 | |||||
Principal Amount | $ 8,102 | $ 7,500 | |||||
Investments at cost | 8,009 | 7,371 | |||||
Investments at fair value | $ 6,754 | $ 7,371 | |||||
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 15.50% | 14.50% | |||||
Margin | 7% | 7% | |||||
Floor | 10.25% | 10.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.50% | 2.50% | |||||
Maturity Date | Jul. 01, 2026 | Jul. 01, 2026 | |||||
Principal Amount | $ 5,402 | $ 5,000 | |||||
Investments at cost | 5,332 | 4,903 | |||||
Investments at fair value | $ 4,496 | $ 4,903 | |||||
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Five [Member] | |||||||
Cash Rate | 15.50% | 14.50% | |||||
Margin | 7% | 7% | |||||
Floor | 10.25% | 10.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.50% | 2.50% | |||||
Maturity Date | Jul. 01, 2026 | Jul. 01, 2026 | |||||
Principal Amount | $ 5,402 | $ 5,000 | |||||
Investments at cost | 5,332 | 4,903 | |||||
Investments at fair value | $ 4,496 | $ 4,903 | |||||
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Six [Member] | |||||||
Cash Rate | 15.50% | ||||||
Margin | 7% | ||||||
Floor | 10.25% | ||||||
Ceiling | 0% | ||||||
ETP | 2.50% | ||||||
Maturity Date | Sep. 30, 2023 | ||||||
Principal Amount | $ 707 | ||||||
Investments at cost | 707 | ||||||
Investments at fair value | $ 596 | ||||||
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Seven [Member] | |||||||
Cash Rate | 15.50% | ||||||
Margin | 7% | ||||||
Floor | 10.25% | ||||||
Ceiling | 0% | ||||||
ETP | 2.50% | ||||||
Maturity Date | Sep. 30, 2023 | ||||||
Principal Amount | $ 564 | ||||||
Investments at cost | 564 | ||||||
Investments at fair value | $ 475 | ||||||
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Eight [Member] | |||||||
Cash Rate | 15.50% | ||||||
Margin | 7% | ||||||
Floor | 10.25% | ||||||
Ceiling | 0% | ||||||
ETP | 2.50% | ||||||
Maturity Date | Sep. 30, 2023 | ||||||
Principal Amount | $ 281 | ||||||
Investments at cost | 281 | ||||||
Investments at fair value | $ 237 | ||||||
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Nine [Member] | |||||||
Cash Rate | 15.50% | ||||||
Margin | 7% | ||||||
Floor | 10.25% | ||||||
Ceiling | 0% | ||||||
ETP | 2.50% | ||||||
Maturity Date | Sep. 30, 2023 | ||||||
Principal Amount | $ 279 | ||||||
Investments at cost | 279 | ||||||
Investments at fair value | $ 235 | ||||||
Investment, Unaffiliated Issuer [Member] | Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, Ten [Member] | |||||||
Cash Rate | 15.50% | ||||||
Margin | 7% | ||||||
Floor | 10.25% | ||||||
Ceiling | 0% | ||||||
ETP | 2.50% | ||||||
Maturity Date | Sep. 30, 2023 | ||||||
Principal Amount | $ 167 | ||||||
Investments at cost | 167 | ||||||
Investments at fair value | $ 141 | ||||||
Investment, Unaffiliated Issuer [Member] | Noodle Partners, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 13.50% | ||||||
Margin | 5% | ||||||
Floor | 12% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Mar. 01, 2027 | ||||||
Principal Amount | $ 10,000 | ||||||
Investments at cost | 9,814 | ||||||
Investments at fair value | $ 9,814 | ||||||
Investment, Unaffiliated Issuer [Member] | Noodle Partners, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 13.50% | ||||||
Margin | 5% | ||||||
Floor | 12% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Mar. 01, 2027 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,938 | ||||||
Investments at fair value | 4,938 | ||||||
Investment, Unaffiliated Issuer [Member] | Noodle Partners, Inc. [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 115 | ||||||
Investments at fair value | $ 79 | ||||||
Number of Shares (in shares) | 84,037 | ||||||
Investment, Unaffiliated Issuer [Member] | Noodle Partners, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 13.50% | ||||||
Margin | 5% | ||||||
Floor | 12% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Mar. 01, 2027 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,939 | ||||||
Investments at fair value | $ 4,939 | ||||||
Investment, Unaffiliated Issuer [Member] | Candesant Biomedical, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 12% | ||||||
Margin | 3.50% | ||||||
Floor | 11.50% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Sep. 01, 2027 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,751 | ||||||
Investments at fair value | $ 4,751 | ||||||
Investment, Unaffiliated Issuer [Member] | Candesant Biomedical, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 12% | ||||||
Margin | 3.50% | ||||||
Floor | 11.50% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Sep. 01, 2027 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,451 | ||||||
Investment, Unaffiliated Issuer [Member] | Candesant Biomedical, Inc. [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 152 | ||||||
Investments at fair value | $ 152 | ||||||
Number of Shares (in shares) | 93,336 | ||||||
Investment, Unaffiliated Issuer [Member] | Candesant Biomedical, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 12% | ||||||
Margin | 3.50% | ||||||
Floor | 11.50% | ||||||
Ceiling | 0% | ||||||
ETP | 5% | ||||||
Maturity Date | Sep. 01, 2027 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,451 | ||||||
Investments at fair value | $ 2,451 | ||||||
Investment, Unaffiliated Issuer [Member] | Unagi, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 16.25% | 15.25% | |||||
Margin | 7.75% | 7.75% | |||||
Floor | 11% | 11% | |||||
Ceiling | 0% | 0% | |||||
ETP | 0% | 0% | |||||
Maturity Date | May 01, 2027 | Jul. 01, 2025 | |||||
Principal Amount | $ 1,108 | $ 2,500 | |||||
Investments at cost | 1,086 | 2,473 | |||||
Investments at fair value | $ 872 | $ 2,473 | |||||
Investment, Unaffiliated Issuer [Member] | Unagi, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 16.25% | 15.25% | |||||
Margin | 7.75% | 7.75% | |||||
Floor | 11% | 11% | |||||
Ceiling | 0% | 0% | |||||
ETP | 0% | 0% | |||||
Maturity Date | May 01, 2027 | Jul. 01, 2025 | |||||
Principal Amount | $ 554 | $ 1,250 | |||||
Investments at cost | 543 | 1,236 | |||||
Investments at fair value | 436 | 1,236 | |||||
Investment, Unaffiliated Issuer [Member] | Unagi, Inc [Member] | Consumer-related Technologies [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 32 | 32 | |||||
Investments at fair value | $ 0 | $ 22 | |||||
Number of Shares (in shares) | 171,081 | 171,081 | |||||
Investment, Unaffiliated Issuer [Member] | Unagi, Inc [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 16.25% | 15.25% | |||||
Margin | 7.75% | 7.75% | |||||
Floor | 11% | 11% | |||||
Ceiling | 0% | 0% | |||||
ETP | 0% | 0% | |||||
Maturity Date | May 01, 2027 | Jul. 01, 2025 | |||||
Principal Amount | $ 554 | $ 1,250 | |||||
Investments at cost | 543 | 1,236 | |||||
Investments at fair value | $ 436 | $ 1,236 | |||||
Investment, Unaffiliated Issuer [Member] | Ceribell, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 12% | 10.50% | |||||
Margin | 3.50% | 3.50% | |||||
Floor | 8.25% | 8.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5.50% | 5.50% | |||||
Maturity Date | Oct. 01, 2024 | Oct. 01, 2024 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,985 | 4,973 | |||||
Investments at fair value | $ 4,985 | $ 4,973 | |||||
Investment, Unaffiliated Issuer [Member] | Ceribell, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 12% | 10.50% | |||||
Margin | 3.50% | 3.50% | |||||
Floor | 8.25% | 8.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5.50% | 5.50% | |||||
Maturity Date | Oct. 01, 2024 | Oct. 01, 2024 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,985 | 4,973 | |||||
Investments at fair value | 4,985 | 4,973 | |||||
Investment, Unaffiliated Issuer [Member] | Ceribell, Inc. [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 69 | 69 | |||||
Investments at fair value | $ 213 | $ 209 | |||||
Number of Shares (in shares) | 145,483 | 145,483 | |||||
Investment, Unaffiliated Issuer [Member] | Ceribell, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 12% | 10.50% | |||||
Margin | 3.50% | 3.50% | |||||
Floor | 8.25% | 8.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5.50% | 5.50% | |||||
Maturity Date | Oct. 01, 2024 | Oct. 01, 2024 | |||||
Principal Amount | $ 2,500 | $ 2,500 | |||||
Investments at cost | 2,488 | 2,478 | |||||
Investments at fair value | $ 2,488 | $ 2,478 | |||||
Investment, Unaffiliated Issuer [Member] | Ceribell, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 12% | 10.50% | |||||
Margin | 3.50% | 3.50% | |||||
Floor | 8.25% | 8.25% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5.50% | 5.50% | |||||
Maturity Date | Oct. 01, 2024 | Oct. 01, 2024 | |||||
Principal Amount | $ 2,500 | $ 2,500 | |||||
Investments at cost | 2,488 | 2,478 | |||||
Investments at fair value | 2,488 | 2,478 | |||||
Investment, Unaffiliated Issuer [Member] | Tigo Energy, Inc. [Member] | Other Sustainability Sector [Member] | Common Stock [Member] | |||||||
Investments at cost | 111 | ||||||
Investments at fair value | $ 36 | ||||||
Number of Shares (in shares) | 5,205 | ||||||
Investment, Unaffiliated Issuer [Member] | Tigo Energy, Inc. [Member] | Other Sustainability Sector [Member] | Preferred Stock [Member] | |||||||
Investments at cost | 8 | ||||||
Investments at fair value | $ 27 | ||||||
Number of Shares (in shares) | 22,313 | ||||||
Investment, Unaffiliated Issuer [Member] | Updater, Inc [Member] | Consumer-related Technologies [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | $ 34 | $ 34 | |||||
Investments at fair value | $ 0 | $ 42 | |||||
Number of Shares (in shares) | 108,333 | 108,333 | |||||
Investment, Unaffiliated Issuer [Member] | Cognoa, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 14% | 13% | |||||
Margin | 5.50% | 5.50% | |||||
Floor | 8.75% | 8.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 6% | 6% | |||||
Maturity Date | Aug. 01, 2026 | Aug. 01, 2026 | |||||
Principal Amount | $ 4,722 | $ 2,500 | |||||
Investments at cost | 4,678 | 2,466 | |||||
Investments at fair value | $ 4,678 | $ 2,466 | |||||
Investment, Unaffiliated Issuer [Member] | Cognoa, Inc. [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 14% | 13% | |||||
Margin | 5.50% | 5.50% | |||||
Floor | 8.75% | 8.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 6% | 6% | |||||
Maturity Date | Aug. 01, 2026 | Aug. 01, 2026 | |||||
Principal Amount | $ 2,361 | $ 5,000 | |||||
Investments at cost | 2,339 | 4,932 | |||||
Investments at fair value | 2,339 | 4,932 | |||||
Investment, Unaffiliated Issuer [Member] | Cognoa, Inc. [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 148 | 148 | |||||
Investments at fair value | $ 184 | $ 179 | |||||
Number of Shares (in shares) | 4,106,174 | 775,000 | |||||
Investment, Unaffiliated Issuer [Member] | Branded Online, Inc [Member] | Software Sector [Member] | Common Stock [Member] | |||||||
Investments at cost | $ 1,079 | $ 1,079 | |||||
Investments at fair value | $ 3 | $ 83 | |||||
Number of Shares (in shares) | 5,398 | 108,004 | |||||
Investment, Unaffiliated Issuer [Member] | CPG Beyond, Inc [Member] | Data Storage Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | $ 242 | $ 242 | |||||
Investments at fair value | $ 917 | $ 909 | |||||
Number of Shares (in shares) | 500,000 | 500,000 | |||||
Investment, Unaffiliated Issuer [Member] | Reputation Institute, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 15.75% | 14.25% | |||||
Margin | 7.25% | 7.25% | |||||
Floor | 10.50% | 10.50% | |||||
Ceiling | 0% | 0% | |||||
ETP | 3% | 3% | |||||
Maturity Date | Aug. 01, 2025 | Aug. 01, 2025 | |||||
Principal Amount | $ 3,833 | $ 5,000 | |||||
Investments at cost | 3,785 | 4,932 | |||||
Investments at fair value | 3,785 | 4,932 | |||||
Investment, Unaffiliated Issuer [Member] | Reputation Institute, Inc [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 56 | 56 | |||||
Investments at fair value | $ 48 | $ 39 | |||||
Number of Shares (in shares) | 3,731 | 3,731 | |||||
Investment, Unaffiliated Issuer [Member] | Conventus Orthopaedics, Inc [Member] | Medical Device Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 13.32% | ||||||
Margin | 4.82% | ||||||
Floor | 9.25% | ||||||
Ceiling | 0% | ||||||
ETP | 10.36% | ||||||
Maturity Date | Jul. 01, 2025 | ||||||
Principal Amount | $ 3,960 | ||||||
Investments at cost | 3,916 | ||||||
Investments at fair value | 3,916 | ||||||
Investment, Unaffiliated Issuer [Member] | Conventus Orthopaedics, Inc [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 218 | $ 221 | |||||
Investments at fair value | $ 236 | $ 226 | |||||
Number of Shares (in shares) | 7,972,222 | 7,972,222 | |||||
Investment, Unaffiliated Issuer [Member] | Conventus Orthopaedics, Inc [Member] | Medical Device Sector [Member] | Term Loan, LIBOR Index, One [Member] | |||||||
Cash Rate | 12.17% | ||||||
Margin | 8% | ||||||
Floor | 9.25% | ||||||
Ceiling | 0% | ||||||
ETP | 10.36% | ||||||
Maturity Date | Jul. 01, 2025 | ||||||
Principal Amount | $ 3,960 | ||||||
Investments at cost | 3,898 | ||||||
Investments at fair value | $ 3,898 | ||||||
Investment, Unaffiliated Issuer [Member] | Conventus Orthopaedics, Inc [Member] | Medical Device Sector [Member] | Term Loan, LIBOR Index, Two [Member] | |||||||
Cash Rate | 12.17% | ||||||
Margin | 8% | ||||||
Floor | 9.25% | ||||||
Ceiling | 0% | ||||||
ETP | 10.36% | ||||||
Maturity Date | Jul. 01, 2025 | ||||||
Principal Amount | $ 3,960 | ||||||
Investments at cost | 3,898 | ||||||
Investments at fair value | $ 3,898 | ||||||
Investment, Unaffiliated Issuer [Member] | Decisyon, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 16.93% | ||||||
Margin | 9.43% | ||||||
Floor | 12.68% | ||||||
Ceiling | 0% | ||||||
ETP | 50.43% | ||||||
Maturity Date | Dec. 31, 2022 | ||||||
Principal Amount | $ 3,295 | ||||||
Investments at cost | 3,295 | ||||||
Investments at fair value | 3,295 | ||||||
Investment, Unaffiliated Issuer [Member] | Decisyon, Inc [Member] | Software Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | 46 | ||||||
Investments at fair value | $ 0 | ||||||
Number of Shares (in shares) | 82,967 | ||||||
Investment, Unaffiliated Issuer [Member] | Decisyon, Inc [Member] | Software Sector [Member] | Equity Securities [Member] | |||||||
Investments at cost | $ 230 | ||||||
Investments at fair value | $ 0 | ||||||
Number of Shares (in shares) | 72,638,663 | ||||||
Investment, Unaffiliated Issuer [Member] | Decisyon, Inc [Member] | Software Sector [Member] | Preferred Stock [Member] | |||||||
Investments at cost | $ 2,800 | ||||||
Investments at fair value | $ 1,281 | ||||||
Number of Shares (in shares) | 280,000 | ||||||
Investment, Unaffiliated Issuer [Member] | Silk, Inc [Member] | Data Storage Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | $ 175 | $ 234 | |||||
Investments at fair value | $ 153 | $ 407 | |||||
Number of Shares (in shares) | 394,110 | 442,110 | |||||
Investment, Unaffiliated Issuer [Member] | Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 14.25% | 13.25% | |||||
Margin | 5.75% | 5.75% | |||||
Floor | 9.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5% | 5% | |||||
Maturity Date | Aug. 01, 2026 | Aug. 01, 2026 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,952 | 4,870 | |||||
Investments at fair value | $ 4,952 | $ 4,870 | |||||
Investment, Unaffiliated Issuer [Member] | Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 14.25% | 13.25% | |||||
Margin | 5.75% | 5.75% | |||||
Floor | 9.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5% | 5% | |||||
Maturity Date | Aug. 01, 2026 | Aug. 01, 2026 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,952 | 4,933 | |||||
Investments at fair value | 4,952 | 4,933 | |||||
Investment, Unaffiliated Issuer [Member] | Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 123 | 123 | |||||
Investments at fair value | $ 135 | $ 133 | |||||
Number of Shares (in shares) | 309,208 | 309,208 | |||||
Investment, Unaffiliated Issuer [Member] | Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 14.25% | 13.25% | |||||
Margin | 5.75% | 5.75% | |||||
Floor | 9.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5% | 5% | |||||
Maturity Date | Aug. 01, 2026 | Aug. 01, 2026 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,952 | 4,933 | |||||
Investments at fair value | $ 4,952 | $ 4,933 | |||||
Investment, Unaffiliated Issuer [Member] | Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 14.25% | 13.25% | |||||
Margin | 5.75% | 5.75% | |||||
Floor | 9.75% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 5% | 5% | |||||
Maturity Date | Aug. 01, 2026 | Aug. 01, 2026 | |||||
Principal Amount | $ 5,000 | $ 5,000 | |||||
Investments at cost | 4,952 | 4,933 | |||||
Investments at fair value | 4,952 | 4,933 | |||||
Investment, Unaffiliated Issuer [Member] | Lotame Solutions, Inc. [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 18 | 22 | |||||
Investments at fair value | $ 44 | $ 312 | |||||
Number of Shares (in shares) | 71,305 | 288,115 | |||||
Investment, Unaffiliated Issuer [Member] | Lotame Solutions, Inc. [Member] | Software Sector [Member] | Preferred Stock [Member] | |||||||
Investments at cost | $ 4 | ||||||
Investments at fair value | $ 193 | ||||||
Number of Shares (in shares) | 66,127 | ||||||
Investment, Unaffiliated Issuer [Member] | Global Worldwide LLC [Member] | Internet and Media Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | $ 75 | $ 75 | |||||
Investments at fair value | $ 63 | $ 0 | |||||
Number of Shares (in shares) | 245,810 | 245,810 | |||||
Investment, Unaffiliated Issuer [Member] | CVRx, Inc [Member] | Medical Device Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | $ 76 | $ 76 | |||||
Investments at fair value | $ 272 | $ 394 | |||||
Number of Shares (in shares) | 47,410 | 47,410 | |||||
Investment, Unaffiliated Issuer [Member] | Rocket Lawyer Incorporated [Member] | Internet and Media Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | $ 92 | $ 92 | |||||
Investments at fair value | $ 336 | $ 357 | |||||
Number of Shares (in shares) | 261,721 | 261,721 | |||||
Investment, Unaffiliated Issuer [Member] | Skillshare, Inc [Member] | Internet and Media Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | $ 162 | $ 162 | |||||
Investments at fair value | $ 1,216 | $ 802 | |||||
Number of Shares (in shares) | 139,074 | 139,074 | |||||
Investment, Unaffiliated Issuer [Member] | Liqid, Inc [Member] | Software Sector [Member] | Term Loan, Prime Index, Five [Member] | |||||||
Cash Rate | 14.75% | ||||||
Margin | 6.25% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 4% | ||||||
Maturity Date | Sep. 01, 2024 | ||||||
Principal Amount | $ 917 | ||||||
Investments at cost | 887 | ||||||
Investments at fair value | $ 887 | ||||||
Investment, Unaffiliated Issuer [Member] | Liqid, Inc [Member] | Networking Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 14.75% | 13.25% | |||||
Margin | 6.25% | 6.25% | |||||
Floor | 9.50% | 9.50% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 4% | |||||
Maturity Date | Sep. 01, 2024 | Sep. 01, 2024 | |||||
Principal Amount | $ 1,833 | $ 3,333 | |||||
Investments at cost | 1,807 | 3,286 | |||||
Investments at fair value | $ 1,807 | $ 3,286 | |||||
Investment, Unaffiliated Issuer [Member] | Liqid, Inc [Member] | Networking Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 14.75% | 13.25% | |||||
Margin | 6.25% | 6.25% | |||||
Floor | 9.50% | 9.50% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 4% | |||||
Maturity Date | Sep. 01, 2024 | Sep. 01, 2024 | |||||
Principal Amount | $ 1,833 | $ 3,333 | |||||
Investments at cost | 1,807 | 3,286 | |||||
Investments at fair value | 1,807 | 3,286 | |||||
Investment, Unaffiliated Issuer [Member] | Liqid, Inc [Member] | Networking Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 364 | 364 | |||||
Investments at fair value | $ 251 | $ 243 | |||||
Number of Shares (in shares) | 344,102 | 344,102 | |||||
Investment, Unaffiliated Issuer [Member] | Liqid, Inc [Member] | Networking Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 14.75% | 13.25% | |||||
Margin | 6.25% | 6.25% | |||||
Floor | 9.50% | 9.50% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 4% | |||||
Maturity Date | Sep. 01, 2024 | Sep. 01, 2024 | |||||
Principal Amount | $ 917 | $ 1,667 | |||||
Investments at cost | 903 | 1,641 | |||||
Investments at fair value | $ 903 | $ 1,641 | |||||
Investment, Unaffiliated Issuer [Member] | Liqid, Inc [Member] | Networking Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 14.75% | 13.25% | |||||
Margin | 6.25% | 6.25% | |||||
Floor | 9.50% | 9.50% | |||||
Ceiling | 0% | 0% | |||||
ETP | 4% | 4% | |||||
Maturity Date | Sep. 01, 2024 | Sep. 01, 2024 | |||||
Principal Amount | $ 917 | $ 1,667 | |||||
Investments at cost | 903 | 1,641 | |||||
Investments at fair value | $ 903 | $ 1,641 | |||||
Investment, Unaffiliated Issuer [Member] | Liqid, Inc [Member] | Networking Sector [Member] | Term Loan, Prime Index, Five [Member] | |||||||
Cash Rate | 13.25% | ||||||
Margin | 6.25% | ||||||
Floor | 9.50% | ||||||
Ceiling | 0% | ||||||
ETP | 4% | ||||||
Maturity Date | Sep. 01, 2024 | ||||||
Principal Amount | $ 1,667 | ||||||
Investments at cost | 1,613 | ||||||
Investments at fair value | $ 1,613 | ||||||
Investment, Unaffiliated Issuer [Member] | Supply Network Visibility Holdings, LLC [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 12.75% | 13.50% | |||||
Margin | 4.25% | 6.50% | |||||
Floor | 12% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.50% | 4% | |||||
Maturity Date | Jun. 01, 2028 | Feb. 01, 2025 | |||||
Principal Amount | $ 2,500 | $ 3,500 | |||||
Investments at cost | 2,457 | 3,472 | |||||
Investments at fair value | $ 2,457 | $ 3,472 | |||||
Investment, Unaffiliated Issuer [Member] | Supply Network Visibility Holdings, LLC [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 12.75% | 13.50% | |||||
Margin | 4.25% | 6.50% | |||||
Floor | 12% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.50% | 4% | |||||
Maturity Date | Jun. 01, 2028 | Feb. 01, 2025 | |||||
Principal Amount | $ 3,500 | $ 3,500 | |||||
Investments at cost | 3,489 | 3,472 | |||||
Investments at fair value | 3,489 | $ 3,472 | |||||
Investment, Unaffiliated Issuer [Member] | Supply Network Visibility Holdings, LLC [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 64 | ||||||
Investments at fair value | $ 146 | ||||||
Number of Shares (in shares) | 682 | ||||||
Investment, Unaffiliated Issuer [Member] | Supply Network Visibility Holdings, LLC [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 12.75% | 13.50% | |||||
Margin | 4.25% | 6.50% | |||||
Floor | 12% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.50% | 4% | |||||
Maturity Date | Jun. 01, 2028 | Dec. 01, 2025 | |||||
Principal Amount | $ 2,500 | $ 2,500 | |||||
Investments at cost | 2,492 | 2,472 | |||||
Investments at fair value | $ 2,492 | $ 2,472 | |||||
Investment, Unaffiliated Issuer [Member] | Supply Network Visibility Holdings, LLC [Member] | Software Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 12.75% | 13.50% | |||||
Margin | 4.25% | 6.50% | |||||
Floor | 12% | 9.75% | |||||
Ceiling | 0% | 0% | |||||
ETP | 2.50% | 4% | |||||
Maturity Date | Jun. 01, 2028 | Dec. 01, 2025 | |||||
Principal Amount | $ 1,500 | $ 2,500 | |||||
Investments at cost | 1,495 | 2,472 | |||||
Investments at fair value | 1,495 | 2,472 | |||||
Investment, Unaffiliated Issuer [Member] | Meditrina, Inc [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 83 | 83 | |||||
Investments at fair value | $ 104 | $ 101 | |||||
Number of Shares (in shares) | 233,993 | 233,993 | |||||
Investment, Unaffiliated Issuer [Member] | Halio, Inc [Member] | Power Management Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | $ 1,585 | $ 1,585 | |||||
Investments at fair value | $ 2,901 | $ 2,610 | |||||
Number of Shares (in shares) | 5,002,574 | 5,002,574 | |||||
Investment, Unaffiliated Issuer [Member] | Avalanche Technology, Inc [Member] | Semiconductor Sector [Member] | Preferred and Common Stock [Member] | |||||||
Investments at cost | $ 56 | ||||||
Investments at fair value | $ 0 | ||||||
Number of Shares (in shares) | 6,081 | ||||||
Investment, Unaffiliated Issuer [Member] | Avalanche Technology, Inc [Member] | Semiconductor Sector [Member] | Warrant [Member] | |||||||
Investments at cost | $ 56 | ||||||
Investments at fair value | $ 0 | ||||||
Number of Shares (in shares) | 6,081 | ||||||
Investment, Unaffiliated Issuer [Member] | Aerofarms, Inc. [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 14.25% | ||||||
Margin | 6.75% | ||||||
Floor | 10% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Apr. 01, 2026 | ||||||
Principal Amount | $ 3,750 | ||||||
Investments at cost | 3,699 | ||||||
Investments at fair value | $ 3,699 | ||||||
Investment, Unaffiliated Issuer [Member] | Aerofarms, Inc. [Member] | Other Sustainability Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 14.25% | ||||||
Margin | 6.75% | ||||||
Floor | 10% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Apr. 01, 2026 | ||||||
Principal Amount | $ 3,750 | ||||||
Investments at cost | 3,699 | ||||||
Investments at fair value | 3,699 | ||||||
Investment, Unaffiliated Issuer [Member] | Aerofarms, Inc. [Member] | Other Sustainability Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 61 | ||||||
Investments at fair value | $ 74 | ||||||
Number of Shares (in shares) | 201,537 | ||||||
Investment, Unaffiliated Issuer [Member] | Britecore Holdings, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 14% | 13.75% | |||||
Margin | 5.50% | 6.75% | |||||
Floor | 14% | 10% | |||||
Ceiling | 0% | 0% | |||||
ETP | 3% | 5% | |||||
Maturity Date | Oct. 01, 2028 | Mar. 01, 2026 | |||||
Principal Amount | $ 5,000 | $ 2,500 | |||||
Investments at cost | 4,857 | 2,421 | |||||
Investments at fair value | $ 4,857 | $ 2,421 | |||||
Investment, Unaffiliated Issuer [Member] | Britecore Holdings, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 14% | 13.75% | |||||
Margin | 5.50% | 6.75% | |||||
Floor | 14% | 10% | |||||
Ceiling | 0% | 0% | |||||
ETP | 3% | 5% | |||||
Maturity Date | Oct. 01, 2028 | Mar. 01, 2026 | |||||
Principal Amount | $ 2,500 | $ 2,500 | |||||
Investments at cost | 2,464 | 2,487 | |||||
Investments at fair value | 2,464 | 2,487 | |||||
Investment, Unaffiliated Issuer [Member] | Britecore Holdings, Inc. [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 98 | 21 | |||||
Investments at fair value | $ 147 | $ 69 | |||||
Number of Shares (in shares) | 161,215 | 77,828 | |||||
Investment, Unaffiliated Issuer [Member] | Britecore Holdings, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 14% | ||||||
Margin | 5.50% | ||||||
Floor | 14% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Oct. 01, 2028 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,464 | ||||||
Investments at fair value | $ 2,464 | ||||||
Investment, Unaffiliated Issuer [Member] | Britecore Holdings, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 14% | ||||||
Margin | 5.50% | ||||||
Floor | 14% | ||||||
Ceiling | 0% | ||||||
ETP | 3% | ||||||
Maturity Date | Oct. 01, 2028 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,464 | ||||||
Investments at fair value | $ 2,464 | ||||||
Investment, Unaffiliated Issuer [Member] | Viken Detection Corporation [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 12.50% | ||||||
Margin | 4% | ||||||
Floor | 11.75% | ||||||
Ceiling | 0% | ||||||
ETP | 3.50% | ||||||
Maturity Date | Jun. 01, 2027 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,768 | ||||||
Investments at fair value | $ 4,768 | ||||||
Investment, Unaffiliated Issuer [Member] | Viken Detection Corporation [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 12.50% | ||||||
Margin | 4% | ||||||
Floor | 11.75% | ||||||
Ceiling | 0% | ||||||
ETP | 3.50% | ||||||
Maturity Date | Jun. 01, 2027 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,464 | ||||||
Investments at fair value | 2,464 | ||||||
Investment, Unaffiliated Issuer [Member] | Viken Detection Corporation [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 120 | ||||||
Investments at fair value | $ 122 | ||||||
Number of Shares (in shares) | 345,443 | ||||||
Investment, Unaffiliated Issuer [Member] | Viken Detection Corporation [Member] | Software Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 12.50% | ||||||
Margin | 4% | ||||||
Floor | 11.75% | ||||||
Ceiling | 0% | ||||||
ETP | 3.50% | ||||||
Maturity Date | Jun. 01, 2027 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,464 | ||||||
Investments at fair value | 2,464 | ||||||
Investment, Unaffiliated Issuer [Member] | VERO Biotech LLC [Member] | Medical Device Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 53 | $ 53 | |||||
Investments at fair value | $ 1 | $ 1 | |||||
Number of Shares (in shares) | 408 | 408 | |||||
Investment, Unaffiliated Issuer [Member] | E La Carte, Inc [Member] | Software Sector [Member] | Common Stock Warrants [Member] | |||||||
Investments at cost | $ 60 | $ 60 | |||||
Investments at fair value | $ 0 | $ 3 | |||||
Number of Shares (in shares) | 147,361 | 147,361 | |||||
Investment, Unaffiliated Issuer [Member] | Groundspeed Analytics, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 13% | ||||||
Margin | 5.50% | ||||||
Floor | 11% | ||||||
Ceiling | 18% | ||||||
ETP | 3% | ||||||
Maturity Date | Dec. 01, 2026 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,798 | ||||||
Investments at fair value | $ 4,798 | ||||||
Investment, Unaffiliated Issuer [Member] | Groundspeed Analytics, Inc. [Member] | Software Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 13% | ||||||
Margin | 5.50% | ||||||
Floor | 11% | ||||||
Ceiling | 18% | ||||||
ETP | 3% | ||||||
Maturity Date | Dec. 01, 2026 | ||||||
Principal Amount | $ 5,000 | ||||||
Investments at cost | 4,948 | ||||||
Investments at fair value | 4,948 | ||||||
Investment, Unaffiliated Issuer [Member] | Groundspeed Analytics, Inc. [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 6 | ||||||
Investments at fair value | $ 6 | ||||||
Number of Shares (in shares) | 86,300 | ||||||
Investment, Unaffiliated Issuer [Member] | Everstream Holdings, LLC [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | $ 70 | ||||||
Investments at fair value | $ 71 | ||||||
Number of Shares (in shares) | 350,000 | ||||||
Investment, Unaffiliated Issuer [Member] | Revinate Holdings, Inc [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | $ 44 | $ 46 | |||||
Investments at fair value | $ 103 | $ 99 | |||||
Number of Shares (in shares) | 682,034 | 682,034 | |||||
Investment, Unaffiliated Issuer [Member] | Riv Data Corp [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | $ 12 | ||||||
Investments at fair value | $ 296 | ||||||
Number of Shares (in shares) | 321,428 | ||||||
Investment, Unaffiliated Issuer [Member] | SIGNiX, Inc [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | $ 225 | $ 225 | |||||
Investments at fair value | $ 0 | $ 0 | |||||
Number of Shares (in shares) | 186,235 | 186,235 | |||||
Investment, Unaffiliated Issuer [Member] | Skyword, Inc [Member] | Software Sector [Member] | Warrant [Member] | |||||||
Investments at cost | $ 48 | ||||||
Investments at fair value | $ 1 | ||||||
Number of Shares (in shares) | 301,055 | ||||||
Investment, Unaffiliated Issuer [Member] | Supply Network Visiblity Holdings LLC [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | $ 64 | ||||||
Investments at fair value | $ 83 | ||||||
Number of Shares (in shares) | 682 | ||||||
Investment, Unaffiliated Issuer [Member] | Topia Mobility, Inc [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | $ 138 | $ 138 | |||||
Investments at fair value | $ 0 | $ 0 | |||||
Number of Shares (in shares) | 3,049,607 | 3,049,607 | |||||
Investment, Unaffiliated Issuer [Member] | xAd, Inc [Member] | Software Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | $ 177 | $ 177 | |||||
Investments at fair value | $ 12 | $ 12 | |||||
Number of Shares (in shares) | 4,343,348 | 4,343,348 | |||||
Investment, Unaffiliated Issuer [Member] | Secure Transfusion Services, Inc [Member] | Other Healthcare Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 13.25% | ||||||
Margin | 5.75% | ||||||
Floor | 9% | ||||||
Ceiling | 0% | ||||||
ETP | 4% | ||||||
Maturity Date | Oct. 01, 2025 | ||||||
Principal Amount | $ 4,943 | ||||||
Investments at cost | 4,943 | ||||||
Investments at fair value | $ 1,668 | ||||||
Investment, Unaffiliated Issuer [Member] | Secure Transfusion Services, Inc [Member] | Other Healthcare Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 13.25% | ||||||
Margin | 5.75% | ||||||
Floor | 9% | ||||||
Ceiling | 0% | ||||||
ETP | 4% | ||||||
Maturity Date | Dec. 31, 2025 | ||||||
Principal Amount | $ 2,500 | ||||||
Investments at cost | 2,467 | ||||||
Investments at fair value | 832 | ||||||
Investment, Unaffiliated Issuer [Member] | Secure Transfusion Services, Inc [Member] | Other Healthcare Sector [Member] | Preferred Stock Warrants [Member] | |||||||
Investments at cost | 47 | ||||||
Investments at fair value | $ 0 | ||||||
Number of Shares (in shares) | 77,690 | ||||||
Investment, Affiliated Issuer, Noncontrolled [Member] | |||||||
Investments at cost | $ 39,666 | $ 0 | |||||
Investments at fair value | 20,485 | $ 906 | 0 | $ 0 | $ 0 | $ 0 | |
Investment, Affiliated Issuer, Noncontrolled [Member] | Debt Securities [Member] | |||||||
Investments at cost | 34,540 | ||||||
Investments at fair value | 12,000 | ||||||
Investment, Affiliated Issuer, Noncontrolled [Member] | Warrant [Member] | |||||||
Investments at cost | 126 | ||||||
Investments at fair value | 0 | ||||||
Investment, Affiliated Issuer, Noncontrolled [Member] | Life Science [Member] | Equity Securities [Member] | |||||||
Investments at cost | 5,000 | ||||||
Investments at fair value | $ 8,485 | ||||||
Number of Shares (in shares) | |||||||
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 12.75% | ||||||
Margin | 4.25% | ||||||
Floor | 11% | ||||||
Ceiling | 0% | ||||||
ETP | 4.25% | ||||||
Maturity Date | Jan. 01, 2028 | ||||||
Principal Amount | $ 7,778 | ||||||
Investments at cost | 7,672 | ||||||
Investments at fair value | $ 2,666 | ||||||
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 12.75% | ||||||
Margin | 4.25% | ||||||
Floor | 11% | ||||||
Ceiling | 0% | ||||||
ETP | 4.25% | ||||||
Maturity Date | Jan. 01, 2028 | ||||||
Principal Amount | $ 11,667 | ||||||
Investments at cost | 11,509 | ||||||
Investments at fair value | 3,997 | ||||||
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Common Stock [Member] | |||||||
Investments at cost | 5,000 | ||||||
Investments at fair value | $ 8,485 | ||||||
Number of Shares (in shares) | 2,164,502 | ||||||
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index Three [Member] | |||||||
Cash Rate | 12.75% | ||||||
Margin | 4.25% | ||||||
Floor | 11% | ||||||
Ceiling | 0% | ||||||
ETP | 4.25% | ||||||
Maturity Date | Jan. 01, 2028 | ||||||
Principal Amount | $ 4,681 | ||||||
Investments at cost | 4,618 | ||||||
Investments at fair value | $ 1,604 | ||||||
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Four [Member] | |||||||
Cash Rate | 12.75% | ||||||
Margin | 4.25% | ||||||
Floor | 11% | ||||||
Ceiling | 0% | ||||||
ETP | 4.25% | ||||||
Maturity Date | Jan. 01, 2028 | ||||||
Principal Amount | $ 4,667 | ||||||
Investments at cost | 4,603 | ||||||
Investments at fair value | $ 1,597 | ||||||
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Five [Member] | |||||||
Cash Rate | 12.75% | ||||||
Margin | 4.25% | ||||||
Floor | 11% | ||||||
Ceiling | 0% | ||||||
ETP | 4.25% | ||||||
Maturity Date | Jan. 01, 2028 | ||||||
Principal Amount | $ 3,111 | ||||||
Investments at cost | 3,069 | ||||||
Investments at fair value | 1,068 | ||||||
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Warrant [Member] | |||||||
Investments at cost | 126 | ||||||
Investments at fair value | $ 0 | ||||||
Number of Shares (in shares) | 23,196 | ||||||
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Term Loan, Prime Index, Six [Member] | |||||||
Cash Rate | 12.75% | ||||||
Margin | 4.25% | ||||||
Floor | 11% | ||||||
Ceiling | 0% | ||||||
ETP | 4.25% | ||||||
Maturity Date | Jan. 01, 2028 | ||||||
Principal Amount | $ 3,111 | ||||||
Investments at cost | 3,069 | ||||||
Investments at fair value | 1,068 | ||||||
Investment, Affiliated Issuer, Noncontrolled [Member] | Aulea Medical, Inc. [Member] | |||||||
Investments at fair value | 0 | 0 | 0 | ||||
Investment, Affiliated Issuer, Noncontrolled [Member] | Aulea Medical, Inc. [Member] | Medical Device Sector [Member] | Common Stock [Member] | |||||||
Investments at cost | 0 | ||||||
Investments at fair value | $ 0 | ||||||
Number of Shares (in shares) | 660,537 | ||||||
Investment, Affiliated Issuer, Noncontrolled [Member] | Cadrenal Therapeutics, Inc. [Member] | |||||||
Investments at fair value | [1] | $ 0 | 906 | 0 | |||
Investment, Affiliated Issuer, Noncontrolled [Member] | Cadrenal Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Common Stock [Member] | |||||||
Investments at cost | 0 | ||||||
Investments at fair value | $ 408 | ||||||
Number of Shares (in shares) | 600,000 | ||||||
Investment, Affiliated Issuer, Controlled [Member] | |||||||
Investments at cost | $ 14,216 | 0 | |||||
Investments at fair value | 13,145 | 0 | 0 | $ 0 | $ 0 | $ 0 | |
Investment, Affiliated Issuer, Controlled [Member] | Biotechnology Sector [Member] | Other Investments [Member] | |||||||
Investments at cost | 6,154 | ||||||
Investments at fair value | 6,154 | ||||||
Investment, Affiliated Issuer, Controlled [Member] | Consumer-related Technologies [Member] | Debt Securities [Member] | |||||||
Investments at cost | 5,251 | ||||||
Investments at fair value | 4,439 | ||||||
Investment, Affiliated Issuer, Controlled [Member] | Technology Sector [Member] | Equity Securities [Member] | |||||||
Investments at cost | 2,811 | ||||||
Investments at fair value | $ 2,552 | ||||||
Investment, Affiliated Issuer, Controlled [Member] | Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index, One [Member] | |||||||
Cash Rate | 12.25% | ||||||
Margin | 3.75% | ||||||
Floor | 12% | ||||||
Ceiling | 0% | ||||||
ETP | 2.78% | ||||||
Maturity Date | Aug. 01, 2029 | ||||||
Principal Amount | $ 3,604 | ||||||
Investments at cost | 3,556 | ||||||
Investments at fair value | $ 3,006 | ||||||
Investment, Affiliated Issuer, Controlled [Member] | Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Term Loan, Prime Index Two [Member] | |||||||
Cash Rate | 12.25% | ||||||
Margin | 3.75% | ||||||
Floor | 12% | ||||||
Ceiling | 0% | ||||||
ETP | 2.78% | ||||||
Maturity Date | Aug. 01, 2029 | ||||||
Principal Amount | $ 1,719 | ||||||
Investments at cost | 1,695 | ||||||
Investments at fair value | 1,433 | ||||||
Investment, Affiliated Issuer, Controlled [Member] | Better Place Forests Co. [Member] | Technology Sector [Member] | Preferred and Common Stock [Member] | |||||||
Investments at cost | 2,811 | ||||||
Investments at fair value | $ 2,552 | ||||||
Number of Shares (in shares) | 2,551,596 | ||||||
Investment, Affiliated Issuer, Controlled [Member] | HIMV LLC [Member] | |||||||
Investments at fair value | $ 6,154 | $ 0 | $ 0 | ||||
Investment, Affiliated Issuer, Controlled [Member] | HIMV LLC [Member] | Biotechnology Sector [Member] | Other Investments [Member] | |||||||
Investments at cost | 6,154 | ||||||
Investments at fair value | $ 6,154 | ||||||
[1]As of September 30, 2023, the Company no longer owns 5% or more of the portfolio company. |
Consolidated Schedule of Inve_5
Consolidated Schedule of Investments (Unaudited) - Investments (Details) (Parentheticals) | Sep. 30, 2023 | Dec. 31, 2022 |
NAV % | 210.40% | 226.10% |
Investment, Affiliated Issuer, Controlled [Member] | Debt Securities [Member] | ||
NAV % | 3.80% | |
Investment, Affiliated Issuer, Controlled [Member] | Debt Securities [Member] | Consumer-related Technologies [Member] | ||
NAV % | 1.30% | |
Investment, Affiliated Issuer, Controlled [Member] | Preferred and Common Stock [Member] | Technology Sector [Member] | ||
NAV % | 0.70% | |
Investment, Affiliated Issuer, Controlled [Member] | Other Investments [Member] | Biotechnology Sector [Member] | ||
NAV % | 1.80% | |
Investment, Affiliated Issuer, Noncontrolled [Member] | ||
NAV % | 5.90% | |
Investment, Affiliated Issuer, Noncontrolled [Member] | Debt Securities [Member] | Life Science [Member] | ||
NAV % | 3.50% | |
Investment, Affiliated Issuer, Noncontrolled [Member] | Equity Securities [Member] | Life Science [Member] | ||
NAV % | 2.40% | |
Investment, Affiliated Issuer, Noncontrolled [Member] | Warrant [Member] | Life Science [Member] | ||
NAV % | 0% | |
Investment, Unaffiliated Issuer [Member] | ||
NAV % | 200.70% | 226.10% |
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | ||
NAV % | 191.40% | 215.50% |
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Life Science [Member] | ||
NAV % | 69.70% | 99.70% |
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Technology Sector [Member] | ||
NAV % | 80.50% | 81.40% |
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Other Sustainability Sector [Member] | ||
NAV % | 23.80% | |
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Sustainability Segment [Member] | ||
NAV % | 26.30% | |
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Healthcare Sector [Member] | ||
NAV % | 17.40% | 8.10% |
Investment, Unaffiliated Issuer [Member] | Equity Securities [Member] | ||
NAV % | 1.40% | 0.80% |
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | ||
NAV % | 7.60% | 9.40% |
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Life Science [Member] | ||
NAV % | 3.10% | |
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Technology Sector [Member] | ||
NAV % | 4.70% | 5.10% |
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Healthcare Information and Services Segment [Member] | ||
NAV % | 0.60% | |
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Life Science Segment [Member] | ||
NAV % | 2% | |
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Sustainability Segment [Member] | ||
NAV % | 0.20% | 0.60% |
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Healthcare Sector [Member] | ||
NAV % | 0.60% | |
Investment, Unaffiliated Issuer [Member] | Other Long-Term Investments [Member] | ||
NAV % | 0.40% | |
Investment, Unaffiliated Issuer [Member] | Other Long-Term Investments [Member] | Life Science [Member] | ||
NAV % | 0.30% |
Note 1 - Organization (Details
Note 1 - Organization (Details Textual) - Investment, Affiliated Issuer, Controlled [Member] | Sep. 30, 2023 |
HIMV LLC [Member] | Co-lender [Member] | |
Subsidiary, Ownership Percentage, Noncontrolling Owner | 30% |
HIMV LLC [Member] | Horizon Technology Finance Corporation [Member] | |
Investment Owned, Net Assets, Percentage | 70% |
Note 2 - Basis of Presentatio_2
Note 2 - Basis of Presentation and Significant Accounting Policies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | 29 Months Ended | ||||||||
Jun. 02, 2023 | Mar. 14, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 22, 2023 | Dec. 31, 2022 | Apr. 28, 2022 | Aug. 02, 2021 | |
Investments, Nonaccrual, Interest Income | $ 0 | $ 0 | $ 0 | $ 0 | |||||||
Interest Income, Operating, Paid in Kind | $ 3,900 | $ 0 | $ 6,088 | $ 0 | |||||||
Investment, Nonaccrual, Income Not Received in Cash, Percent | 5.10% | 7% | 4.90% | 7.50% | |||||||
Debt Issuance Costs, Net | $ 6,400 | $ 6,400 | $ 6,400 | $ 7,100 | |||||||
Accumulated Amortization, Debt Issuance Costs | 6,300 | 6,300 | $ 6,300 | 4,800 | |||||||
Amortization of Debt Issuance Costs | $ 500 | $ 400 | $ 1,433 | $ 1,142 | |||||||
Federal Excise Tax, Percent | 4% | 4% | 4% | ||||||||
Investment Income, Operating, Tax Expense (Benefit) | $ 179 | $ 100 | $ 542 | 306 | |||||||
Open Tax Year | 2022 2021 2020 | ||||||||||
Proceeds from Issuance of Common Stock | $ 65,031 | $ 67,525 | |||||||||
Stock Repurchase Program, Remaining Authorized Repurchase Amount | $ 5,000 | ||||||||||
Stock Repurchased During Period, Shares (in shares) | 0 | 0 | 0 | 0 | 167,465 | ||||||
Stock Repurchased During Period, Per Share (in dollars per share) | $ 11.22 | ||||||||||
Stock Repurchased During Period, Value | $ 1,900 | ||||||||||
The 2021 Equity Distribution Agreement [Member] | |||||||||||
Equity Sales Agreement, Maximum Value | $ 100,000 | ||||||||||
Equity Sales Agreement, Remaining Amount Available for Issuance | $ 0 | ||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,523,519 | 2,641,920 | |||||||||
Proceeds from Issuance of Common Stock | $ 19,000 | $ 33,200 | |||||||||
Payments of Stock Issuance Costs | $ 400 | $ 600 | |||||||||
The 2023 Equity Distribution Agreement [Member] | |||||||||||
Equity Sales Agreement, Maximum Value | $ 150,000 | ||||||||||
Equity Sales Agreement, Remaining Amount Available for Issuance | $ 146,800 | $ 146,800 | 146,800 | ||||||||
The2023 Equity Distribution Agreement and the 2021 Equity Distribution Agreement [Member] | |||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,186,303 | 2,240,326 | |||||||||
Proceeds from Issuance of Common Stock | $ 13,900 | $ 26,100 | |||||||||
Payments of Stock Issuance Costs | 400 | 700 | |||||||||
Public Offering [Member] | |||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 3,250,000 | 2,500,000 | |||||||||
Proceeds from Issuance of Common Stock | $ 38,900 | $ 34,300 | |||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 12.50 | $ 14.35 | |||||||||
Three Investments [Member] | |||||||||||
Investments, Cost, Nonaccrual Status | 43,600 | 43,600 | 43,600 | 20,900 | |||||||
Investments, Fair Value, Nonaccrual Status | $ 17,200 | $ 17,200 | $ 17,200 | $ 8,300 |
Note 3 - Related Party Transa_2
Note 3 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | |
Management Fee Payable | $ 1,080 | $ 1,080 | $ 1,065 | ||
Management Fee Expense | 3,213 | $ 2,788 | 9,621 | $ 7,555 | |
Incentive Fee Payable | 0 | 0 | 1,392 | ||
Administrative Fees Expense | $ 441 | 412 | 1,249 | 1,147 | |
Investment Management Agreement [Member] | |||||
Base Management Fee, Annual, Percent | 2% | ||||
Base Management Fee, Annual, Percent, Gross Assets Exceeding $250 Million | 1.60% | ||||
Management Fee Payable | $ 1,100 | 1,100 | 1,100 | ||
Management Fee Expense | $ 3,200 | 2,800 | 9,600 | 7,600 | |
Incentive Fee to Pre-incentive Net Investment Income | 20% | ||||
Pre-Incentive Fee Net Investment Income, Hurdle Rate | 1.75% | ||||
Pre-Incentive Fee Net Investment Income, Hurdle Rate, Annualized | 7% | ||||
Pre-Incentive Fee Net Investment Income, Catch-up, Percent | 100% | ||||
Pre-Incentive Fee Net Investment Income, Maximum Rate to Trigger Catch-up | 2.1875% | ||||
Pre-Incentive Fee Net Investment Income, Maximum Rate to Trigger Catch-up, Annualized | 8.75% | ||||
Incentive Fee Expense | $ 0 | 2,800 | 3,100 | 6,400 | |
Incentive Fee Cap and Deferral Mechanism Reduction to Expense | 3,500 | 6,800 | |||
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability | 7,800 | 7,800 | |||
Incentive Fee Payable | 0 | 0 | $ 1,400 | ||
Investment Management Agreement [Member] | December 31, 2025 Expiration [Member] | |||||
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability | 1,000 | 1,000 | |||
Investment Management Agreement [Member] | March 31, 2026 Expiration [Member] | |||||
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability | 200 | 200 | |||
Investment Management Agreement [Member] | June 30, 2026 Expiration [Member] | |||||
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability | 3,100 | 3,100 | |||
Investment Management Agreement [Member] | September 30, 2026 Expiration [Member] | |||||
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability | 3,500 | 3,500 | |||
Administration Agreement [Member] | |||||
Administrative Fees Expense | $ 400 | $ 400 | $ 1,200 | $ 1,100 |
Note 4 - Investments - Investme
Note 4 - Investments - Investments (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Investments at cost | $ 754,814 | $ 721,248 |
Investments at fair value | 729,053 | 720,026 |
Biotechnology Sector [Member] | ||
Investments at cost | 158,953 | 193,372 |
Investments at fair value | 139,935 | 195,006 |
Medical Device Sector [Member] | ||
Investments at cost | 140,172 | 132,803 |
Investments at fair value | 139,039 | 135,960 |
Communications Sector [Member] | ||
Investments at cost | 21,057 | 22,892 |
Investments at fair value | 24,317 | 26,176 |
Consumer-related Sector [Member] | ||
Investments at cost | 110,245 | 121,961 |
Investments at fair value | 106,559 | 114,050 |
Data Storage Sector [Member] | ||
Investments at cost | 417 | 476 |
Investments at fair value | 1,070 | 1,316 |
Internet and Media Sector [Member] | ||
Investments at cost | 329 | 329 |
Investments at fair value | 1,615 | 1,159 |
Networking Sector [Member] | ||
Investments at cost | 6,671 | 11,831 |
Investments at fair value | 6,558 | 11,710 |
Power Management Sector [Member] | ||
Investments at cost | 1,585 | 1,585 |
Investments at fair value | 2,901 | 2,610 |
Semiconductor Sector [Member] | ||
Investments at cost | 56 | 56 |
Investments at fair value | 0 | 0 |
Software Sector [Member] | ||
Investments at cost | 164,903 | 120,157 |
Investments at fair value | 161,258 | 118,716 |
Energy Efficiency [Member] | ||
Investments at cost | 111 | 8 |
Investments at fair value | 36 | 27 |
Other Sustainability Sector [Member] | ||
Investments at cost | 89,395 | 84,633 |
Investments at fair value | 83,476 | 85,524 |
Diagnostics Sector [Member] | ||
Investments at cost | 9,971 | 9,851 |
Investments at fair value | 9,939 | 9,858 |
Other Healthcare Sector [Member] | ||
Investments at cost | 102 | 7,559 |
Investments at fair value | 1,379 | 3,870 |
Software, Healthcare Information and Service [Member] | ||
Investments at cost | 50,847 | 13,735 |
Investments at fair value | 50,971 | 14,044 |
Debt [Member] | ||
Investments at cost | 716,655 | 701,074 |
Investments at fair value | 679,838 | 686,458 |
Warrant [Member] | ||
Investments at cost | 15,783 | 14,790 |
Investments at fair value | 26,189 | 29,712 |
Other Debt Obligations [Member] | ||
Investments at cost | 7,354 | 1,200 |
Investments at fair value | 7,254 | 1,300 |
Equity Securities [Member] | ||
Investments at cost | 15,022 | 4,184 |
Investments at fair value | $ 15,772 | $ 2,556 |
Note 5 - Transactions With Af_3
Note 5 - Transactions With Affiliated Companies (Details Textual) | Sep. 30, 2023 |
Cadrenal Therapeutics, Inc. [Member] | Investment, Unaffiliated Issuer [Member] | Percentage of Net Assets Previously Held [Member] | |
Investment Owned, Net Assets, Percentage | 5% |
Note 5 - Transactions With Af_4
Note 5 - Transactions With Affiliated Companies - Investments in Controlled Affiliated Companies (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | ||
Investments, fair value | $ 720,026 | ||||
Net unrealized appreciation (depreciation) on investments | $ (17,518) | $ 3,442 | (24,448) | $ 1,169 | |
Net realized gain (loss) on investments | (11,816) | (8,585) | (28,513) | (9,484) | |
Investments, fair value | 729,053 | 729,053 | |||
Interest Income, Operating, Paid in Kind | 3,900 | 0 | 6,088 | 0 | |
Investments, fair value | (729,053) | (729,053) | |||
Evelo Biosciences, Inc. [Member] | |||||
Investments, fair value | 8,500 | 8,500 | |||
Investments, fair value | (8,500) | (8,500) | |||
Investment, Affiliated Issuer, Noncontrolled [Member] | |||||
Investments, fair value | 906 | 0 | 0 | 0 | |
Purchases | 0 | 0 | 0 | 0 | |
Reductions | 0 | (30) | 0 | (30) | |
Transfers in/(out) at fair value | 38,599 | 0 | 38,599 | 0 | |
Discount accretion | 35 | 0 | 35 | 0 | |
Net unrealized appreciation (depreciation) on investments | (19,055) | 0 | (18,149) | 0 | |
Net realized gain (loss) on investments | 0 | 30 | 0 | 30 | |
Investments, fair value | 20,485 | 0 | 20,485 | 0 | |
Interest income | 1,246 | 0 | 1,246 | 0 | |
Transfers in/(out) at fair value | 38,599 | 0 | 38,599 | 0 | |
Investments, fair value | (20,485) | 0 | (20,485) | 0 | |
Investment, Affiliated Issuer, Noncontrolled [Member] | MVI (ABC) LLC fka StereoVision, Inc [Member] | |||||
Investments, fair value | 0 | 0 | |||
Purchases | 0 | 0 | |||
Reductions | (30) | (30) | |||
Transfers in/(out) at fair value | 0 | 0 | |||
Discount accretion | 0 | 0 | |||
Net unrealized appreciation (depreciation) on investments | 0 | 0 | |||
Net realized gain (loss) on investments | 30 | 30 | |||
Investments, fair value | 0 | 0 | |||
Interest income | 0 | 0 | |||
Transfers in/(out) at fair value | 0 | 0 | |||
Investments, fair value | 0 | 0 | |||
Investment, Affiliated Issuer, Noncontrolled [Member] | Aulea Medical, Inc. [Member] | |||||
Investments, fair value | 0 | 0 | |||
Purchases | 0 | 0 | |||
Reductions | 0 | 0 | |||
Transfers in/(out) at fair value | 0 | 0 | |||
Discount accretion | 0 | 0 | |||
Net unrealized appreciation (depreciation) on investments | 0 | 0 | |||
Net realized gain (loss) on investments | 0 | 0 | |||
Investments, fair value | 0 | 0 | |||
Interest income | 0 | 0 | |||
Transfers in/(out) at fair value | 0 | 0 | |||
Investments, fair value | 0 | 0 | |||
Investment, Affiliated Issuer, Noncontrolled [Member] | Cadrenal Therapeutics, Inc. [Member] | |||||
Investments, fair value | [1] | 906 | 0 | ||
Purchases | [1] | 0 | 0 | ||
Reductions | [1] | 0 | 0 | ||
Transfers in/(out) at fair value | [1] | (906) | (906) | ||
Discount accretion | [1] | 0 | 0 | ||
Net unrealized appreciation (depreciation) on investments | [1] | 0 | 906 | ||
Net realized gain (loss) on investments | [1] | 0 | 0 | ||
Investments, fair value | [1] | 0 | 0 | ||
Interest income | [1] | 0 | 0 | ||
Transfers in/(out) at fair value | [1] | (906) | (906) | ||
Investments, fair value | [1] | 0 | 0 | ||
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Investment One [Member] | |||||
Investments, fair value | 0 | 0 | |||
Purchases | 0 | 0 | |||
Reductions | 0 | 0 | |||
Transfers in/(out) at fair value | 7,665 | 7,665 | |||
Discount accretion | 8 | 8 | |||
Net unrealized appreciation (depreciation) on investments | (5,007) | (5,007) | |||
Net realized gain (loss) on investments | 0 | 0 | |||
Investments, fair value | 2,666 | 2,666 | |||
Interest income | 277 | 277 | |||
Transfers in/(out) at fair value | 7,665 | 7,665 | |||
Investments, fair value | (2,666) | (2,666) | |||
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Investment Two [Member] | |||||
Investments, fair value | 0 | 0 | |||
Purchases | 0 | 0 | |||
Reductions | 0 | 0 | |||
Transfers in/(out) at fair value | 11,496 | 11,496 | |||
Discount accretion | 11 | 11 | |||
Net unrealized appreciation (depreciation) on investments | (7,510) | (7,510) | |||
Net realized gain (loss) on investments | 0 | 0 | |||
Investments, fair value | 3,997 | 3,997 | |||
Interest income | 415 | 415 | |||
Transfers in/(out) at fair value | 11,496 | 11,496 | |||
Investments, fair value | (3,997) | (3,997) | |||
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Investment Three [Member] | |||||
Investments, fair value | 0 | 0 | |||
Purchases | 0 | 0 | |||
Reductions | 0 | 0 | |||
Transfers in/(out) at fair value | 4,612 | 4,612 | |||
Discount accretion | 5 | 5 | |||
Net unrealized appreciation (depreciation) on investments | (3,013) | (3,013) | |||
Net realized gain (loss) on investments | 0 | 0 | |||
Investments, fair value | 1,604 | 1,604 | |||
Interest income | 166 | 166 | |||
Transfers in/(out) at fair value | 4,612 | 4,612 | |||
Investments, fair value | (1,604) | (1,604) | |||
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Investment Four [Member] | |||||
Investments, fair value | 0 | 0 | |||
Purchases | 0 | 0 | |||
Reductions | 0 | 0 | |||
Transfers in/(out) at fair value | 4,598 | 4,598 | |||
Discount accretion | 3 | 3 | |||
Net unrealized appreciation (depreciation) on investments | (3,004) | (3,004) | |||
Net realized gain (loss) on investments | 0 | 0 | |||
Investments, fair value | 1,597 | 1,597 | |||
Interest income | 163 | 163 | |||
Transfers in/(out) at fair value | 4,598 | 4,598 | |||
Investments, fair value | (1,597) | (1,597) | |||
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Investment Five [Member] | |||||
Investments, fair value | 0 | 0 | |||
Purchases | 0 | 0 | |||
Reductions | 0 | 0 | |||
Transfers in/(out) at fair value | 3,067 | 3,067 | |||
Discount accretion | 4 | 4 | |||
Net unrealized appreciation (depreciation) on investments | (2,003) | (2,003) | |||
Net realized gain (loss) on investments | 0 | 0 | |||
Investments, fair value | 1,068 | 1,068 | |||
Interest income | 114 | 114 | |||
Transfers in/(out) at fair value | 3,067 | 3,067 | |||
Investments, fair value | (1,068) | (1,068) | |||
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Investment Six [Member] | |||||
Investments, fair value | 0 | 0 | |||
Purchases | 0 | 0 | |||
Reductions | 0 | 0 | |||
Transfers in/(out) at fair value | 3,067 | 3,067 | |||
Discount accretion | 4 | 4 | |||
Net unrealized appreciation (depreciation) on investments | (2,003) | (2,003) | |||
Net realized gain (loss) on investments | 0 | 0 | |||
Investments, fair value | 1,068 | 1,068 | |||
Interest income | 111 | 111 | |||
Transfers in/(out) at fair value | 3,067 | 3,067 | |||
Investments, fair value | (1,068) | (1,068) | |||
Investment, Affiliated Issuer, Noncontrolled [Member] | Evelo Biosciences, Inc. [Member] | Investment Seven [Member] | |||||
Investments, fair value | 0 | 0 | |||
Purchases | 0 | 0 | |||
Reductions | 0 | 0 | |||
Transfers in/(out) at fair value | 5,000 | 5,000 | |||
Discount accretion | 0 | 0 | |||
Net unrealized appreciation (depreciation) on investments | 3,485 | 3,485 | |||
Net realized gain (loss) on investments | 0 | 0 | |||
Investments, fair value | 8,485 | 8,485 | |||
Interest income | 0 | 0 | |||
Transfers in/(out) at fair value | 5,000 | 5,000 | |||
Investments, fair value | (8,485) | (8,485) | |||
Investment, Affiliated Issuer, Controlled [Member] | |||||
Investments, fair value | 0 | 0 | 0 | 0 | |
Purchases | 809 | 0 | 809 | 0 | |
Reductions | 0 | (50) | 0 | (300) | |
Transfers in/(out) at fair value | 10,818 | 0 | 10,818 | 0 | |
Discount accretion | 3 | 0 | 3 | 0 | |
Net unrealized appreciation (depreciation) on investments | 1,357 | 0 | 1,357 | 1,450 | |
Net realized gain (loss) on investments | 0 | 50 | 0 | (1,150) | |
Investments, fair value | 13,145 | 0 | 13,145 | 0 | |
Interest income | 8 | 0 | 8 | 0 | |
Interest Income, Operating, Paid in Kind | 158 | 0 | 158 | 0 | |
Transfers in/(out) at fair value | 10,818 | 0 | 10,818 | 0 | |
Investments, fair value | (13,145) | 0 | (13,145) | 0 | |
Investment, Affiliated Issuer, Controlled [Member] | Investment [Member] | |||||
Interest income | 166 | 166 | |||
Investment, Affiliated Issuer, Controlled [Member] | Better Place Forests Co. [Member] | Investment One [Member] | |||||
Investments, fair value | 0 | 0 | |||
Purchases | 59 | 59 | |||
Reductions | 0 | 0 | |||
Transfers in/(out) at fair value | 1,759 | 1,759 | |||
Discount accretion | 2 | 2 | |||
Net unrealized appreciation (depreciation) on investments | 1,080 | 1,080 | |||
Net realized gain (loss) on investments | 0 | 0 | |||
Investments, fair value | 3,005 | 3,005 | |||
Interest income | 111 | 111 | |||
Interest Income, Operating, Paid in Kind | 105 | 105 | |||
Transfers in/(out) at fair value | 1,759 | 1,759 | |||
Investments, fair value | (3,005) | (3,005) | |||
Investment, Affiliated Issuer, Controlled [Member] | Better Place Forests Co. [Member] | Investment Two [Member] | |||||
Investments, fair value | 0 | 0 | |||
Purchases | 0 | 0 | |||
Reductions | 0 | 0 | |||
Transfers in/(out) at fair value | 844 | 844 | |||
Discount accretion | 1 | 1 | |||
Net unrealized appreciation (depreciation) on investments | 536 | 536 | |||
Net realized gain (loss) on investments | 0 | 0 | |||
Investments, fair value | 1,434 | 1,434 | |||
Interest income | 55 | 55 | |||
Interest Income, Operating, Paid in Kind | 53 | 53 | |||
Transfers in/(out) at fair value | 844 | 844 | |||
Investments, fair value | (1,434) | (1,434) | |||
Investment, Affiliated Issuer, Controlled [Member] | Better Place Forests Co. [Member] | Investment Three [Member] | |||||
Investments, fair value | 0 | 0 | |||
Purchases | 0 | 0 | |||
Reductions | 0 | 0 | |||
Transfers in/(out) at fair value | 2,061 | 2,061 | |||
Discount accretion | 0 | 0 | |||
Net unrealized appreciation (depreciation) on investments | 0 | 0 | |||
Net realized gain (loss) on investments | 0 | 0 | |||
Investments, fair value | 2,061 | 2,061 | |||
Interest income | 0 | 0 | |||
Interest Income, Operating, Paid in Kind | 0 | 0 | |||
Transfers in/(out) at fair value | 2,061 | 2,061 | |||
Investments, fair value | (2,061) | (2,061) | |||
Investment, Affiliated Issuer, Controlled [Member] | Better Place Forests Co. [Member] | Investment Four [Member] | |||||
Investments, fair value | 0 | 0 | |||
Purchases | 750 | 750 | |||
Reductions | 0 | 0 | |||
Transfers in/(out) at fair value | 0 | 0 | |||
Discount accretion | 0 | 0 | |||
Net unrealized appreciation (depreciation) on investments | (259) | (259) | |||
Net realized gain (loss) on investments | 0 | 0 | |||
Investments, fair value | 491 | 491 | |||
Interest income | 0 | 0 | |||
Interest Income, Operating, Paid in Kind | 0 | 0 | |||
Transfers in/(out) at fair value | 0 | 0 | |||
Investments, fair value | (491) | (491) | |||
Investment, Affiliated Issuer, Controlled [Member] | HESP LLC [Member] | |||||
Investments, fair value | 0 | 0 | |||
Purchases | 0 | 0 | |||
Reductions | (50) | (300) | |||
Transfers in/(out) at fair value | 0 | 0 | |||
Discount accretion | 0 | 0 | |||
Net unrealized appreciation (depreciation) on investments | 0 | 1,450 | |||
Net realized gain (loss) on investments | 50 | (1,150) | |||
Investments, fair value | 0 | 0 | |||
Interest income | 0 | 0 | |||
Transfers in/(out) at fair value | 0 | 0 | |||
Investments, fair value | $ 0 | $ 0 | |||
Investment, Affiliated Issuer, Controlled [Member] | HIMV LLC [Member] | |||||
Investments, fair value | 0 | 0 | |||
Purchases | 0 | 0 | |||
Reductions | 0 | 0 | |||
Transfers in/(out) at fair value | 6,154 | 6,154 | |||
Discount accretion | 0 | 0 | |||
Net unrealized appreciation (depreciation) on investments | 0 | 0 | |||
Net realized gain (loss) on investments | 0 | 0 | |||
Investments, fair value | 6,154 | 6,154 | |||
Interest income | 0 | 0 | |||
Interest Income, Operating, Paid in Kind | 0 | 0 | |||
Transfers in/(out) at fair value | 6,154 | 6,154 | |||
Investments, fair value | $ (6,154) | $ (6,154) | |||
[1]As of September 30, 2023, the Company no longer owns 5% or more of the portfolio company. |
Note 6 - Fair Value (Details Te
Note 6 - Fair Value (Details Textual) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | |||
Sep. 30, 2023 USD ($) $ / shares | Sep. 30, 2022 USD ($) | Sep. 30, 2023 USD ($) $ / shares | Sep. 30, 2022 USD ($) | Jun. 30, 2022 | |
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net | $ (5,000) | $ (1,117) | $ (5,111) | $ (1,117) | |
Unrealized Gain (Loss) on Investments | (17,518) | 3,442 | (24,448) | 1,169 | |
Warrant [Member] | |||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net | 0 | (1,117) | 0 | (1,117) | |
Equity Securities [Member] | |||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net | 0 | 0 | (111) | 0 | |
Fair Value, Inputs, Level 1 [Member] | Debt Securities [Member] | |||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 | $ 5,000 | ||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net | 5,000 | ||||
Fair Value, Inputs, Level 1 [Member] | Warrant [Member] | |||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 | 1,100 | 1,100 | |||
Fair Value, Inputs, Level 1 [Member] | Equity Securities [Member] | |||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 | 100 | ||||
Fair Value, Inputs, Level 3 [Member] | Debt Securities [Member] | |||||
Unrealized Gain (Loss) on Investments | (33,600) | (3,500) | |||
Fair Value, Inputs, Level 3 [Member] | Warrant [Member] | |||||
Unrealized Gain (Loss) on Investments | (2,100) | 1,200 | |||
Fair Value, Inputs, Level 3 [Member] | Equity Securities [Member] | |||||
Unrealized Gain (Loss) on Investments | $ (1,600) | (400) | |||
Fair Value, Inputs, Level 2 [Member] | Warrant [Member] | |||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 | $ 40 | $ 40 | |||
The 2026 Notes [Member] | |||||
Debt Instrument, Share Price (in dollars per share) | $ / shares | $ 23.60 | $ 23.60 | |||
The 2026 Notes [Member] | Fair Value, Inputs, Level 1 [Member] | |||||
Debt Instrument, Fair Value Disclosure | $ 54,300 | $ 54,300 | |||
The 2027 Notes [Member] | |||||
Debt Instrument, Share Price (in dollars per share) | $ / shares | $ 24.18 | $ 24.18 | |||
The 2027 Notes [Member] | Fair Value, Inputs, Level 1 [Member] | |||||
Debt Instrument, Fair Value Disclosure | $ 55,600 | $ 55,600 | |||
Asset-backed Notes 2019 [Member] | Fair Value, Inputs, Level 3 [Member] | |||||
Debt Instrument, Fair Value Disclosure | 18,700 | 18,700 | |||
Asset-backed Notes 2022 [Member] | Fair Value, Inputs, Level 3 [Member] | |||||
Debt Instrument, Fair Value Disclosure | $ 100,000 | $ 100,000 | |||
Measurement Input, Hypothetical Market Yields [Member] | |||||
Debt Instrument, Measurement Input | 0.25 |
Note 6 - Fair Value - Assets at
Note 6 - Fair Value - Assets at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Fair Value, Recurring [Member] | ||
Investments, fair value | $ 729,053 | $ 720,026 |
Fair Value, Recurring [Member] | Debt [Member] | ||
Investments, fair value | 679,838 | 686,458 |
Fair Value, Recurring [Member] | Warrant [Member] | ||
Investments, fair value | 26,189 | 29,712 |
Fair Value, Recurring [Member] | Other Investments [Member] | ||
Investments, fair value | 7,254 | 1,300 |
Fair Value, Recurring [Member] | Equity Securities [Member] | ||
Investments, fair value | 15,772 | 2,556 |
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | ||
Investments, fair value | 8,962 | 140 |
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Debt [Member] | ||
Investments, fair value | 0 | 0 |
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Warrant [Member] | ||
Investments, fair value | 0 | 0 |
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Other Investments [Member] | ||
Investments, fair value | 0 | 0 |
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Equity Securities [Member] | ||
Investments, fair value | 8,962 | 140 |
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | ||
Investments, fair value | 956 | 3,567 |
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Debt [Member] | ||
Investments, fair value | 0 | 0 |
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Warrant [Member] | ||
Investments, fair value | 956 | 3,567 |
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Other Investments [Member] | ||
Investments, fair value | 0 | 0 |
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Equity Securities [Member] | ||
Investments, fair value | 0 | 0 |
Fair Value, Inputs, Level 3 [Member] | ||
Investments, fair value | 719,135 | 716,319 |
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | ||
Investments, fair value | 719,135 | 716,319 |
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Debt [Member] | ||
Investments, fair value | 679,838 | 686,458 |
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Warrant [Member] | ||
Investments, fair value | 25,233 | 26,145 |
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Other Investments [Member] | ||
Investments, fair value | 7,254 | 1,300 |
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Equity Securities [Member] | ||
Investments, fair value | $ 6,810 | $ 2,416 |
Note 6 - Fair Value - Significa
Note 6 - Fair Value - Significant Level 3 Fair Value Measurement Inputs (Details) - Fair Value, Inputs, Level 3 [Member] $ in Thousands | Sep. 30, 2023 USD ($) | Dec. 31, 2022 USD ($) | |
Investments, fair value | $ 719,135 | $ 716,319 | |
Investments, measurement input | [1] | 0.83 | |
Minimum [Member] | |||
Investments, measurement input | 0.30 | ||
Maximum [Member] | |||
Investments, measurement input | 1 | ||
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | |||
Investments, fair value | $ 607,193 | $ 669,617 | |
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Minimum [Member] | Hypothetical Market Yield [Member] | |||
Investments, measurement input | 0.11 | 0.03 | |
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Maximum [Member] | Hypothetical Market Yield [Member] | |||
Investments, measurement input | 0.20 | 0.22 | |
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Weighted Average [Member] | Hypothetical Market Yield [Member] | |||
Investments, measurement input | [1] | 0.14 | 0.14 |
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | |||
Investments, fair value | $ 72,645 | $ 16,545 | |
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Minimum [Member] | Probability Weighting [Member] | |||
Investments, measurement input | 0.20 | 0.10 | |
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Maximum [Member] | Probability Weighting [Member] | |||
Investments, measurement input | 1 | 0.75 | |
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Probability Weighting [Member] | |||
Investments, measurement input | [1] | 0.50 | 0.31 |
Debt [Member] | Black-scholes Valuation Model [Member] | |||
Investments, fair value | $ 26,145 | ||
Debt [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Price Volatility [Member] | |||
Investments, measurement input | 0.28 | ||
Debt [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Discount for Lack of Marketability [Member] | |||
Investments, measurement input | 0.20 | ||
Debt [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Measurement Input, Share Price [Member] | |||
Investments, measurement input | 0 | ||
Debt [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Estimated Time to Exit [Member] | |||
Investments, measurement input | 1 | ||
Debt [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Measurement Input, Share Price [Member] | |||
Investments, measurement input | 1.89 | ||
Debt [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Estimated Time to Exit [Member] | |||
Investments, measurement input | 5 | ||
Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member] | |||
Investments, measurement input | [1] | 58.52 | |
Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Price Volatility [Member] | |||
Investments, measurement input | [1] | 0.28 | |
Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Discount for Lack of Marketability [Member] | |||
Investments, measurement input | [1] | 0.20 | |
Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Estimated Time to Exit [Member] | |||
Investments, measurement input | [1] | 3 | |
Debt [Member] | Convertible Note Analysis [Member] | |||
Investments, fair value | $ 296 | ||
Debt [Member] | Convertible Note Analysis [Member] | Measurement Input, Share Price [Member] | |||
Investments, measurement input | 168.93 | ||
Debt [Member] | Convertible Note Analysis [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member] | |||
Investments, measurement input | [1] | 168.93 | |
Warrant [Member] | Black-scholes Valuation Model [Member] | |||
Investments, fair value | $ 25,171 | ||
Warrant [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Price Volatility [Member] | |||
Investments, measurement input | 0.28 | ||
Warrant [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Discount for Lack of Marketability [Member] | |||
Investments, measurement input | 0.20 | ||
Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Measurement Input, Share Price [Member] | |||
Investments, measurement input | 0 | ||
Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Measurement Input, Discount for Lack of Marketability [Member] | |||
Investments, measurement input | [1] | 0.20 | |
Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Estimated Time to Exit [Member] | |||
Investments, measurement input | 1 | ||
Warrant [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Measurement Input, Share Price [Member] | |||
Investments, measurement input | 1,899 | ||
Warrant [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Estimated Time to Exit [Member] | |||
Investments, measurement input | 5 | ||
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member] | |||
Investments, measurement input | [1] | 58.11 | |
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Price Volatility [Member] | |||
Investments, measurement input | [1] | 0.28 | |
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Estimated Time to Exit [Member] | |||
Investments, measurement input | [1] | 3 | |
Warrant [Member] | Expected Proceeds [Member] | |||
Investments, fair value | $ 62 | ||
Warrant [Member] | Expected Proceeds [Member] | Measurement Input, Share Price [Member] | |||
Investments, measurement input | 0.25 | ||
Warrant [Member] | Expected Proceeds [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member] | |||
Investments, measurement input | [1] | 0.25 | |
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | |||
Investments, fair value | $ 7,254 | $ 1,300 | |
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Probability Weighting [Member] | |||
Investments, measurement input | 1 | ||
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Measurement Input, Discount Rate [Member] | |||
Investments, measurement input | 0.25 | 0.25 | |
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Probability Weighting [Member] | |||
Investments, measurement input | [1] | 1 | |
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Measurement Input, Discount Rate [Member] | |||
Investments, measurement input | [1] | 0.25 | 0.25 |
Equity Securities [Member] | Last Equity Financing [Member] | |||
Investments, fair value | $ 6,810 | $ 2,416 | |
Equity Securities [Member] | Last Equity Financing [Member] | Minimum [Member] | Measurement Input, Share Price [Member] | |||
Investments, measurement input | 0.03 | ||
Equity Securities [Member] | Last Equity Financing [Member] | Maximum [Member] | Measurement Input, Share Price [Member] | |||
Investments, measurement input | 215.03 | ||
Equity Securities [Member] | Last Equity Financing [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member] | |||
Investments, measurement input | [1] | 18.30 | 26.93 |
[1]Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) (1) the fair value of the related investment in the investment type divided by (2) the total fair value of the investment type. |
Note 6 - Fair Value - Reconcili
Note 6 - Fair Value - Reconciliation of Level 3 Assets Measured on a Recurring Basis (Details) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Balance | $ 713,244 | $ 577,380 | $ 716,319 | $ 457,557 |
Purchase of investments | 66,935 | 94,627 | 154,488 | 348,347 |
Warrants received and classified as Level 3 | 1,294 | 964 | 2,039 | 2,441 |
Principal payments received on investments | (25,726) | 26,960 | (90,222) | 114,433 |
Payment-in-kind interest on investments | 3,934 | 6,088 | ||
Proceeds from sale of investments | (2,557) | 6,126 | (11,063) | 49,552 |
Net realized (loss) gain on investments | (11,552) | (8,195) | (28,198) | (9,094) |
Unrealized (depreciation) appreciation included in earnings | (20,722) | 4,227 | (26,384) | 2,720 |
Transfer out of Level 3 | (5,000) | (1,117) | (5,111) | (1,117) |
Transfer out of debt investments | 0 | 0 | 0 | 0 |
Other | (715) | (541) | 1,179 | (2,610) |
Balance | 719,135 | 634,259 | 719,135 | 634,259 |
Principal payments received on investments | 25,726 | (26,960) | 90,222 | (114,433) |
Proceeds from sale of investments | 2,557 | (6,126) | 11,063 | (49,552) |
Debt [Member] | ||||
Balance | 683,309 | 551,560 | 686,458 | 437,317 |
Purchase of investments | 66,185 | 94,627 | 153,728 | 348,097 |
Warrants received and classified as Level 3 | 0 | 0 | 0 | 0 |
Principal payments received on investments | (25,726) | 26,929 | (90,222) | 114,120 |
Payment-in-kind interest on investments | 3,934 | 6,088 | ||
Proceeds from sale of investments | (2,528) | 6,088 | (9,564) | 49,088 |
Net realized (loss) gain on investments | (11,440) | (8,492) | (29,105) | (8,492) |
Unrealized (depreciation) appreciation included in earnings | (18,877) | 8,095 | (21,325) | 1,128 |
Transfer out of Level 3 | (5,000) | 0 | (5,000) | 0 |
Transfer out of debt investments | (9,304) | (3,200) | (12,399) | (3,200) |
Other | (715) | (541) | 1,179 | (2,610) |
Balance | 679,838 | 609,032 | 679,838 | 609,032 |
Principal payments received on investments | 25,726 | (26,929) | 90,222 | (114,120) |
Proceeds from sale of investments | 2,528 | (6,088) | 9,564 | (49,088) |
Warrant [Member] | ||||
Balance | 24,376 | 25,167 | 26,145 | 19,837 |
Purchase of investments | 0 | 0 | 0 | 0 |
Warrants received and classified as Level 3 | 1,294 | 964 | 1,950 | 2,441 |
Principal payments received on investments | 0 | 0 | 0 | 0 |
Payment-in-kind interest on investments | 0 | 0 | ||
Proceeds from sale of investments | (23) | 38 | (1,493) | 464 |
Net realized (loss) gain on investments | (118) | 266 | 1,028 | 535 |
Unrealized (depreciation) appreciation included in earnings | (296) | (3,348) | (2,392) | 662 |
Transfer out of Level 3 | 0 | (1,117) | 0 | (1,117) |
Transfer out of debt investments | 0 | 0 | (5) | 0 |
Other | 0 | 0 | 0 | 0 |
Balance | 25,233 | 21,894 | 25,233 | 21,894 |
Principal payments received on investments | 0 | 0 | 0 | 0 |
Proceeds from sale of investments | 23 | (38) | 1,493 | (464) |
Equity Securities [Member] | ||||
Balance | 4,259 | 453 | 2,416 | 203 |
Purchase of investments | 750 | 0 | 760 | 250 |
Warrants received and classified as Level 3 | 0 | 0 | 89 | 0 |
Principal payments received on investments | 0 | 0 | 0 | 0 |
Payment-in-kind interest on investments | 0 | 0 | ||
Proceeds from sale of investments | (6) | 0 | (6) | 0 |
Net realized (loss) gain on investments | 6 | 0 | (121) | 0 |
Unrealized (depreciation) appreciation included in earnings | (1,349) | (420) | (2,467) | (420) |
Transfer out of Level 3 | 0 | 0 | (111) | 0 |
Transfer out of debt investments | 3,150 | 2,000 | 6,250 | 2,000 |
Other | 0 | 0 | 0 | 0 |
Balance | 6,810 | 2,033 | 6,810 | 2,033 |
Principal payments received on investments | 0 | 0 | 0 | 0 |
Proceeds from sale of investments | 6 | 0 | 6 | 0 |
Other Investments [Member] | ||||
Balance | 1,300 | 200 | 1,300 | 200 |
Purchase of investments | 0 | 0 | 0 | 0 |
Warrants received and classified as Level 3 | 0 | 0 | 0 | 0 |
Principal payments received on investments | 0 | 31 | 0 | 313 |
Payment-in-kind interest on investments | 0 | 0 | ||
Proceeds from sale of investments | 0 | 0 | 0 | 0 |
Net realized (loss) gain on investments | 0 | 31 | 0 | (1,137) |
Unrealized (depreciation) appreciation included in earnings | (200) | (100) | (200) | 1,350 |
Transfer out of Level 3 | 0 | 0 | 0 | 0 |
Transfer out of debt investments | 6,154 | 1,200 | 6,154 | 1,200 |
Other | 0 | 0 | 0 | 0 |
Balance | 7,254 | 1,300 | 7,254 | 1,300 |
Principal payments received on investments | 0 | (31) | 0 | (313) |
Proceeds from sale of investments | $ 0 | $ 0 | $ 0 | $ 0 |
Note 7 - Borrowings (Details Te
Note 7 - Borrowings (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | |||||||||||
May 24, 2023 | Feb. 25, 2022 | Apr. 21, 2020 | Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Jun. 29, 2023 | Dec. 31, 2022 | Nov. 09, 2022 | Jun. 15, 2022 | Mar. 30, 2021 | Aug. 13, 2019 | |
Asset Coverage to Borrowings, Ratio, Percent | 179% | ||||||||||||
Restricted Investments | $ 2,838 | $ 2,838 | $ 2,788 | ||||||||||
Long-Term Debt, Gross | 439,696 | 439,696 | 439,323 | ||||||||||
Debt Instrument, Face Amount | $ 633,696 | $ 633,696 | 582,573 | ||||||||||
Key Facility [Member] | |||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity, Accordian Feature | $ 150,000 | ||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 300,000 | ||||||||||||
Line of Credit Facility, Advance Rate of Eligible Debt Investments | 60% | ||||||||||||
Long-Term Debt, Weighted Average Interest Rate, over Time | 8.68% | 5.60% | 8.34% | 4.75% | |||||||||
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage | 0.50% | ||||||||||||
Line of Credit Facility, Current Borrowing Capacity | $ 125,000 | $ 125,000 | 120,000 | ||||||||||
Line of Credit Facility, Remaining Borrowing Capacity | 38,300 | 38,300 | 40,200 | ||||||||||
Long-Term Debt, Gross | 25,000 | 25,000 | 5,000 | ||||||||||
Debt Instrument, Face Amount | $ 150,000 | $ 150,000 | $ 125,000 | ||||||||||
Key Facility [Member] | Prime Rate [Member] | |||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 0.25% | ||||||||||||
Debt Instrument, Variable Rate | 8.50% | 8.50% | 7.50% | ||||||||||
NYL Facility [Member] | |||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 250,000 | $ 100,000 | |||||||||||
Line of Credit Facility, Current Borrowing Capacity | $ 69,000 | $ 69,000 | $ 23,200 | ||||||||||
Line of Credit Facility, Remaining Borrowing Capacity | 5,100 | 5,100 | 23,200 | ||||||||||
Line of Credit Facility, Maximum Borrowing Capacity, Accordion Feature | $ 200,000 | ||||||||||||
Line of Credit Facility, Advance Rate | 67% | ||||||||||||
Line of Credit Facility, Change in Maximum Borrowing Capacity | $ 50,000 | $ 100,000 | |||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 4.60% | ||||||||||||
Long-Term Line of Credit | $ 181,000 | $ 181,000 | $ 176,800 | ||||||||||
Line of Credit Facility, Interest Rate at Period End | 5.85% | 5.85% | 5.57% | ||||||||||
Restricted Investments | $ 1,300 | $ 1,300 | $ 1,000 | ||||||||||
Long-Term Debt, Gross | 181,000 | 181,000 | 176,750 | ||||||||||
Debt Instrument, Face Amount | 250,000 | 250,000 | 200,000 | ||||||||||
NYL Facility [Member] | USD Mid-market Swap Rate [Member] | |||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 3% | ||||||||||||
NYL Facility [Member] | Three Year I Curve [Member] | |||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 3.50% | ||||||||||||
Asset-backed Notes 2019 [Member] | |||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 4.21% | ||||||||||||
Restricted Investments | 400 | 400 | 600 | ||||||||||
Long-Term Debt, Gross | 18,696 | 18,696 | 42,573 | ||||||||||
Debt Instrument, Face Amount | 18,696 | 18,696 | 42,573 | $ 160,000 | |||||||||
Asset-backed Notes 2022 [Member] | |||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 7.56% | ||||||||||||
Restricted Investments | 1,200 | 1,200 | |||||||||||
Long-Term Debt, Gross | 100,000 | 100,000 | 100,000 | ||||||||||
Debt Instrument, Face Amount | 100,000 | 100,000 | 100,000 | $ 157,800 | |||||||||
The 2026 Notes [Member] | |||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 4.875% | ||||||||||||
Long-Term Debt, Gross | 57,500 | 57,500 | 57,500 | ||||||||||
Debt Instrument, Face Amount | 57,500 | 57,500 | 57,500 | $ 57,500 | |||||||||
The 2026 Notes Underwriter Option [Member] | |||||||||||||
Debt Instrument, Face Amount | $ 7,500 | ||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 25 | ||||||||||||
The 2027 Notes [Member] | |||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6.25% | ||||||||||||
Long-Term Debt, Gross | 57,500 | 57,500 | 57,500 | ||||||||||
Debt Instrument, Face Amount | $ 57,500 | $ 57,500 | $ 57,500 | $ 50,000 | |||||||||
The 2027 Notes Underwriter Option [Member] | |||||||||||||
Debt Instrument, Face Amount | $ 7,500 | ||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 25 | ||||||||||||
Minimum [Member] | |||||||||||||
Asset Coverage to Borrowings, Ratio, Percent | 150% | ||||||||||||
Minimum [Member] | Key Facility [Member] | Prime Rate [Member] | |||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 4.25% | ||||||||||||
Minimum [Member] | NYL Facility [Member] | USD Mid-market Swap Rate [Member] | |||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 3.55% | ||||||||||||
Maximum [Member] | NYL Facility [Member] | USD Mid-market Swap Rate [Member] | |||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 5.15% |
Note 7 - Borrowings - Borrowing
Note 7 - Borrowings - Borrowings (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 | Nov. 09, 2022 | Jun. 15, 2022 | Mar. 30, 2021 | Aug. 13, 2019 |
Total commitment | $ 633,696 | $ 582,573 | ||||
Balance outstanding | 439,696 | 439,323 | ||||
Unused commitment | 194,000 | 143,250 | ||||
Unamortized debt issuance costs attributable to term borrowings | (4,196) | (5,245) | ||||
Total borrowings outstanding, net | 435,500 | 434,078 | ||||
Key Facility [Member] | ||||||
Total commitment | 150,000 | 125,000 | ||||
Balance outstanding | 25,000 | 5,000 | ||||
Unused commitment | 125,000 | 120,000 | ||||
NYL Facility [Member] | ||||||
Total commitment | 250,000 | 200,000 | ||||
Balance outstanding | 181,000 | 176,750 | ||||
Unused commitment | 69,000 | 23,250 | ||||
Asset-backed Notes 2019 [Member] | ||||||
Total commitment | 18,696 | 42,573 | $ 160,000 | |||
Balance outstanding | 18,696 | 42,573 | ||||
Unused commitment | 0 | 0 | ||||
Asset-backed Notes 2022 [Member] | ||||||
Total commitment | 100,000 | 100,000 | $ 157,800 | |||
Balance outstanding | 100,000 | 100,000 | ||||
Unused commitment | 0 | 0 | ||||
The 2027 Notes [Member] | ||||||
Total commitment | 57,500 | 57,500 | $ 50,000 | |||
Balance outstanding | 57,500 | 57,500 | ||||
Unused commitment | 0 | 0 | ||||
The 2026 Notes [Member] | ||||||
Total commitment | 57,500 | 57,500 | $ 57,500 | |||
Balance outstanding | 57,500 | 57,500 | ||||
Unused commitment | $ 0 | $ 0 |
Note 8 - Financial Instrument_3
Note 8 - Financial Instruments With Off-balance-sheet Risk (Details Textual) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Other Commitment | $ 181,800 | |
Fair Value Disclosure, off-Balance-Sheet Risks, Amount, Liability | 2,036 | $ 1,761 |
Commitments to Extend Credit [Member] | ||
Other Commitment | $ 190,000 |
Note 8 - Financial Instrument_4
Note 8 - Financial Instruments With Off-balance-sheet Risk - Unfunded Commitments (Details) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
Unfunded commitments, principal balance | $ 181,750 | $ 190,000 |
Fair value of unfunded commitment liability | 2,036 | 1,761 |
BrightInsight, Inc. [Member] | ||
Unfunded commitments, principal balance | 18,250 | 21,000 |
Fair value of unfunded commitment liability | 241 | 278 |
Britecore Holdings, Inc. [Member] | ||
Unfunded commitments, principal balance | 5,000 | 5,000 |
Fair value of unfunded commitment liability | 72 | 66 |
Candesant Biomedical Corporation [Member] | ||
Unfunded commitments, principal balance | 10,000 | 0 |
Fair value of unfunded commitment liability | 151 | 0 |
Castle Creek Biosciences [Member] | ||
Unfunded commitments, principal balance | 4,000 | 4,000 |
Fair value of unfunded commitment liability | 72 | 72 |
Divergent Technologies, Inc. [Member] | ||
Unfunded commitments, principal balance | 11,250 | 22,500 |
Fair value of unfunded commitment liability | 118 | 236 |
Elligo Healthcare Research, Inc. [Member] | ||
Unfunded commitments, principal balance | 15,000 | 0 |
Fair value of unfunded commitment liability | 194 | 0 |
Engage3, LLC [Member] | ||
Unfunded commitments, principal balance | 0 | 8,000 |
Fair value of unfunded commitment liability | 0 | 40 |
Groundspeed Analytics, Inc. [Member] | ||
Unfunded commitments, principal balance | 0 | 15,000 |
Fair value of unfunded commitment liability | 0 | 150 |
Hound Labs, Inc. [Member] | ||
Unfunded commitments, principal balance | 0 | 7,500 |
Fair value of unfunded commitment liability | 0 | 88 |
KSQ Therapeutics, Inc. [Member] | ||
Unfunded commitments, principal balance | 0 | 10,000 |
Fair value of unfunded commitment liability | 0 | 100 |
Lytics, Inc. [Member] | ||
Unfunded commitments, principal balance | 4,000 | 5,000 |
Fair value of unfunded commitment liability | 52 | 65 |
Mirantis, Inc [Member] | ||
Unfunded commitments, principal balance | 15,000 | 0 |
Fair value of unfunded commitment liability | 136 | 0 |
Native Microbials, Inc. [Member] | ||
Unfunded commitments, principal balance | 0 | 7,500 |
Fair value of unfunded commitment liability | 0 | 72 |
Noodle Partners, Inc. [Member] | ||
Unfunded commitments, principal balance | 5,000 | 0 |
Fair value of unfunded commitment liability | 61 | 0 |
Optoro, Inc. [Member] | ||
Unfunded commitments, principal balance | 6,250 | 15,000 |
Fair value of unfunded commitment liability | 0 | 38 |
PDS Biotechnology Corporation [Member] | ||
Unfunded commitments, principal balance | 0 | 10,000 |
Fair value of unfunded commitment liability | 0 | 158 |
Robin Healthcare, Inc. [Member] | ||
Unfunded commitments, principal balance | 0 | 10,000 |
Fair value of unfunded commitment liability | 0 | 100 |
SafelyYou, Inc [Member] | ||
Unfunded commitments, principal balance | 20,000 | 0 |
Fair value of unfunded commitment liability | 270 | 0 |
Scientia Vascular, Inc. [Member] | ||
Unfunded commitments, principal balance | 5,000 | 10,000 |
Fair value of unfunded commitment liability | 55 | 110 |
Slingshot Aerospace, Inc. [Member] | ||
Unfunded commitments, principal balance | 0 | 5,000 |
Fair value of unfunded commitment liability | 0 | 64 |
Sonex Health, Inc. [Member] | ||
Unfunded commitments, principal balance | 15,000 | 0 |
Fair value of unfunded commitment liability | 176 | 0 |
Supply Network Visibility Holdings, LLC [Member] | ||
Unfunded commitments, principal balance | 10,000 | 0 |
Fair value of unfunded commitment liability | 35 | 0 |
Swift Health Systems Inc. [Member] | ||
Unfunded commitments, principal balance | 11,500 | 25,500 |
Fair value of unfunded commitment liability | 0 | 105 |
Tallac Therapeutics, Inc [Member] | ||
Unfunded commitments, principal balance | 10,000 | 0 |
Fair value of unfunded commitment liability | 229 | 0 |
Temperpack Technologies, Inc [Member] | ||
Unfunded commitments, principal balance | 6,500 | 9,000 |
Fair value of unfunded commitment liability | 14 | 19 |
Viken Detection Corporation [Member] | ||
Unfunded commitments, principal balance | 10,000 | 0 |
Fair value of unfunded commitment liability | $ 160 | $ 0 |
Note 9 - Concentrations of Cr_2
Note 9 - Concentrations of Credit Risk (Details Textual) - Debt Investments [Member] - Five Largest Debt Investments [Member] | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | |
Investment Concentration Risk [Member] | Reported Value Measurement [Member] | |||||
Concentration Risk, Percentage | 23% | 23% | |||
Investment Concentration Risk [Member] | Estimate of Fair Value Measurement [Member] | |||||
Concentration Risk, Percentage | 22% | 23% | |||
Investment Income Concentration Risk [Member] | Reported Value Measurement [Member] | |||||
Concentration Risk, Percentage | 24% | 18% | 23% | ||
Investment Income Concentration Risk [Member] | Estimate of Fair Value Measurement [Member] | |||||
Concentration Risk, Percentage | 21% | 18% | |||
Interest Income [Member] | Reported Value Measurement [Member] | |||||
Concentration Risk, Percentage | 18% | ||||
Interest Income [Member] | Estimate of Fair Value Measurement [Member] | |||||
Concentration Risk, Percentage | 22% | 18% |
Note 10 - Distributions (Detail
Note 10 - Distributions (Details Textual) - $ / shares | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
Common Stock, Dividends, Per Share, Cash Paid (in dollars per share) | $ 0.33 | |||
Earnings Per Share, Basic (in dollars per share) | 0.53 | $ 0.43 | $ 1.54 | $ 1.06 |
Earnings Per Share, Basic, Undistributed (in dollars per share) | $ 1.23 |
Note 10 - Distributions - Distr
Note 10 - Distributions - Distribution Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||
Oct. 27, 2023 | Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | |
Distributions declared per share (in dollars per share) | $ 0.33 | $ 0.30 | $ 0.99 | $ 0.90 | $ 1.28 | |
Dividends, cash | $ 22,954 | $ 32,659 | ||||
Dividends, shares (in shares) | 60,190 | 61,859 | ||||
Dividends, stock | $ 742 | $ 754 | ||||
February 15, 2024 Dividend [Member] | Forecast [Member] | ||||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
November 16, 2023 Dividend [Member] | Forecast [Member] | ||||||
Distributions declared per share (in dollars per share) | 0.05 | |||||
January 17, 2024 Dividend [Member] | Forecast [Member] | ||||||
Distributions declared per share (in dollars per share) | 0.11 | |||||
First 7/28/2023 Dividend [Member] | ||||||
Record date | Nov. 17, 2023 | |||||
Payment date | Dec. 15, 2023 | |||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Dividends, cash | $ 0 | |||||
Dividends, shares (in shares) | 0 | |||||
Dividends, stock | $ 0 | |||||
December 18, 2023 Dividend [Member] | Forecast [Member] | ||||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Second 7/28/2023 Dividend [Member] | ||||||
Record date | Oct. 18, 2023 | |||||
Payment date | Nov. 11, 2023 | |||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Dividends, cash | $ 0 | |||||
Dividends, shares (in shares) | 0 | |||||
Dividends, stock | $ 0 | |||||
Third 7/28/2023 Dividend [Member] | ||||||
Record date | Sep. 19, 2023 | |||||
Payment date | Oct. 16, 2023 | |||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Dividends, cash | $ 3,445 | |||||
Dividends, shares (in shares) | 15,067 | |||||
Dividends, stock | $ 184 | |||||
First 4/28/2023 Dividend [Member] | ||||||
Record date | Aug. 17, 2023 | |||||
Payment date | Sep. 15, 2023 | |||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Dividends, cash | $ 3,458 | |||||
Dividends, shares (in shares) | 8,665 | |||||
Dividends, stock | $ 106 | |||||
Second 4/28/2023 [Member] | ||||||
Record date | Jul. 18, 2023 | |||||
Payment date | Aug. 15, 2023 | |||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Dividends, cash | $ 3,427 | |||||
Dividends, shares (in shares) | 8,307 | |||||
Dividends, stock | $ 105 | |||||
Third 4/28/2023 Dividend [Member] | ||||||
Record date | Jun. 16, 2023 | |||||
Payment date | Jul. 14, 2023 | |||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Dividends, cash | $ 3,434 | |||||
Dividends, shares (in shares) | 7,424 | |||||
Dividends, stock | $ 96 | |||||
First 2/23/2023 Dividend [Member] | ||||||
Record date | May 18, 2023 | |||||
Payment date | Jun. 14, 2023 | |||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Dividends, cash | $ 3,087 | |||||
Dividends, shares (in shares) | 7,128 | |||||
Dividends, stock | $ 86 | |||||
Second 2/23/2023 Dividend [Member] | ||||||
Record date | Apr. 18, 2023 | |||||
Payment date | May 16, 2023 | |||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Dividends, cash | $ 3,068 | |||||
Dividends, shares (in shares) | 6,705 | |||||
Dividends, stock | $ 84 | |||||
Third 2/23/2023 Dividend [Member] | ||||||
Record date | Mar. 17, 2023 | |||||
Payment date | Apr. 14, 2023 | |||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Dividends, cash | $ 3,035 | |||||
Dividends, shares (in shares) | 6,894 | |||||
Dividends, stock | $ 81 | |||||
First 10/28/2022 Dividend [Member] | ||||||
Record date | Feb. 17, 2023 | |||||
Payment date | Mar. 15, 2023 | |||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Dividends, cash | $ 3,040 | |||||
Dividends, shares (in shares) | 6,764 | |||||
Dividends, stock | $ 75 | |||||
Second 10/28/2022 Dividend [Member] | ||||||
Record date | Jan. 18, 2023 | |||||
Payment date | Feb. 15, 2023 | |||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Dividends, cash | $ 3,021 | |||||
Dividends, shares (in shares) | 5,754 | |||||
Dividends, stock | $ 74 | |||||
Third 10/28/2022 Dividend [Member] | ||||||
Record date | Dec. 19, 2022 | |||||
Payment date | Jan. 13, 2023 | |||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Dividends, cash | $ 2,978 | |||||
Dividends, shares (in shares) | 5,618 | |||||
Dividends, stock | $ 69 | |||||
Fourth 10/28/2022 Dividend [Member] | ||||||
Record date | Nov. 17, 2022 | |||||
Payment date | Dec. 15, 2022 | |||||
Distributions declared per share (in dollars per share) | $ 0.05 | |||||
Dividends, cash | $ 1,319 | |||||
Dividends, shares (in shares) | 2,171 | |||||
Dividends, stock | $ 27 | |||||
First 7/29/2022 Dividend [Member] | ||||||
Record date | Nov. 17, 2022 | |||||
Payment date | Dec. 15, 2022 | |||||
Distributions declared per share (in dollars per share) | $ 0.10 | |||||
Dividends, cash | $ 2,638 | |||||
Dividends, shares (in shares) | 4,341 | |||||
Dividends, stock | $ 57 | |||||
Second 7/29/2022 Dividend [Member] | ||||||
Record date | Oct. 18, 2022 | |||||
Payment date | Nov. 15, 2022 | |||||
Distributions declared per share (in dollars per share) | $ 0.10 | |||||
Dividends, cash | $ 2,580 | |||||
Dividends, shares (in shares) | 4,621 | |||||
Dividends, stock | $ 60 | |||||
Third 7/29/2022 Dividend [Member] | ||||||
Record date | Sep. 19, 2022 | |||||
Payment date | Oct. 14, 2022 | |||||
Distributions declared per share (in dollars per share) | $ 0.10 | |||||
Dividends, cash | $ 2,558 | |||||
Dividends, shares (in shares) | 7,703 | |||||
Dividends, stock | $ 81 | |||||
First 4/29/22 Dividend [Member] | ||||||
Record date | Aug. 18, 2022 | |||||
Payment date | Sep. 15, 2022 | |||||
Distributions declared per share (in dollars per share) | $ 0.10 | |||||
Dividends, cash | $ 2,528 | |||||
Dividends, shares (in shares) | 4,925 | |||||
Dividends, stock | $ 60 | |||||
Second 4/29/2022 Dividend [Member] | ||||||
Record date | Jul. 19, 2022 | |||||
Payment date | Aug. 16, 2022 | |||||
Distributions declared per share (in dollars per share) | $ 0.10 | |||||
Dividends, cash | $ 2,484 | |||||
Dividends, shares (in shares) | 3,939 | |||||
Dividends, stock | $ 55 | |||||
Third 4/29/2022 Dividend [Member] | ||||||
Record date | Jun. 17, 2022 | |||||
Payment date | Jul. 15, 2022 | |||||
Distributions declared per share (in dollars per share) | $ 0.10 | |||||
Dividends, cash | $ 2,434 | |||||
Dividends, shares (in shares) | 4,286 | |||||
Dividends, stock | $ 51 | |||||
First 2/25/2022 Dividend [Member] | ||||||
Record date | May 18, 2022 | |||||
Payment date | Jun. 15, 2022 | |||||
Distributions declared per share (in dollars per share) | $ 0.10 | |||||
Dividends, cash | $ 2,378 | |||||
Dividends, shares (in shares) | 4,428 | |||||
Dividends, stock | $ 50 | |||||
Second 2/25/2022 Dividend [Member] | ||||||
Record date | Apr. 19, 2022 | |||||
Payment date | May 16, 2022 | |||||
Distributions declared per share (in dollars per share) | $ 0.10 | |||||
Dividends, cash | $ 2,349 | |||||
Dividends, shares (in shares) | 4,088 | |||||
Dividends, stock | $ 49 | |||||
Third 2/25/2022 Dividend [Member] | ||||||
Record date | Mar. 18, 2022 | |||||
Payment date | Apr. 14, 2022 | |||||
Distributions declared per share (in dollars per share) | $ 0.10 | |||||
Dividends, cash | $ 2,352 | |||||
Dividends, shares (in shares) | 3,221 | |||||
Dividends, stock | $ 46 |
Note 11 - Financial Highlight_2
Note 11 - Financial Highlights - Financial Highlights (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 9 Months Ended | ||||
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | ||
Net asset value at beginning of period (in dollars per share) | $ 11.47 | $ 11.56 | ||||
Net investment income (in dollars per share) | 1.54 | 1.06 | ||||
Realized loss (in dollars per share) | (0.95) | (0.40) | ||||
Unrealized (depreciation) appreciation on investments (in dollars per share) | (0.81) | 0.05 | ||||
Net increase in net assets resulting from operations (in dollars per share) | $ (0.37) | $ 0.23 | (0.22) | 0.71 | ||
Distributions declared (in dollars per share) | [1] | (0.99) | (0.90) | |||
From net investment income (in dollars per share) | (0.99) | (0.90) | ||||
From net realized gain on investments (in dollars per share) | 0 | 0 | 0 | 0 | ||
Return of capital (in dollars per share) | 0 | 0 | ||||
Other (in dollars per share) | [2] | 0.15 | 0.29 | |||
Net asset value at end of period (in dollars per share) | 10.41 | 11.66 | 10.41 | 11.66 | ||
Per share market value, beginning of period (in dollars per share) | 11.60 | 15.92 | ||||
Per share market value, end of period (in dollars per share) | $ 11.88 | $ 10.01 | $ 11.88 | $ 10.01 | ||
Total return based on a market value | [3] | 10.90% | (31.50%) | |||
Shares outstanding at end of period (in shares) | 33,306,958 | 26,393,773 | 33,306,958 | 26,393,773 | 27,753,373 | |
Expenses without incentive value | [4] | 14% | 11.40% | |||
Incentive fees | [4] | 1.20% | 3% | |||
Net expenses | [4] | 15.20% | 14.40% | |||
Net investment income with incentive fees | [4] | 18.50% | 12.10% | |||
Net assets at the end of the period | $ 346,575 | $ 307,687 | $ 346,575 | $ 307,687 | $ 318,448 | |
Average net asset value | $ 335,531 | $ 280,904 | $ 335,531 | $ 280,904 | ||
Average debt per share (in dollars per share) | $ 14.29 | $ 13.32 | ||||
Portfolio turnover ratio | [5] | 10% | 14.90% | |||
[1]Distributions are determined based on taxable income calculated in accordance with income tax regulations, which may differ from amounts determined under GAAP due to (i) changes in unrealized appreciation and depreciation, (ii) temporary and permanent differences in income and expense recognition, and (iii) the amount of spillover income carried over from a given tax year for distribution in the following tax year. The final determination of taxable income for each tax year, as well as the tax attributes for distributions in such tax year, will be made after the close of the tax year.[2]Includes the impact of the different share amounts as a result of calculating per share data based on the weighted average basic shares outstanding during the period and certain per share data based on the shares outstanding as of a period end or transaction date. The issuance of common stock on a per share basis reflects the incremental net asset value changes as a result of the issuance of common stock in the Company’s continuous public offering and pursuant to the Company’s distribution reinvestment plan. The issuance of common stock at an offering price, net of sales commissions and dealer manager fees, that is greater than the net asset value per share results in an increase in net asset value per share.[3]The total return equals the change in the ending market value over the beginning of period price per share plus distributions paid per share during the period, divided by the beginning price.[4]Annualized.[5]Calculated by dividing the lesser of purchases or the sum of (1) principal prepayments and (2) maturities by the monthly average debt investment balance. |
Note 12 - Subsequent Events (De
Note 12 - Subsequent Events (Details Textual) - USD ($) $ in Thousands | Oct. 30, 2023 | Sep. 30, 2023 | Dec. 31, 2022 |
Investment Owned, Fair Value | $ 729,053 | $ 720,026 | |
Evelo Biosciences, Inc. [Member] | |||
Investment Owned, Fair Value | $ 8,500 | ||
Subsequent Event [Member] | Evelo Biosciences, Inc. [Member] | |||
Investment Owned, Fair Value | $ 1,100 |